var title_f28_53_29520="Thymoma CT I";
var content_f28_53_29520=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73685&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73685&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thymoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan of a thymoma originating from the right lobe of the thymus. A large rounded mass is seen in the retrosternal location, to the right of the midline (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_53_29520=[""].join("\n");
var outline_f28_53_29520=null;
var title_f28_53_29521="Intermediate case 8 with answer";
var content_f28_53_29521=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69487&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69487&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mobitz type I (Wenckebach) AV block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 98px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sinus rhythm with Mobitz type I (Wenckebach) atrioventricular block. Note the progressive prolongation of the PR interval with the sixth P wave not being conducted (arrow). This is followed by resumption of AV conduction as the seventh P wave is conducted with a relatively short PR interval that then begins to increase with the next P wave.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_53_29521=[""].join("\n");
var outline_f28_53_29521=null;
var title_f28_53_29522="Patient information: Rotator cuff injury (The Basics)";
var content_f28_53_29522=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16298\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/37/12895\">",
"         Pendulum stretch exercise",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?2/32/2563\">",
"         Patient information: Biceps tendinopathy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?22/26/22946\">",
"         Patient information: Frozen shoulder (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/35/26162\">",
"         Patient information: Shoulder impingement (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/36/25153\">",
"         Patient information: Biceps tendinitis or tendinopathy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/21/37201\">",
"         Patient information: Frozen shoulder (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/49/24341\">",
"         Patient information: Rotator cuff tendinitis and tear (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?8/49/8977\">",
"         Patient information: Shoulder impingement syndrome (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Rotator cuff injury (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/rotator-cuff-injury-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H9392884\">",
"      <span class=\"h1\">",
"       What is a rotator cuff injury?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A rotator cuff injury is a condition that can cause shoulder pain. The rotator cuff is made up of 4 shoulder muscles and their tendons. Tendons are strong bands of tissue that connect muscles to bones.",
"     </p>",
"     <p>",
"      People can get different types of rotator cuff injuries. One common injury is &ldquo;tendinopathy,&rdquo; which is when people have a problem with 1 of their tendons. In most people with tendinopathy, the tendons are not inflamed or swollen. If they do get inflamed or swollen, doctors call it &ldquo;tendinitis.&rdquo; Tendinopathy and tendinitis can happen if people use their rotator cuff muscles too much or do a lot of activity with their arms overhead.",
"     </p>",
"     <p>",
"      Another type of rotator cuff injury is a tear in a tendon. Tears can happen if a person falls on the shoulder or moves the shoulder too fast and with too much force. Tears can also happen as a tendon wears out over time.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9392891\">",
"      <span class=\"h1\">",
"       What are the symptoms of a rotator cuff injury?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people with tendinopathy or tendinitis have pain around the tip of the shoulder and outer part of the upper arm. The pain is usually worse when they move their arm over their head or lie on their shoulder.",
"     </p>",
"     <p>",
"      People with a torn tendon usually have shoulder pain and might also have weakness of the shoulder muscles.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9392898\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You might. Your doctor or nurse will talk with you and do an exam. If he or she suspects a tear, you might need an imaging test of the shoulder. Imaging tests create pictures of the inside of the body.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9392905\">",
"      <span class=\"h1\">",
"       How is a rotator cuff injury treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many rotator cuff injuries get better on their own, but they can take months to heal completely. To help your shoulder get better, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Rest your shoulder &mdash; Avoid doing any activities that strain your shoulder, such as raising your arm overhead or reaching behind you. In general, try to keep your arm down, close to, and in front of your body. But you can move your shoulder gently if you need to.",
"       </li>",
"       <li>",
"        Ice your shoulder &mdash; Put a cold gel pack, bag of ice, or bag of frozen vegetables on the injured area every 1 to 2 hours, for 15 minutes each time. Put a thin towel between the ice (or other cold object) and your skin.",
"       </li>",
"       <li>",
"        Take medicine to reduce the pain and swelling &mdash; Your doctor or nurse might recommend that you take",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil&reg;, Motrin&reg;) or",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44597?source=see_link\">",
"         naproxen",
"        </a>",
"        (sample brand names: Aleve&reg;, Naprosyn&reg;).",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some tears, especially large tears, might need to be treated with surgery.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9392912\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Different exercises can help your shoulder feel better. Ask your doctor or nurse which exercises you should do, when to start them, and how often to do them.",
"     </p>",
"     <p>",
"      Some exercises help keep your shoulder from getting too stiff. One of these is called the pendulum stretch. To do this exercise, let your arm relax and hang down. Move your arm back and forth, then side to side, and then around in small circles (",
"      <a class=\"graphic graphic_figure graphicRef50148 \" href=\"UTD.htm?12/37/12895\">",
"       figure 1",
"      </a>",
"      ). Your doctor or nurse can also show you other stretches that you can do.",
"     </p>",
"     <p>",
"      Other exercises can help strengthen your shoulder muscles. Your doctor, nurse, or physical therapist (exercise expert) can show you how to do these types of exercises.",
"     </p>",
"     <p>",
"      When you do shoulder exercises, it&rsquo;s important to:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Warm up your shoulder first by taking a hot shower or bath, or massaging the area",
"       </li>",
"       <li>",
"        Start slowly and make the exercises harder over time",
"       </li>",
"       <li>",
"        Know that some soreness is normal. If you have sharp or tearing pain, stop what you&rsquo;re doing and let your doctor or nurse know.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9392919\">",
"      <span class=\"h1\">",
"       What if my symptoms don&rsquo;t get better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your symptoms don&rsquo;t get better, talk with your doctor or nurse about other possible treatments, such as:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Getting a shot of medicine into your shoulder",
"       </li>",
"       <li>",
"        Surgery",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9392926\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/26/22946?source=see_link\">",
"       Patient information: Frozen shoulder (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/32/2563?source=see_link\">",
"       Patient information: Biceps tendinopathy (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/35/26162?source=see_link\">",
"       Patient information: Shoulder impingement (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/49/24341?source=see_link\">",
"       Patient information: Rotator cuff tendinitis and tear (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/21/37201?source=see_link\">",
"       Patient information: Frozen shoulder (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?8/49/8977?source=see_link\">",
"       Patient information: Shoulder impingement syndrome (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/36/25153?source=see_link\">",
"       Patient information: Biceps tendinitis or tendinopathy (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?28/53/29522?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16298 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-36135ECCB4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_53_29522=[""].join("\n");
var outline_f28_53_29522=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9392884\">",
"      What is a rotator cuff injury?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9392891\">",
"      What are the symptoms of a rotator cuff injury?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9392898\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9392905\">",
"      How is a rotator cuff injury treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9392912\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9392919\">",
"      What if my symptoms don&rsquo;t get better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9392926\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16298\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/37/12895\">",
"      Pendulum stretch exercise",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/36/25153?source=related_link\">",
"      Patient information: Biceps tendinitis or tendinopathy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/32/2563?source=related_link\">",
"      Patient information: Biceps tendinopathy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/21/37201?source=related_link\">",
"      Patient information: Frozen shoulder (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/26/22946?source=related_link\">",
"      Patient information: Frozen shoulder (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/49/24341?source=related_link\">",
"      Patient information: Rotator cuff tendinitis and tear (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/35/26162?source=related_link\">",
"      Patient information: Shoulder impingement (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/49/8977?source=related_link\">",
"      Patient information: Shoulder impingement syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_53_29523="Naphazoline (nasal): Drug information";
var content_f28_53_29523=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Naphazoline (nasal): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?39/52/40772?source=see_link\">",
"    see \"Naphazoline (nasal): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/57/10131?source=see_link\">",
"    see \"Naphazoline (nasal): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F15511986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Issues Warning on Accidental Ingestion of Imidazoline Derivative Eye Drops and Nasal Sprays",
"     </span>",
"     <span class=\"collapsible-date\">",
"      October 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The U.S. Food and Drug Administration (FDA) has issued a warning that accidental ingestion by children of over-the-counter (OTC) imidazoline derivative eye drops and nasal sprays may result in serious harm. The eye drops and nasal sprays involved in cases of accidental ingestion contain the imidazoline derivatives tetrahydrozoline, oxymetazoline, or naphazoline. Serious adverse reactions (eg, coma, bradycardia, respiratory depression, sedation) requiring hospitalization were reported in children &le;5 years who had ingested even small amounts (eg, 1-2 mL). These products should be stored out of reach of children at all times; parents and caregivers should note that not all products are packaged in child-resistant packaging. If a child accidentally ingests these products, parents and caregivers should contact a poison control center at 1-800-222-1222 and seek emergency medical care immediately.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For more information, please refer to:",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/ucm325257.htm\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/ucm325257.htm",
"       </a>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9348230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Privine&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9348257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alpha;",
"      <sub>",
"       1",
"      </sub>",
"      Agonist",
"     </li>",
"     <li>",
"      Imidazoline Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9348307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Nasal congestion (decongestant):",
"     </b>",
"     Intranasal: 0.05%, instill 1-2 drops or sprays every 6 hours if needed; therapy should not exceed 3 days",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F9348305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/57/10131?source=see_link\">",
"      see \"Naphazoline (nasal): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Nasal congestion (decongestant):",
"     </b>",
"     Intranasal: Children &gt;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9348310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9348351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal, as hydrochloride [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Privine&reg;: 0.05% (25 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal, as hydrochloride [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Privine&reg;: 0.05% (20 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9348234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary relief of nasal congestion associated with the common cold, upper respiratory allergies, or sinusitis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F15801078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Accidental ingestion: Serious adverse reactions (eg, coma, bradycardia, respiratory depression, sedation) requiring hospitalization have been reported in children &le;5 years of age who have accidentally ingested even small amounts (eg, 1-2 mL) of imidazoline-derivative (ie, tetrahydrozoline, oxymetazoline, or naphazoline) eye drops or nasal sprays. Store these products out of reach of children at all times. Contact poison control or seek medical attention if accidental ingestion occurs.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9348275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Transient stinging, nasal mucosa irritation, dryness, rebound congestion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Sneezing",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9348238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to naphazoline or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9348248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rebound nasal congestion: May occur with extended use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with hypertension, heart failure, or  coronary artery disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperthyroidism: Use with caution in patients with hyperthyroidism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia: Use with caution in patients with benign prostatic hyperplasia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Not recommended for use in children &lt;12 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; OTC labeling: Patients should notify healthcare provider if symptoms last &gt;72 hours or if condition worsens.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9348279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Dazolin (AR, UY);",
"     </li>",
"     <li>",
"      Gotinal (VE);",
"     </li>",
"     <li>",
"      Hu Tai (CL);",
"     </li>",
"     <li>",
"      Napha-Nasal (BG);",
"     </li>",
"     <li>",
"      Neusinol (BE);",
"     </li>",
"     <li>",
"      Ninazo (VE);",
"     </li>",
"     <li>",
"      Priciasol (BE);",
"     </li>",
"     <li>",
"      Privin (AT);",
"     </li>",
"     <li>",
"      Privina (BR);",
"     </li>",
"     <li>",
"      Rhinaf (EC);",
"     </li>",
"     <li>",
"      Rhinal (PY);",
"     </li>",
"     <li>",
"      Rhinex (DE);",
"     </li>",
"     <li>",
"      Rinol (IT);",
"     </li>",
"     <li>",
"      Rintal (PE);",
"     </li>",
"     <li>",
"      Sanorin (CZ, EE, RU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9348289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates alpha-adrenergic receptors in the arterioles of the conjunctiva and the nasal mucosa to produce vasoconstriction",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9348292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Decongestant: Topical: ~10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 2-6 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9852 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-2.133.93.82-E575B2020D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_53_29523=[""].join("\n");
var outline_f28_53_29523=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15511986\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348230\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348257\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348307\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348305\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348310\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348351\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348234\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15801078\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348275\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348238\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348248\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299741\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348279\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961994\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348289\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348292\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9852\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9852|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/52/40772?source=related_link\">",
"      Naphazoline (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/57/10131?source=related_link\">",
"      Naphazoline (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/60/15300?source=related_link\">",
"      Naphazoline (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/47/19188?source=related_link\">",
"      Naphazoline (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/60/27587?source=related_link\">",
"      Naphazoline (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_53_29524="Cromolyn sodium (systemic therapy and oral inhalation): Patient drug information";
var content_f28_53_29524=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Cromolyn sodium (systemic therapy and oral inhalation): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/12/17605?source=see_link\">",
"     see \"Cromolyn sodium (systemic therapy and oral inhalation): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/63/28660?source=see_link\">",
"     see \"Cromolyn sodium (systemic therapy and oral inhalation): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8012087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Gastrocrom&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8012088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Nalcrom&reg;;",
"     </li>",
"     <li>",
"      Nu-Cromolyn;",
"     </li>",
"     <li>",
"      PMS-Sodium Cromoglycate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691433",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop asthma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691847",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat food allergies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat inflammatory bowel disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691953",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat mastocytosis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701867",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to cromolyn sodium or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697685",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is not helpful in urgent times.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694637",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep taking this drug to stop the allergy. Once signs start, this drug will not help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695829",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 30 minutes before meals and at bedtime.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696406",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not swallow ampul. Open it and empty powder into a",
"       <sup>",
"        1",
"       </sup>",
"       /",
"       <sub>",
"        2",
"       </sub>",
"       glass of hot water. Add a",
"       <sup>",
"        1",
"       </sup>",
"       /",
"       <sub>",
"        2",
"       </sub>",
"       glass of cold water. Mix and drink.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695955",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is also a solution for use in a special machine (nebulizer). Your doctor will teach you how to use this.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11640 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-CAE323FBD7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_53_29524=[""].join("\n");
var outline_f28_53_29524=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012087\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012088\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030369\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030368\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030373\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030374\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030376\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030371\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030372\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030377\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030378\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/27/23987?source=related_link\">",
"      Cromolyn sodium (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/12/197?source=related_link\">",
"      Cromolyn sodium (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/24/35202?source=related_link\">",
"      Cromolyn sodium (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/3/28723?source=related_link\">",
"      Cromolyn sodium (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/46/17124?source=related_link\">",
"      Cromolyn sodium (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/45/19154?source=related_link\">",
"      Cromolyn sodium (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?17/12/17605?source=related_link\">",
"      Cromolyn sodium (systemic therapy and oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/63/28660?source=related_link\">",
"      Cromolyn sodium (systemic therapy and oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_53_29525="Crizotinib: Patient drug information";
var content_f28_53_29525=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Crizotinib: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/58/30631?source=see_link\">",
"     see \"Crizotinib: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13209738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Xalkori&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14330250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Xalkori&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F13210640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F13210642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691944",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat lung cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F13210641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3518623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to crizotinib or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F13210646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a heart problem called congenital QT syndrome, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696668",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid grapefruit and grapefruit juice.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy. Use birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F13210647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697975",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697967",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F13210649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698654",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in your legs or belly.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F13210644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3516750",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A tumor sample test will be done to see if you can take this drug. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695716",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, open, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F13210645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696588",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it has been 6 hours or more since the missed dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F13210650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F13210651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16811 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-BD889E7001-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_53_29525=[""].join("\n");
var outline_f28_53_29525=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13209738\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14330250\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13210640\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13210642\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13210641\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13210646\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13210647\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13210649\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13210644\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13210645\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13210650\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13210651\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/58/30631?source=related_link\">",
"      Crizotinib: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_53_29526="Pyogenic liver abscess";
var content_f28_53_29526=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pyogenic liver abscess",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/53/29526/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/53/29526/contributors\">",
"     Joshua Davis, MBBS, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/53/29526/contributors\">",
"     Malcolm McDonald, PhD, FRACP, FRCPA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/53/29526/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/53/29526/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/53/29526/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/53/29526/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/53/29526/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 18, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pyogenic liver abscesses usually develop following peritonitis due to leakage of intraabdominal bowel contents that subsequently spread to liver via the portal circulation or via direct spread from biliary infection. They may also result from arterial hematogenous seeding in the setting of systemic infection.",
"   </p>",
"   <p>",
"    The clinical approach to pyogenic liver abscess will be reviewed here. Amebic abscesses are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33031?source=see_link\">",
"     \"Extraintestinal Entamoeba histolytica amebiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver abscesses are the most common type of visceral abscess; in a report of 540 cases of intraabdominal abscesses, pyogenic liver abscesses accounted for 48 percent of visceral abscesses and 13 percent of intraabdominal abscesses [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29526/abstract/1\">",
"     1",
"    </a>",
"    ]. The annual incidence of liver abscess has been estimated at 2.3 cases per 100,000 population and is higher among men than women (3.3 versus 1.3 per 100,000) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29526/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]; substantially higher rates have been reported in Taiwan (17.6 cases per 100,000) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29526/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors include diabetes, underlying hepatobiliary or pancreatic disease, and liver transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29526/abstract/2,3,6,7\">",
"     2,3,6,7",
"    </a>",
"    ]. Geographic and host factors may also play a role; for example, a primary invasive liver abscess syndrome due to K. pneumoniae has been described in East Asia. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29176?source=see_link\">",
"     \"Invasive liver abscess syndrome caused by Klebsiella pneumoniae\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mortality rate in developed countries ranges from 2 to 12 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29526/abstract/3,8\">",
"     3,8",
"    </a>",
"    ]. Independent risk factors for mortality include need for open surgical drainage, the presence of malignancy, and the presence of anaerobic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29526/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A considerable proportion of pyogenic liver abscesses follow one or more episodes of portal vein pyemia, usually related to bowel leakage and peritonitis. Another important route is direct spread from biliary infection. Underlying biliary tract disease such as gallstones or malignant obstruction is present in 40 to 60 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29526/abstract/2,8,11\">",
"     2,8,11",
"    </a>",
"    ]. Occasionally, abscesses arise from surgical or penetrating wounds [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29526/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Liver abscesses may also result from hematogenous seeding from the systemic circulation. A monomicrobial liver abscess due to a streptococcal or staphylococcal species should prompt evaluation for an additional source of infection.",
"   </p>",
"   <p>",
"    Liver abscesses most commonly involve the right lobe of the liver, probably because it is larger and has greater blood supply than the left and caudate lobes. Liver abscess may also be accompanied by pylephlebitis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29526/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33254?source=see_link\">",
"     \"Pylephlebitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many pathogens have been described; this variability reflects the different causes, types of medical intervention (such as biliary tree stenting, or immunosuppression due to cancer chemotherapy) and geographic differences. Most pyogenic liver abscesses are polymicrobial; mixed enteric facultative and anaerobic species are the most common pathogens. Anaerobes are probably under-reported because they are difficult to culture and characterize in the laboratory. For example, in one series of 233 cases, mixed facultative and anaerobic species were implicated in one-third of patients, and bacteremia was documented in 56 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29526/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The highly variable microbiology justifies pursuing a microbiological diagnosis in virtually every case. Potential pathogens include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Streptococcus milleri or S. anginosus group (including S. constellatus and S. intermedius) is an important cause of liver abscess. When implicated, it should prompt a search for simultaneous metastatic infections at other locations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/41/34456?source=see_link\">",
"       \"Infections due to the Streptococcus anginosus group\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      S. aureus, S. pyogenes, and other Gram positive cocci are recognized pathogens in specific circumstances [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29526/abstract/14\">",
"       14",
"      </a>",
"      ]. For example, in a report of liver abscesses in patients who underwent transarterial embolization for hepatocellular carcinoma, they accounted for 60 percent of pathogens. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/9/41114?source=see_link&amp;anchor=H1248650342#H1248650342\">",
"       \"Nonsurgical therapies for localized hepatocellular carcinoma: Transarterial embolization, radiotherapy, and radioembolization\", section on 'Complications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Candida species have also been implicated in pyogenic liver abscess and accounted for 22 percent of liver abscesses in one series [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29526/abstract/2\">",
"       2",
"      </a>",
"      ]. Hepatosplenic candidiasis can occur in patients who have received chemotherapy and presents with recovery of neutrophil counts following a neutropenic episode. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10071?source=see_link\">",
"       \"Hepatosplenic candidiasis (chronic disseminated candidiasis)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Klebsiella pneumoniae is an important emerging pathogen. This syndrome is discussed in detail separately (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29176?source=see_link\">",
"       \"Invasive liver abscess syndrome caused by Klebsiella pneumoniae\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Tuberculous liver abscesses are uncommon but should be considered when typical pyogenic organisms are not recovered from cultures [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29526/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/21/20826?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and treatment of extrapulmonary and miliary tuberculosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Burkholderia pseudomallei (the agent of Melioidosis) should be considered in patients from endemic areas (Southeast Asia and Northern Australia). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39577?source=see_link\">",
"       \"Epidemiology, pathogenesis, clinical manifestations, and diagnosis of melioidosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Amebiasis should be considered as a cause of primary liver abscess, especially in patients who are from or have traveled to an endemic area within the past six months. The clinical course and appearance may be difficult to distinguish from pyogenic liver abscess; this is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33031?source=see_link\">",
"       \"Extraintestinal Entamoeba histolytica amebiasis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical clinical manifestations of pyogenic liver abscess are fever and abdominal pain. Other common symptoms include nausea, vomiting, anorexia, weight loss, and malaise.",
"   </p>",
"   <p>",
"    Fever occurs in approximately 90 percent of patients, and abdominal symptoms occur in 50 to 75 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29526/abstract/2,3,8,17\">",
"     2,3,8,17",
"    </a>",
"    ]. Abdominal symptoms and signs are usually localized to the right upper quadrant and may include pain, guarding, rocking tenderness (pain caused by gently rocking the patient's abdomen), and even rebound tenderness. About one-half of patients with liver abscess have hepatomegaly, right upper quadrant tenderness, or jaundice [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29526/abstract/17\">",
"     17",
"    </a>",
"    ]. The absence of right upper quadrant findings does not exclude liver abscess.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of pyogenic liver abscess is made by history, clinical examination, and radiographic imaging followed by aspiration and culture of the abscess material.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT) scan and ultrasound are the modalities of choice (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61510 \" href=\"UTD.htm?0/28/449\">",
"     image 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29526/abstract/12\">",
"     12",
"    </a>",
"    ]. CT usually shows a fluid collection with surrounding edema. There may also be stranding and loculated subcollections. Pyogenic liver abscess cannot be reliably distinguished from amebic abscess by imaging studies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29526/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33031?source=see_link&amp;anchor=H2#H2\">",
"     \"Extraintestinal Entamoeba histolytica amebiasis\", section on 'Amebic liver abscess'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Abscesses must be distinguished from tumors and cysts. Tumors have a solid radiographic appearance and may contain areas of calcification. Necrosis and bleeding within a tumor may lead to a fluid-filled appearance; in such circumstances radiographic differentiation from abscess can be challenging. Cysts appear as fluid collections without surrounding stranding or hyperemia.",
"   </p>",
"   <p>",
"    An elevated right hemidiaphragm, right basilar infiltrate, or right-sided pleural effusion can be seen in 25 to 35 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29526/abstract/18\">",
"     18",
"    </a>",
"    ]; these findings should prompt further investigation of the right upper quadrant with CT or ultrasonography. Magnetic resonance imaging and tagged white blood cell scans are less useful for distinguishing abscess from other causes of liver mass.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Microbial cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Material obtained from CT or ultrasound-guided aspiration should be sent to the laboratory for gram stain and culture (both aerobic and anaerobic). Anaerobic culture should be specifically requested on the laboratory requisition.",
"   </p>",
"   <p>",
"    Blood cultures are essential; they are positive in up to 50 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29526/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cultures obtained from existing drains are NOT adequate for guiding antimicrobial therapy, since they are often contaminated with skin flora and other organisms. This was demonstrated in a study of 66 cases of liver abscess; cultures results obtained via radiographic guidance were compared with cultures obtained from a drain that had been in place for at least 48 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29526/abstract/16\">",
"     16",
"    </a>",
"    ]. Cultures from percutaneous specimens correlated with cultures from drainage catheters in only one-half of cases. Treatment based upon drainage culture results alone would have led to inappropriate therapy for the remaining patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory abnormalities may include elevated bilirubin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    liver enzymes. Serum alkaline phosphatase is elevated in 67 to 90 percent of cases and serum bilirubin and aspartate aminotransferase concentrations are elevated in about one-half of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29526/abstract/2,8,17\">",
"     2,8,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other laboratory abnormalities may include leukocytosis, hypoalbuminemia, and anemia (normochromic, normocytic).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of pyogenic liver abscess should include drainage and antibiotic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drainage techniques include CT-guided or ultrasound-guided percutaneous drainage (with or without catheter placement), surgical drainage, or drainage by endoscopic retrograde cholangiopancreatography (ERCP).",
"   </p>",
"   <p>",
"    For single abscesses with a diameter &le;5 cm, either percutaneous catheter drainage or needle aspiration is acceptable [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29526/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. Drainage catheters should remain in place until drainage is minimal (usually up to seven days). Repeat needle aspiration may be required in up to half of cases if a catheter is not left in situ [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29526/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For percutaneous management of single abscesses with diameter &gt;5 cm, catheter drainage is preferred over needle aspiration. These principles were illustrated in a trial of 60 patients with pyogenic liver abscess treated with antibiotics and percutaneous drainage via catheter or needle aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29526/abstract/23\">",
"     23",
"    </a>",
"    ]. Among patients with an abscess diameter &gt;5 cm, treatment was successful in 100 percent of patients treated with catheter drainage compared with 50 percent of patients with needle aspiration. Successful outcomes were observed for all patients with abscess &le;5 cm, regardless of drainage modality.",
"   </p>",
"   <p>",
"    For single abscesses with diameter &gt;5 cm, some favor surgical intervention over percutaneous drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29526/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. The efficacy of this approach was suggested in a retrospective study of 80 patients with abscess &gt;5 cm managed with percutaneous or surgical drainage; there was no difference in mortality, morbidity, duration of fever or complication rates. However, the rate of treatment failure was lower with surgical drainage (7 versus 28 percent).",
"   </p>",
"   <p>",
"    Surgical drainage is also appropriate in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Multiple abscesses",
"     </li>",
"     <li>",
"      Loculated abscesses",
"     </li>",
"     <li>",
"      Abscesses with viscous contents obstructing the drainage catheter",
"     </li>",
"     <li>",
"      Underlying disease requiring primary surgical management",
"     </li>",
"     <li>",
"      Inadequate response to percutaneous drainage within seven days",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Multiple or loculated abscesses may be successfully managed by percutaneous drainage; this was illustrated in a retrospective study of patients with pyogenic liver abscess [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29526/abstract/26\">",
"     26",
"    </a>",
"    ]. Successful percutaneous drainage was achieved in the setting of multiple abscesses (22 of 24 patients) and multiloculated abscesses (51 of 54 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29526/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endoscopic retrograde cholangiopancreatography (ERCP) can be useful for drainage of liver abscesses in patients with previous biliary procedures whose infection communicates with the biliary tree [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29526/abstract/11,27\">",
"     11,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;No randomized controlled trials have evaluated empiric antibiotic regimens for treatment of pyogenic liver abscess. Treatment recommendations are based upon the probable source of infection and should be guided by local bacterial resistance patterns, if known. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Microbiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Empiric broad-spectrum parenteral antibiotics should be administered pending abscess gram stain and culture results. We suggest one of the regimens outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef67894 \" href=\"UTD.htm?7/21/7517\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Regardless of the initial empiric regimen, the therapeutic regimen should be revisited once culture and susceptibility results are available. Recovery of more than one organism should suggest polymicrobial infection including anaerobes, even if no anaerobes are isolated in culture. In such circumstances, anaerobic coverage should be continued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized controlled trials evaluating the optimal duration of therapy. This is typically determined by the extent of infection and the patient's clinical response to initial management. Patients with abscess(es) that are difficult to drain or slow to resolve on follow-up imaging usually require longer courses of therapy.",
"   </p>",
"   <p>",
"    Useful clinical indicators to follow are temperature, white blood cell count and serum C-reactive protein. Follow-up imaging should only be performed in the setting of persistent clinical symptoms or if drainage is not proceeding as expected; radiological abnormalities resolve much more slowly than clinical and biochemical markers. Among 102 pyogenic liver abscess patients in Nepal, the mean time to ultrasonographic resolution of abscesses &lt;10 cm was 16 weeks; mean time to resolution for abscesses &gt;10 cm was 22 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29526/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drainage catheters should remain in place until drainage is minimal (usually up to seven days). If percutaneous needle aspiration was performed without catheter placement, repeat aspiration may be required in up to one-half of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29526/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antibiotic therapy should be continued for four to six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29526/abstract/29\">",
"     29",
"    </a>",
"    ]. Patients who have had a good response to initial drainage should be treated with two to four weeks of parenteral therapy, while patients with incomplete drainage should receive four to six weeks of parenteral therapy. The remainder of the course can then be completed with oral therapy tailored to culture results [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29526/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. If culture results are not available, reasonable empiric oral antibiotic choices include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    alone or a fluoroquinolone (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    ) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical manifestations of pyogenic liver abscess usually include fever and abdominal pain; other symptoms may include nausea, vomiting, anorexia, weight loss and malaise. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of pyogenic liver abscess is confirmed by radiographic imaging (computed tomography or ultrasound) followed by aspiration and culture of the abscess material. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most pyogenic liver abscesses are polymicrobial. Amebic abscess is best distinguished from pyogenic liver abscess by serology. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend draining liver abscesses (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For drainage of abscesses &le;5 cm in diameter, we suggest needle aspiration rather than percutaneous catheter drainage (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Repeat needle aspiration may be required. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Drainage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For drainage of abscesses &gt;5 cm in diameter, we suggest percutaneous catheter drainage rather than needle aspiration (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Drainage catheters should remain in place until drainage ceases (usually up to seven days). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Drainage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest surgical drainage (rather than percutaneous drainage) in the following circumstances (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Drainage'",
"      </a>",
"      above.):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Multiple abscesses (depending on number, position, and size)",
"     </li>",
"     <li>",
"      Loculated abscesses",
"     </li>",
"     <li>",
"      Abscesses with viscous contents obstructing drainage catheter",
"     </li>",
"     <li>",
"      Underlying disease requiring primary surgical management",
"     </li>",
"     <li>",
"      Inadequate response to percutaneous drainage within seven days",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend empiric parenteral antibiotic therapy pending culture and susceptibility results (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Suggested regimens are outlined in the table (",
"      <a class=\"graphic graphic_table graphicRef67894 \" href=\"UTD.htm?7/21/7517\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When there is a clinical response to therapy, oral antibiotics may be substituted for parenteral therapy (with the guidance of susceptibility testing) to complete a four to six week course of treatment. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29526/abstract/1\">",
"      Altemeier WA, Culbertson WR, Fullen WD, Shook CD. Intra-abdominal abscesses. Am J Surg 1973; 125:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29526/abstract/2\">",
"      Huang CJ, Pitt HA, Lipsett PA, et al. Pyogenic hepatic abscess. Changing trends over 42 years. Ann Surg 1996; 223:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29526/abstract/3\">",
"      Mohsen AH, Green ST, Read RC, McKendrick MW. Liver abscess in adults: ten years experience in a UK centre. QJM 2002; 95:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29526/abstract/4\">",
"      Kaplan GG, Gregson DB, Laupland KB. Population-based study of the epidemiology of and the risk factors for pyogenic liver abscess. Clin Gastroenterol Hepatol 2004; 2:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29526/abstract/5\">",
"      Tsai FC, Huang YT, Chang LY, Wang JT. Pyogenic liver abscess as endemic disease, Taiwan. Emerg Infect Dis 2008; 14:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29526/abstract/6\">",
"      Chan KS, Chen CM, Cheng KC, et al. Pyogenic liver abscess: a retrospective analysis of 107 patients during a 3-year period. Jpn J Infect Dis 2005; 58:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29526/abstract/7\">",
"      Thomsen RW, Jepsen P, S&oslash;rensen HT. Diabetes mellitus and pyogenic liver abscess: risk and prognosis. Clin Infect Dis 2007; 44:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29526/abstract/8\">",
"      Rahimian J, Wilson T, Oram V, Holzman RS. Pyogenic liver abscess: recent trends in etiology and mortality. Clin Infect Dis 2004; 39:1654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29526/abstract/9\">",
"      Chen SC, Huang CC, Tsai SJ, et al. Severity of disease as main predictor for mortality in patients with pyogenic liver abscess. Am J Surg 2009; 198:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29526/abstract/10\">",
"      Lok KH, Li KF, Li KK, Szeto ML. Pyogenic liver abscess: clinical profile, microbiological characteristics, and management in a Hong Kong hospital. J Microbiol Immunol Infect 2008; 41:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29526/abstract/11\">",
"      Lam YH, Wong SK, Lee DW, et al. ERCP and pyogenic liver abscess. Gastrointest Endosc 1999; 50:340.",
"     </a>",
"    </li>",
"    <li>",
"     Zaleznik, DF, Kasper, DL. Intra-abdominal abscesses. In: Gastrointestinal Infections: Diagnosis and Management, Lamont, JT (Ed), Marcel Dekker, New York 1997. p.397.",
"    </li>",
"    <li>",
"     Kasper, DL, Zaleznik, DF. Intra-abdominal infections and abscesses. In: Harrison's Principles of Internal Medicine. 16th ed. Kasper, DL, Braunwald, E, Fauci, AS, Hauser, SL, Longo, DL, Jameson, JL (Eds), McGraw-Hill, New York 2005. p.749.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29526/abstract/14\">",
"      Chen C, Chen PJ, Yang PM, et al. Clinical and microbiological features of liver abscess after transarterial embolization for hepatocellular carcinoma. Am J Gastroenterol 1997; 92:2257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29526/abstract/15\">",
"      Lodhi S, Sarwari AR, Muzammil M, et al. Features distinguishing amoebic from pyogenic liver abscess: a review of 577 adult cases. Trop Med Int Health 2004; 9:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29526/abstract/16\">",
"      Everts RJ, Heneghan JP, Adholla PO, Reller LB. Validity of cultures of fluid collected through drainage catheters versus those obtained by direct aspiration. J Clin Microbiol 2001; 39:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29526/abstract/17\">",
"      Rubin RH, Swartz MN, Malt R. Hepatic abscess: changes in clinical, bacteriologic and therapeutic aspects. Am J Med 1974; 57:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29526/abstract/18\">",
"      McDonald MI, Corey GR, Gallis HA, Durack DT. Single and multiple pyogenic liver abscesses. Natural history, diagnosis and treatment, with emphasis on percutaneous drainage. Medicine (Baltimore) 1984; 63:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29526/abstract/19\">",
"      Chemaly RF, Hall GS, Keys TF, Procop GW. Microbiology of liver abscesses and the predictive value of abscess gram stain and associated blood cultures. Diagn Microbiol Infect Dis 2003; 46:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29526/abstract/20\">",
"      Rajak CL, Gupta S, Jain S, et al. Percutaneous treatment of liver abscesses: needle aspiration versus catheter drainage. AJR Am J Roentgenol 1998; 170:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29526/abstract/21\">",
"      Ch Yu S, Hg Lo R, Kan PS, Metreweli C. Pyogenic liver abscess: treatment with needle aspiration. Clin Radiol 1997; 52:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29526/abstract/22\">",
"      Yu SC, Ho SS, Lau WY, et al. Treatment of pyogenic liver abscess: prospective randomized comparison of catheter drainage and needle aspiration. Hepatology 2004; 39:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29526/abstract/23\">",
"      Zerem E, Hadzic A. Sonographically guided percutaneous catheter drainage versus needle aspiration in the management of pyogenic liver abscess. AJR Am J Roentgenol 2007; 189:W138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29526/abstract/24\">",
"      Tan YM, Chung AY, Chow PK, et al. An appraisal of surgical and percutaneous drainage for pyogenic liver abscesses larger than 5 cm. Ann Surg 2005; 241:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29526/abstract/25\">",
"      Bertel, CK, van Heerden, JA, Sheedy, PF. Treatment of pyogenic hepatic abscesses: Surgical vs percutaneous drainage. Arch Surg 1986; 121:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29526/abstract/26\">",
"      Liu CH, Gervais DA, Hahn PF, et al. Percutaneous hepatic abscess drainage: do multiple abscesses or multiloculated abscesses preclude drainage or affect outcome? J Vasc Interv Radiol 2009; 20:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29526/abstract/27\">",
"      Serst&eacute; T, Bourgeois N, Vanden Eynden F, et al. Endoscopic drainage of pyogenic liver abscesses with suspected biliary origin. Am J Gastroenterol 2007; 102:1209.",
"     </a>",
"    </li>",
"    <li>",
"     K C S, Sharma D. Long-term follow-up of pyogenic liver abscess by ultrasound. Eur J Radiol 2009; [Epub ahead of print].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29526/abstract/29\">",
"      Chen YW, Chen YS, Lee SS, et al. A pilot study of oral fleroxacin once daily compared with conventional therapy in patients with pyogenic liver abscess. J Microbiol Immunol Infect 2002; 35:179.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2680 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-B1A854215F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_53_29526=[""].join("\n");
var outline_f28_53_29526=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Microbial cultures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Drainage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2680\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2680|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/28/449\" title=\"diagnostic image 1\">",
"      Liver abscess CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2680|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/21/7517\" title=\"table 1\">",
"      Empiric therapy gram negatives and anaerobes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/21/20826?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of extrapulmonary and miliary tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39577?source=related_link\">",
"      Epidemiology, pathogenesis, clinical manifestations, and diagnosis of melioidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33031?source=related_link\">",
"      Extraintestinal Entamoeba histolytica amebiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10071?source=related_link\">",
"      Hepatosplenic candidiasis (chronic disseminated candidiasis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/41/34456?source=related_link\">",
"      Infections due to the Streptococcus anginosus group",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29176?source=related_link\">",
"      Invasive liver abscess syndrome caused by Klebsiella pneumoniae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/9/41114?source=related_link\">",
"      Nonsurgical therapies for localized hepatocellular carcinoma: Transarterial embolization, radiotherapy, and radioembolization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33254?source=related_link\">",
"      Pylephlebitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_53_29527="Pleural fluid eosinophilia";
var content_f28_53_29527=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pleural fluid eosinophilia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/53/29527/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/53/29527/contributors\">",
"     John T Huggins, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/53/29527/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/53/29527/contributors\">",
"     Steven A Sahn, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/53/29527/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/53/29527/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/53/29527/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/53/29527/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleural fluid eosinophilia (PFE, also called eosinophilic pleural effusion) is defined as pleural fluid with a nucleated cell count containing more than 10 percent eosinophils [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. It is estimated that approximately 10 percent of exudative pleural effusions are eosinophilic [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/2,3,5\">",
"     2,3,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of PFE narrows the differential diagnosis of a pleural effusion. Establishing the cause is dependent upon careful analysis of the clinical presentation and the pleural fluid. The most common cause is air or blood in the pleural space.",
"   </p>",
"   <p>",
"    The pathogenesis, etiology, and evaluation of eosinophilic pleural effusions will be reviewed here. The general analysis of pleural fluid and evaluation of systemic eosinophilia and pulmonary parenchymal eosinophilia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=see_link\">",
"     \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24745?source=see_link\">",
"     \"Approach to the patient with eosinophilia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27688?source=see_link\">",
"     \"Causes of pulmonary eosinophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of PFE requires the recruitment of bone marrow derived eosinophils, since eosinophils are not part of the normal cellular milieu of lung and pleural tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/6\">",
"     6",
"    </a>",
"    ]. The mechanisms that lead to the recruitment of eosinophils to the pleural space have not been clearly elucidated.",
"   </p>",
"   <p>",
"    The time course of the development of pleural fluid and serum eosinophilia in response to air or blood in the pleural space suggests that the specific mechanisms that trigger eosinophil accumulation may vary [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/6\">",
"     6",
"    </a>",
"    ]. PFE develops within hours after a spontaneous pneumothorax compared to 10 to 14 days after the onset of a traumatic or hemorrhagic pleural effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/6\">",
"     6",
"    </a>",
"    ]. In addition, pleural trauma and hemothorax, but not pneumothorax, are often associated with peripheral blood eosinophilia that develops days after PFE.",
"   </p>",
"   <p>",
"    One hypothesis for the development of PFE is that stimulation of pleural mesothelial cells by nonspecific injury (eg, air, blood, or trauma) leads to the production of cytokines, chemokines, and adhesion molecules that orchestrate eosinophil recruitment [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. In general, the recruitment of eosinophils into tissues is dependent upon mediators, such as eotaxins (eotaxin-1 [CCL11], eotaxin-2 [CCL24], and eotaxin-3 [CCL26]), interleukin (IL)-3, IL-5,",
"    <span class=\"nowrap\">",
"     granulocyte/macrophage",
"    </span>",
"    stimulating factor (GM-CSF), and RANTES (Regulated upon Activation, Normal T-cell Expressed and Secreted) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These agents cause eosinophil proliferation and maturation in the bone marrow, migration into the circulation, adhesion to the endothelium, and migration across endothelial barriers into tissue. In addition, there must be an interaction between the endothelial cells and circulating eosinophils for migration of eosinophils into the pleural space. Vascular cell adhesion molecule (VCAM-1) and eosinophil very late activation antigen (VLA-4) mediate this important eosinophil-endothelial cell interaction. Soluble VCAM-1 is significantly increased in eosinophilic pleural effusions compared to noneosinophilic effusions and probably contributes to their pathogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Eosinophil survival in the pleural space is also thought to be mediated by cytokines, such as IL-3, IL-5, and GM-CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Eosinophil apoptosis can be inhibited for up to two weeks when eosinophils are incubated with these cytokines; in contrast, eosinophil apoptosis occurs within two days when these cytokines are absent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spectrum of diseases associated with PFE mirrors that of pleural effusions in general and is strongly affected by the diseases prevalent in the population [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/2,3,16,17\">",
"     2,3,16,17",
"    </a>",
"    ]. Pleural irritation or trauma (eg, hemothorax, pneumothorax, thoracic surgery) and malignancy are common causes, but several other processes need to be considered in the differential diagnosis (",
"    <a class=\"graphic graphic_table graphicRef82213 \" href=\"UTD.htm?12/52/13132\">",
"     table 1",
"    </a>",
"    ). The etiology of PFE cannot be determined after careful evaluation in a minority of patients. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Idiopathic'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    One problem with diagnosis is that PFE is not present in all pleural analyses in patients with the disease. In one study in which 40 patients underwent two thoracenteses, PFE was present in both in 16, only in the first in 10, and only in the second in 14.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pleural trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleural irritation or trauma in the form of pneumothorax, hemothorax, thoracotomy, thoracoscopy, or repeated thoracentesis has been associated with pleural fluid eosinophilia in numerous case reports and case series [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/2,16,18,19\">",
"     2,16,18,19",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Air in the pleural space",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many case series, spontaneous pneumothorax is the most common cause of PFE [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/16,18\">",
"     16,18",
"    </a>",
"    ]. An intense eosinophilic pleuritis occurs within hours after air entry into the pleural space.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Blood in the pleural space",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the rapid development of PFE after spontaneous pneumothorax, PFE is delayed with hemothorax, typically appearing by the tenth day, with plasma eosinophilia occurring days later [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Pleural space hemorrhage may contribute to the development of PFE in the setting of thoracotomy, chest trauma, benign asbestos pleural effusion, and pulmonary infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonspecific pleural effusions that develop within 30 days after cardiac surgery are typically hemorrhagic and often eosinophilic. They are more likely to occur when the pleura has been excised (eg, for internal mammary grafting). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16728?source=see_link&amp;anchor=H2#H2\">",
"     \"Pleural effusions following cardiac surgery\", section on 'Nonspecific pleural effusions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Repeated thoracentesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repeated thoracentesis has been suggested as a cause of PFE, but the available data are conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/16,20,22\">",
"     16,20,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Asbestos",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign asbestos pleural effusions (BAPEs) typically develop in the first two decades following asbestos exposure. Approximately one-third of BAPEs have increased pleural eosinophils, ranging up to 50 percent of the total nucleated cell count [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/23\">",
"     23",
"    </a>",
"    ]. BAPEs resolve spontaneously, usually within four to six weeks, although residual pleural thickening may persist indefinitely. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16472?source=see_link&amp;anchor=H11#H11\">",
"     \"Asbestosis\", section on 'Pleural disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 25 drugs have been implicated in the development of PFE (",
"    <a class=\"graphic graphic_table graphicRef72026 \" href=\"UTD.htm?24/45/25308\">",
"     table 2",
"    </a>",
"    ) and other drugs likely have the potential to cause PFE. Symptoms of drug-induced PFE are nonspecific and include pleuritic chest pain, cough, dyspnea, and occasional fever. Concomitant blood eosinophilia has been described with valproic acid,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"     nitrofurantoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/22/22887?source=see_link\">",
"     dantrolene",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/42/34470?source=see_link\">",
"     gliclazide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/35/12855?source=see_link\">",
"     tizanidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/24-32\">",
"     24-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The latency between the development of PFE from first drug exposure is typically several months, with a range from a few days to one to two years (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"     nitrofurantoin",
"    </a>",
"    ) or even 12 years (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/22/22887?source=see_link\">",
"     dantrolene",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/6,24\">",
"     6,24",
"    </a>",
"    ]. Herbal preparations (eg, kampo) have also been implicated in PFE [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms usually begin to improve within the first few days after drug discontinuation and complete resolution of the pleural effusion occurs over several months [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/24\">",
"     24",
"    </a>",
"    ]. Treatment with oral glucocorticoids has been reported to speed resolution in a few cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/32,34,35\">",
"     32,34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections caused by bacteria, fungi, mycobacteria, parasites, and viruses can result in PFE [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/3,16,36-49\">",
"     3,16,36-49",
"    </a>",
"    ]. Eosinophils appear late in the course of a parapneumonic effusion, usually three weeks or more, and often after resolution of the pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/36,50\">",
"     36,50",
"    </a>",
"    ]. An eosinophilic parapneumonic effusion is unlikely to progress to empyema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28089?source=see_link\">",
"     \"Parapneumonic effusion and empyema in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The development of PFE in the setting of tuberculosis is now considered rare. However, older reports from populations with an increased prevalence of tuberculosis found that tuberculosis was responsible for up to 40 percent of PFEs [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12856?source=see_link\">",
"     \"Tuberculous pleural effusions in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Paragonimiasis is the most common parasite associated with PFE and is endemic to southeast Asia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. The pleural fluid characteristics of Paragonimus infection are low pH (&lt;7.10) and glucose less than 60",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.3",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    Cytological examination of the pleural fluid may reveal the parasite. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36967?source=see_link\">",
"     \"Paragonimiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other parasitic infections associated with PFE include sparganosis, toxocariasis, cutaneous myiasis, loiasis, lymphatic filariasis, amebiasis, ascariasis, strongyloidiasis, echinococcosis, and dracunculiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/42-48\">",
"     42-48",
"    </a>",
"    ]. These are discussed further in the appropriate topic reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported frequency of pleural malignancy in patients with PFE ranges from 6 to 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/2,3,16,51\">",
"     2,3,16,51",
"    </a>",
"    ]. This variability appears to be related to the prevalence of malignancy in the population studied [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/2\">",
"     2",
"    </a>",
"    ]. Among the malignancies associated with PFE, lung cancer is the most common [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/3,16\">",
"     3,16",
"    </a>",
"    ]. In a review of 153 pleural fluid samples demonstrating PFE, 47 were associated with malignancy and of these 23 were lung cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The likelihood of pleural malignancy appears to be inversely related to the percentage of eosinophils in the pleural space [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/16,17\">",
"     16,17",
"    </a>",
"    ] but there is no absolute eosinophil percentage that would exclude malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/3,17\">",
"     3,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further investigations, such as thoracic computed tomography and pleural biopsy, either closed or thoracoscopic, should be pursued when pleural fluid cytology is negative but the patient has risk factors for underlying malignancy (eg, heavy smoking for many years) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pulmonary embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleural effusion accompanies pulmonary embolism in 30 to 50 percent of cases, and 18 percent of these effusions are eosinophilic [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/4,52,53\">",
"     4,52,53",
"    </a>",
"    ]. These effusions are typically small (less than one-third of the hemithorax), unilateral exudates. One half to two-thirds are bloody, due to associated pulmonary infarction. Pleuritic chest pain is typically present in the setting of pulmonary embolism with effusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=see_link\">",
"     \"Diagnosis of acute pulmonary embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Rare causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleural fluid eosinophilia (PFE) has rarely been reported in association with chronic eosinophilic pneumonia, rheumatoid pleural effusion, and Churg-Strauss syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/14,54\">",
"     14,54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20581?source=see_link\">",
"     \"Treatment of chronic eosinophilic pneumonia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26969?source=see_link\">",
"     \"Overview of lung disease associated with rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21383?source=see_link\">",
"     \"Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Idiopathic",
"    </span>",
"    &nbsp;&mdash;&nbsp;PFE is idiopathic in 8 to 35 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/2,4,15-18,39,55,56\">",
"     2,4,15-18,39,55,56",
"    </a>",
"    ]. The typical patient with idiopathic PFE is a middle-aged man with a small to moderate-sized unilateral pleural effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/15\">",
"     15",
"    </a>",
"    ]. The prognosis is excellent in these patients, even when the effusion persists for months. At least some of these cases may be due to unidentified asbestos exposure, occult pulmonary embolism, viral infection, or a medication.",
"   </p>",
"   <p>",
"    Patients with idiopathic PFE, a diagnosis of exclusion, should be monitored until the effusion resolves or a known cause becomes apparent.",
"   </p>",
"   <p>",
"    The approach to a patient with a pleural effusion of undetermined etiology is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2632?source=see_link\">",
"     \"Diagnostic evaluation of pleural effusion in adults: Additional tests for undetermined etiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, the evaluation of pleural fluid eosinophilia (PFE) follows the evaluation protocol for pleural effusions. However, certain clinical features may help to determine the etiology. The routine evaluation of pleural effusions is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=see_link\">",
"     \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2632?source=see_link\">",
"     \"Diagnostic evaluation of pleural effusion in adults: Additional tests for undetermined etiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historical information that may help to identify the etiology of PFE include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      List of medications, dietary supplements (eg, L-tryptophan), herbal preparations, and vitamins (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Drugs'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      History of exposure to asbestos (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Asbestos'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Risk factors for lung cancer or history of malignancy (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Malignancy'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Signs of infection (eg, fever, sweats, or chills) or travel or residence in endemic areas of fungi (eg, Coccidioides), tuberculosis, or parasites (eg, Paragonimus, Strongyloides, Dracuncula) (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Infections'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical examination findings are generally nonspecific, but evidence suggesting pleural trauma or skin lesions suggestive of a fungus should be sought. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Pleural trauma'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Laboratory analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory analysis of peripheral blood is usually nonspecific in patients with PFE, since there is only a weak correlation between the eosinophil percentages in the peripheral blood and pleural fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/16\">",
"     16",
"    </a>",
"    ]. Serologic studies for antibodies to fungi and parasites (eg, Coccidioides, Echinococcus, Schistosoma, Strongyloides, Trichinella spiralis, Wuchereria bancrofti) may be helpful in patients with a history of travel to or residence in endemic areas.",
"   </p>",
"   <p>",
"    In patients with other features to suggest rheumatoid arthritis or Churg-Strauss syndrome, measurement of cyclic citrullinated peptide or antineutrophil cytoplasmic antibody (ANCA) titers may be helpful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26969?source=see_link\">",
"     \"Overview of lung disease associated with rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21383?source=see_link\">",
"     \"Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Pleural fluid analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleural fluid eosinophilia (PFE) is defined as pleural fluid with a nucleated cell count containing more than 10 percent eosinophils [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The specific percentage of eosinophils in pleural fluid does NOT help differentiate between the different causes of PFE. The likelihood of pleural malignancy appears to be inversely related to the percentage of eosinophils in the pleural space [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/16\">",
"     16",
"    </a>",
"    ] but there is no absolute eosinophil percentage that would exclude malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29527/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Determination of whether the fluid is an exudate or transudate is helpful. A list of transudative and exudative causes of PFE is provided in the table (",
"    <a class=\"graphic graphic_table graphicRef82213 \" href=\"UTD.htm?12/52/13132\">",
"     table 1",
"    </a>",
"    ). The differentiation of transudates and exudates is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=see_link\">",
"     \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pleural fluid cultures for bacteria, fungi, and mycobacteria should be performed. Cytological analysis should include examination for malignant cells, parasites, and granuloma constituents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Undetermined etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the etiology of a pleural effusion with eosinophilia remains undetermined after the above studies, further evaluation will typically include computed tomographic scanning and pleural biopsy. These tests are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2632?source=see_link\">",
"     \"Diagnostic evaluation of pleural effusion in adults: Additional tests for undetermined etiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/59/42933?source=see_link\">",
"     \"Indications for diagnostic thoracoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After a comprehensive evaluation, a minority of patients have no apparent cause and are considered to have idiopathic PFE. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Idiopathic'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     TREATMENT AND MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of PFE varies with the cause and is discussed on the appropriate topic reviews. Patients with idiopathic PFE, a diagnosis of exclusion, should be monitored until the effusion resolves or a known cause becomes apparent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pleural fluid eosinophilia (PFE) is defined as pleural fluid with a nucleated cell count containing greater than 10 percent eosinophils. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lung and pleural tissue do NOT harbor eosinophils as part of the normal cellular milieu. As a result, the development of PFE requires the recruitment of bone marrow derived eosinophils. Nonspecific injury (eg, air, blood, or trauma) may stimulate pleural mesothelial cells and lead to production of the cytokines, chemokines, and adhesion molecules that orchestrate eosinophil recruitment. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common causes of PFE are pneumothorax, hemothorax, malignancy, and infection. Less common causes include drugs, asbestos, pulmonary thromboembolism, chronic eosinophilic pneumonia, Churg-Strauss syndrome, and rheumatoid pleuritis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately 25 drugs have been implicated in the development of PFE (",
"      <a class=\"graphic graphic_table graphicRef72026 \" href=\"UTD.htm?24/45/25308\">",
"       table 2",
"      </a>",
"      ). Concomitant peripheral blood eosinophilia is sometimes present. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PFE is idiopathic in 8 to 35 percent of patients. Patients with idiopathic PFE, a diagnosis of exclusion, should be monitored until the effusion resolves or a known cause becomes apparent. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Idiopathic'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bacterial (including parapneumonic effusions), fungal, mycobacterial, parasitic, and viral infections can result in PFE. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The frequency of pleural malignancy in PFE is variable and ranges between 6 to 40 percent, depending on the prevalence of malignancy in the population studied. Among malignancies, lung cancer is the most common. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Malignancy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/1\">",
"      Hirsch A, Ruffie P, Nebut M, et al. Pleural effusion: laboratory tests in 300 cases. Thorax 1979; 34:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/2\">",
"      Rubins JB, Rubins HB. Etiology and prognostic significance of eosinophilic pleural effusions. A prospective study. Chest 1996; 110:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/3\">",
"      Mart&iacute;nez-Garc&iacute;a MA, Cases-Viedma E, Cordero-Rodr&iacute;guez PJ, et al. Diagnostic utility of eosinophils in the pleural fluid. Eur Respir J 2000; 15:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/4\">",
"      Kalomenidis I, Light RW. Eosinophilic pleural effusions. Curr Opin Pulm Med 2003; 9:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/5\">",
"      Nash DR, Wallace RJ Jr. Immunoglobulin E and other immunoglobulins in patients with eosinophilic pleural effusions. J Lab Clin Med 1985; 106:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/6\">",
"      Heidecker J, Kaplan A, Sahn SA. Pleural fluid and peripheral eosinophilia from hemothorax: hypothesis of the pathogenesis of EPE in hemothorax and pneumothorax. Am J Med Sci 2006; 332:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/7\">",
"      Katayama H, Yokoyama A, Kohno N, et al. Production of eosinophilic chemokines by normal pleural mesothelial cells. Am J Respir Cell Mol Biol 2002; 26:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/8\">",
"      Georas SN, Beck LA, Stellato C. What is eotaxin doing in the pleura? Insights into innate immunity from pleural mesothelial cells. Am J Respir Cell Mol Biol 2002; 26:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/9\">",
"      Kariyawasam HH, Robinson DS. The eosinophil: the cell and its weapons, the cytokines, its locations. Semin Respir Crit Care Med 2006; 27:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/10\">",
"      De Smedt A, Vanderlinden E, Demanet C, et al. Characterisation of pleural inflammation occurring after primary spontaneous pneumothorax. Eur Respir J 2004; 23:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/11\">",
"      Kalomenidis I, Stathopoulos GT, Barnette R, et al. Eotaxin-3 and interleukin-5 pleural fluid levels are associated with pleural fluid eosinophilia in post-coronary artery bypass grafting pleural effusions. Chest 2005; 127:2094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/12\">",
"      Rothenberg ME, Ownbey R, Mehlhop PD, et al. Eotaxin triggers eosinophil-selective chemotaxis and calcium flux via a distinct receptor and induces pulmonary eosinophilia in the presence of interleukin 5 in mice. Mol Med 1996; 2:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/13\">",
"      Kalomenidis I, Mohamed KH, Lane KB, et al. Pleural fluid levels of vascular cell adhesion molecule-1 are elevated in eosinophilic pleural effusions. Chest 2003; 124:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/14\">",
"      Nakamura Y, Ozaki T, Kamei T, et al. Factors that stimulate the proliferation and survival of eosinophils in eosinophilic pleural effusion: relationship to granulocyte/macrophage colony-stimulating factor, interleukin-5, and interleukin-3. Am J Respir Cell Mol Biol 1993; 8:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/15\">",
"      Kalomenidis I, Light RW. Pathogenesis of the eosinophilic pleural effusions. Curr Opin Pulm Med 2004; 10:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/16\">",
"      Krenke R, Nasilowski J, Korczynski P, et al. Incidence and aetiology of eosinophilic pleural effusion. Eur Respir J 2009; 34:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/17\">",
"      Oba Y, Abu-Salah T. The prevalence and diagnostic significance of eosinophilic pleural effusions: a meta-analysis and systematic review. Respiration 2012; 83:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/18\">",
"      Adelman M, Albelda SM, Gottlieb J, Haponik EF. Diagnostic utility of pleural fluid eosinophilia. Am J Med 1984; 77:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/19\">",
"      Wysenbeek AJ, Lahav M, Aelion JA, Kaufmann L. Eosinophilic pleural effusion: a review of 36 cases. Respiration 1985; 48:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/20\">",
"      Mart&iacute;nez Garc&iacute;a MA, Cases Viedma E, Perpi&ntilde;&aacute; Tordera M, Sanchis-Ald&aacute;s JL. Repeated thoracentesis: an important risk factor for eosinophilic pleural effusion? Respiration 2003; 70:82.",
"     </a>",
"    </li>",
"    <li>",
"     Spriggs AI, Boddington NM. The Cytology of Pleural Effusions, 2d ed, Grune and Stratton, New York 1968.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/22\">",
"      Chung CL, Chen YC, Chang SC. Effect of repeated thoracenteses on fluid characteristics, cytokines, and fibrinolytic activity in malignant pleural effusion. Chest 2003; 123:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/23\">",
"      Epler GR, McLoud TC, Gaensler EA. Prevalence and incidence of benign asbestos pleural effusion in a working population. JAMA 1982; 247:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/24\">",
"      Huggins JT, Sahn SA. Drug-induced pleural disease. Clin Chest Med 2004; 25:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/25\">",
"      Behnia M, Dowdeswell I, Vakili S. Pleural fluid and serum eosinophilia: association with fluoxetine hydrochloride. South Med J 2000; 93:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/26\">",
"      Kuwahara T, Hamada M, Inoue Y, et al. Warfarin-induced eosinophilic pleurisy. Intern Med 1995; 34:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/27\">",
"      Kaufman J, O'Shaughnessy IM. Eosinophilic pleural effusion associated with valproic acid administration. South Med J 1995; 88:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/28\">",
"      Bunker CB, Sheron N, Maurice PD, et al. Isotretinoin and eosinophilic pleural effusion. Lancet 1989; 1:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/29\">",
"      Yoshida H, Hasegawa R, Hayashi H, Irie Y. Imidapril-induced eosinophilic pleurisy. Case report and review of the literature. Respiration 2005; 72:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/30\">",
"      Gujral N, Friedenberg F, Friedenberg J, et al. Pleuropericarditis related to the use of mesalamine. Dig Dis Sci 1996; 41:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/31\">",
"      Middleton KL, Santella R, Couser JI Jr. Eosinophilic pleuritis due to propylthiouracil. Chest 1993; 103:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/32\">",
"      Strong DH, Westcott JY, Biller JA, et al. Eosinophilic \"empyema\" associated with crack cocaine use. Thorax 2003; 58:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/33\">",
"      Yamawaki I, Katsura H, Taira M, et al. [Six patients with pneumonitis related to blended Chinese traditional medicines]. Nihon Kyobu Shikkan Gakkai Zasshi 1996; 34:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/34\">",
"      Sen N, Ermis H, Karatasli M, et al. Propylthiouracil-associated eosinophilic pleural effusion: a case report. Respiration 2007; 74:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/35\">",
"      Felz MW, Haviland-Foley DJ. Eosinophilic pleural effusion due to dantrolene: resolution with steroid therapy. South Med J 2001; 94:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/36\">",
"      Murphy PP, Richardson SG. Q fever pneumonia presenting as an eosinophilic pleural effusion. Thorax 1989; 44:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/37\">",
"      Poppius H, Kokkola K. Diagnosis and differential diagnosis in tuberculous pleurisy. Scand J Respir Dis Suppl 1968; 63:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/38\">",
"      Kokkola K, Valta R. Aetiology and findings in eosinophilic pleural effusion. Scand J Respir Dis Suppl 1974; 89:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/39\">",
"      Kamel A, Chabbou A, el Gharbi B. [Eosinophilic pleural effusion]. Rev Pneumol Clin 1989; 45:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/40\">",
"      Merchant M, Romero AO, Libke RD, Joseph J. Pleural effusion in hospitalized patients with Coccidioidomycosis. Respir Med 2008; 102:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/41\">",
"      Johnson JR, Falk A, Iber C, Davies S. Paragonimiasis in the United States. A report of nine cases in Hmong immigrants. Chest 1982; 82:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/42\">",
"      Johnson RJ, Johnson JR. Paragonimiasis in Indochinese refugees. Roentgenographic findings with clinical correlations. Am Rev Respir Dis 1983; 128:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/43\">",
"      Klion AD, Eisenstein EM, Smirniotopoulos TT, et al. Pulmonary involvement in loiasis. Am Rev Respir Dis 1992; 145:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/44\">",
"      Ishii H, Mukae H, Inoue Y, et al. A rare case of eosinophilic pleuritis due to sparganosis. Intern Med 2001; 40:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/45\">",
"      Emad A. Exudative eosinophilic pleural effusion due to Strongyloides stercoralis in a diabetic man. South Med J 1999; 92:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/46\">",
"      Jacobson ES. A case of secondary echinococcosis diagnosed by cytologic examination of pleural fluid and needle biopsy of pleura. Acta Cytol 1973; 17:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/47\">",
"      Gupta K, Sehgal A, Puri MM, Sidhwa HK. Microfilariae in association with other diseases. A report of six cases. Acta Cytol 2002; 46:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/48\">",
"      Gentilini M, Carme B, Smith M, et al. A case of eosinophilic pleurisy due to Dracunculus medinensis infection. Trans R Soc Trop Med Hyg 1978; 72:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/49\">",
"      Crum NF, Lederman ER, Stafford CM, et al. Coccidioidomycosis: a descriptive survey of a reemerging disease. Clinical characteristics and current controversies. Medicine (Baltimore) 2004; 83:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/50\">",
"      MacMURRAY FG, KATZ S, ZIMMERMAN HJ. Pleural-fluid eosinophilia. N Engl J Med 1950; 243:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/51\">",
"      Kuhn M, Fitting JW, Leuenberger P. Probability of malignancy in pleural fluid eosinophilia. Chest 1989; 96:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/52\">",
"      Bynum LJ, Wilson JE 3rd. Characteristics of pleural effusions associated with pulmonary embolism. Arch Intern Med 1976; 136:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/53\">",
"      Romero Candeira S, Hern&aacute;ndez Blasco L, Soler MJ, et al. Biochemical and cytologic characteristics of pleural effusions secondary to pulmonary embolism. Chest 2002; 121:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/54\">",
"      Boyer D, Vargas SO, Slattery D, et al. Churg-Strauss syndrome in children: a clinical and pathologic review. Pediatrics 2006; 118:e914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/55\">",
"      Bower G. Eosinophilic pleural effusion. A condition with multiple causes. Am Rev Respir Dis 1967; 95:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29527/abstract/56\">",
"      Veress JF, Koss LG, Schreiber K. Eosinophilic pleural effusions. Acta Cytol 1979; 23:40.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6704 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-217.16.9.173-E29AE5AA73-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_53_29527=[""].join("\n");
var outline_f28_53_29527=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pleural trauma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Air in the pleural space",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Blood in the pleural space",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Repeated thoracentesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Asbestos",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Rare causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Idiopathic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Laboratory analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Pleural fluid analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Undetermined etiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      TREATMENT AND MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/6704\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/6704|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/52/13132\" title=\"table 1\">",
"      Causes pleural eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/45/25308\" title=\"table 2\">",
"      Drug pleural eosinophilia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24745?source=related_link\">",
"      Approach to the patient with eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16472?source=related_link\">",
"      Asbestosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27688?source=related_link\">",
"      Causes of pulmonary eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=related_link\">",
"      Diagnostic evaluation of a pleural effusion in adults: Initial testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2632?source=related_link\">",
"      Diagnostic evaluation of pleural effusion in adults: Additional tests for undetermined etiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21383?source=related_link\">",
"      Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/59/42933?source=related_link\">",
"      Indications for diagnostic thoracoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26969?source=related_link\">",
"      Overview of lung disease associated with rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36967?source=related_link\">",
"      Paragonimiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28089?source=related_link\">",
"      Parapneumonic effusion and empyema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16728?source=related_link\">",
"      Pleural effusions following cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20581?source=related_link\">",
"      Treatment of chronic eosinophilic pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12856?source=related_link\">",
"      Tuberculous pleural effusions in HIV-negative patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_53_29528="Systemic treatment for metastatic breast cancer: Single agent chemotherapy";
var content_f28_53_29528=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Systemic treatment for metastatic breast cancer: Single agent chemotherapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/53/29528/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/53/29528/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/53/29528/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/53/29528/contributors\">",
"     Julie R Gralow, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/53/29528/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/53/29528/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/53/29528/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although metastatic breast cancer is unlikely to be cured, meaningful improvements in survival have been seen, coincident with the introduction of newer systemic therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29528/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Median overall survival approaches two years, with a range from a few months to many years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29528/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The selection of a therapeutic strategy depends upon both tumor biology and clinical factors, with the goal being a tailored approach. Although a subset of patients with oligometastatic disease may benefit from an intensified locoregional approach, most patients with metastatic breast cancer receive systemic medical therapy, consisting of chemotherapy, endocrine therapy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    biologic therapies, and supportive care measures [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29528/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy and dosing of single agent chemotherapy is presented here. General principles of management of metastatic breast cancer, selection of chemotherapy regimen, and use of combination chemotherapy, biologics therapies, endocrine therapy, surgical options, and supportive care are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7354?source=see_link\">",
"       \"Systemic treatment for metastatic breast cancer: General principles\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/20/32072?source=see_link\">",
"       \"Systemic treatment for metastatic breast cancer: Selection of chemotherapy regimen\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/27/11705?source=see_link\">",
"       \"Systemic treatment for metastatic breast cancer: Combination chemotherapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22202?source=see_link\">",
"       \"Systemic treatment for metastatic breast cancer: Molecular targeted therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/55/21370?source=see_link\">",
"       \"Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35831?source=see_link\">",
"       \"Metastatic breast cancer: Local treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40903?source=see_link\">",
"       \"Treatment of metastatic breast cancer in older women\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89090483\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment principles for the use of chemotherapy in metastatic breast cancer are outlined here.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment gains in disease response and survival must be balanced with effects on quality of life and tolerability.",
"     </li>",
"     <li>",
"      Chemotherapy is indicated for patients with hormone-insensitive metastatic breast cancer (ie, patients with hormone-receptor-negative breast cancer and those with hormone receptor-positive breast cancer who have become resistant to endocrine therapy) or for those with hormone receptor-positive breast cancer and an aggressive phenotype (ie, visceral crisis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a short disease-free interval).",
"     </li>",
"     <li>",
"      Human epidermal growth factor receptor 2 (HER2)-directed therapy has demonstrated improved survival for patients with tumors that overexpress HER2 and thus should be part of first-line therapy for these patients.",
"     </li>",
"     <li>",
"      Chemotherapy can be given singly or in combination. Without an appreciable survival advantage with combination chemotherapy, sequential therapy with single agents is often preferred. Toxicity is less with single agent therapy and quality of life appears better. However, combination therapy may be a more appropriate first-line choice for symptomatic patients or those with rapidly progressive visceral metastases because of the greater likelihood of an objective response.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The aims and indications for systemic therapy, including chemotherapy, endocrine therapy, and biologic (molecularly targeted) therapy and general principles in selecting systemic treatment for metastatic breast cancer, are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7354?source=see_link\">",
"     \"Systemic treatment for metastatic breast cancer: General principles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H780566854\">",
"    <span class=\"h1\">",
"     ACTIVE CHEMOTHERAPY AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many conventional chemotherapy agents have activity in metastatic breast cancer, but anthracyclines and taxanes are the most active. The selection of chemotherapy, including choice of regimen, timing, and sequencing, are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/20/32072?source=see_link\">",
"     \"Systemic treatment for metastatic breast cancer: Selection of chemotherapy regimen\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Response rates to single agent chemotherapy generally range from 20 to 50 percent and typically last 2 to 6 months, depending upon whether the drug is tested in the first-line setting or in heavily pretreated patients and whether patients were previously exposed to anthracyclines",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    taxanes. Single agents dosed sequentially may have lower response rates, but also lower toxicity, and no loss in survival (median survival 10 to 20 months).",
"   </p>",
"   <p>",
"    Some active single agents are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29528/abstract/7\">",
"     7",
"    </a>",
"    ]. Preferred agents are discussed in detail below.",
"   </p>",
"   <p>",
"    <strong>",
"     Anthracyclines",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       Doxorubicin",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"       Epirubicin",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"       Pegylated liposomal doxorubicin",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"       Mitoxantrone",
"      </a>",
"      (anthracenedione)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Taxanes",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       Paclitaxel",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       Docetaxel",
"      </a>",
"     </li>",
"     <li>",
"      Albumin-bound",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Anti-metabolites",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       Capecitabine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       Gemcitabine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/27/36279?source=see_link\">",
"       Pemetrexed",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29528/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Other microtubule inhibitors",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/42/28325?source=see_link\">",
"       Eribulin",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10423?source=see_link\">",
"       Ixabepilone",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/59/953?source=see_link\">",
"       Vinorelbine",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Other single agents",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       Cyclophosphamide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29528/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       Cisplatin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29528/abstract/11\">",
"       11",
"      </a>",
"      ] &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Biologic therapy",
"    </strong>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22202?source=see_link\">",
"     \"Systemic treatment for metastatic breast cancer: Molecular targeted therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       Trastuzumab",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"       Lapatinib",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84534185\">",
"    <span class=\"h2\">",
"     Anthracyclines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anthracyclines have objective response rates as a single-agent of 35 to 50 percent in women who are anthracycline-naive or who develop metastases more than 12 months after anthracycline-based adjuvant therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29528/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Response rates in women with an anthracycline-free interval of less than 12 months or when administered as second-line therapy are lower [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29528/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"     Mitoxantrone",
"    </a>",
"    may be slightly less effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    , but is associated with less nausea, vomiting, alopecia, and myelosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29528/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Common dosing schedules for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    are doxorubicin (60 to 75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three weeks or 20",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly) and epirubicin (75 to 100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three weeks or 20 to 30",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly). Patients relapsing more than 12 months after anthracycline-based treatment may be reinduced with anthracycline-based chemotherapy up to cumulative doses of doxorubicin (450 to 550",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    and epirubicin (800 to 1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29528/abstract/6,18\">",
"     6,18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both liposome-encapsulated and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"     pegylated liposomal doxorubicin",
"    </a>",
"    have demonstrated comparable efficacy to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , but with reduced cardiotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29528/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. In one trial, pegylated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"     liposomal doxorubicin",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every four weeks) compared to doxorubicin (60",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    showed equivalent progression-free survival (6.9 versus 7.8 months) and overall survival (21 versus 22 months) but with a significantly lower risk of cardiotoxicity (hazard ratio, HR=3.16; 95%CI 1.58-6.31) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29528/abstract/20\">",
"     20",
"    </a>",
"    ]. Pegylated liposomal doxorubicin also induced less alopecia (20 versus 66 percent), nausea (37 versus 53 percent), vomiting (19 versus 31 percent), and neutropenia (4 versus 10 percent), but more often caused plantar-plantar erythrodysesthesia (48 versus 2 percent), stomatitis (22 versus 15 percent), and mucositis (23 versus 13 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84529057\">",
"    <span class=\"h2\">",
"     Taxanes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The taxanes,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    , and nanoparticle albumin-bound paclitaxel (nab-paclitaxel), all have significant activity in metastatic breast cancer.",
"   </p>",
"   <p>",
"    Single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    is active in both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    -naive and doxorubicin-refractory metastatic breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29528/abstract/12,14\">",
"     12,14",
"    </a>",
"    ]. Weekly dosing of paclitaxel (80 to 100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    was shown in a meta-analysis to have an overall survival advantage over every three-week therapy (175",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29528/abstract/22\">",
"     22",
"    </a>",
"    ]. However, grade 3 neuropathy is worse with weekly dosing (24 versus 12 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29528/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, no overall survival difference was noted for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    weekly (30 to 40",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    versus every three week docetaxel (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    schedules [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29528/abstract/22\">",
"     22",
"    </a>",
"    ]. In the adjuvant setting, every three week docetaxel showed superior disease free survival compared to weekly docetaxel [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29528/abstract/24\">",
"     24",
"    </a>",
"    ]. The incidence of nail changes and epiphora (overflow of tears) are significantly lower with every three week docetaxel [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29528/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    was compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    (three-weekly) in a trial of 449 women with advanced breast cancer that had progressed after an anthracycline-containing chemotherapy regimen, docetaxel produced a modest but significantly better median time to progression (5.7 versus 3.6 months) and overall survival (15.4 versus 12.7 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29528/abstract/25\">",
"     25",
"    </a>",
"    ]. Both hematologic and nonhematologic toxicity were worse with docetaxel. Docetaxel has not been compared with weekly paclitaxel, which as discussed above, has a survival advantage over every three week dosing.",
"   </p>",
"   <p>",
"    There is some evidence that there is a partial but not complete cross-resistance between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    , since modest responses are seen in patients pretreated with the alternate taxane [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29528/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. However, using one taxane after progression on the other may be best reserved for patients who relapse greater than 12 months after taxane-containing adjuvant therapy or who had a previous clinical response to a taxane.",
"   </p>",
"   <p>",
"    Nanoparticle albumin-bound",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    (nab-paclitaxel) is a Cremophor-free paclitaxel formulation designed to improve tumor cell penetration and reduce the toxicity associated with Cremophor use [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29528/abstract/29\">",
"     29",
"    </a>",
"    ]. Nab-paclitaxel is approved in the United States for the treatment of metastatic breast cancer as a single agent. Although it has several advantages over paclitaxel and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    , it is also significantly more costly; it has not been compared to weekly paclitaxel.",
"   </p>",
"   <p>",
"    Both weekly (100 to 150",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    and every three-weekly (300",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    nab-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    produce objective response rates of 20 to 60 percent in metastatic breast cancer, even in otherwise taxane-refractory disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29528/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. When compared to both three-weekly paclitaxel and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    , nab-paclitaxel demonstrated better response rates and progression-free survival [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29528/abstract/31,33\">",
"     31,33",
"    </a>",
"    ]. While neuropathy was generally similar, nab-paclitaxel did not cause allergic reaction and had lower rates of neutropenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89090299\">",
"    <span class=\"h2\">",
"     Taxanes versus anthracyclines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of first-line single agent taxanes versus anthracyclines has been compared in randomized trials, with conflicting outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29528/abstract/12,14,34\">",
"     12,14,34",
"    </a>",
"    ]. When the individual patient data was combined in a meta-analysis, there was no significant survival advantage to taxanes over anthracyclines (median overall survival 19.5 versus 18.6 months, HR 1.01, 95% CI 0.88-1.16) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29528/abstract/35\">",
"     35",
"    </a>",
"    ]. There was a moderate benefit of anthracyclines over taxanes seen in response rates (38 versus 33 percent) and progression-free survival (median 5.1 versus 7.2 months). There was considerable heterogeneity between the trials, and the trials clearly differed in taxane used, dose, cross-over rates, and prior exposure to endocrine therapy. While patients may have had previous anthracycline exposure, they did not have previous taxane exposure. In addition, as discussed above, weekly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    , which was not evaluated in these trials, has shown superiority to every three week dosing.",
"   </p>",
"   <p>",
"    Since it is not clear whether single agent anthracycline or taxane is superior as first-line chemotherapy, the selection of one over the other is based upon prior chemotherapy exposure and weighing the different toxicity profiles. Single agent anthracycline may be chosen as first-line therapy for a patient who is anthracycline-naive or who develops metastatic disease more than 12 months after anthracycline-based adjuvant therapy. In contrast, a taxane may be preferred for patients who have an anthracycline-free interval of less than 12 months. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84534376\">",
"    <span class=\"h2\">",
"     Capecitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     Capecitabine",
"    </a>",
"    (1250",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily for 14 days followed by seven days of rest) has yielded objective response rates around 30 percent as first-line chemotherapy and in taxane-pretreated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29528/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. However, lower dose capecitabine (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily) has a superior therapeutic index and may have comparable efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29528/abstract/39-41\">",
"     39-41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84534413\">",
"    <span class=\"h2\">",
"     Gemcitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     Gemcitabine",
"    </a>",
"    (commonly 1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    days 1 and 8 of a 21-day cycle) is well tolerated and active in metastatic breast cancer, though when compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    as first-line chemotherapy, resulted in a significantly shorter time to progressive disease and a lower overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29528/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. Thrombocytopenia can be a dose-limiting toxicity, especially in heavily pretreated patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84534819\">",
"    <span class=\"h2\">",
"     Vinorelbine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/59/953?source=see_link\">",
"     Vinorelbine",
"    </a>",
"    (30",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    days 1 and 8 every 21 days) causes little nausea, vomiting, and hair loss, and is active as a single agent (objective response rates 25 to 45 percent), even in heavily pretreated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29528/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. It is a particularly attractive option for treatment of older women who have significant comorbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29528/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40903?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of metastatic breast cancer in older women\", section on 'Vinorelbine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84535101\">",
"    <span class=\"h2\">",
"     Etoposide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily for 21 days every 28 days) has shown an objective response rate of 30 percent in pretreated patients, but may produce hematologic and gastrointestinal toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29528/abstract/49-51\">",
"     49-51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H347515949\">",
"    <span class=\"h2\">",
"     Ixabepilone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10423?source=see_link\">",
"     Ixabepilone",
"    </a>",
"    is an epothilone, a class of non-taxane tubulin polymerizing agents, that has activity in taxane-resistant patients.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10423?source=see_link\">",
"     Ixabepilone",
"    </a>",
"    monotherapy (40",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every 21 days) was administered to 126 women with metastatic breast cancer previously treated with an anthracycline, a taxane, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29528/abstract/52\">",
"     52",
"    </a>",
"    ]. The objective response rate was 19 percent, with median response duration and overall survival of 5.7 and 8.6 months, respectively. Grade 3 and 4 peripheral sensory neuropathy occurred in 14 percent of patients.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10423?source=see_link\">",
"     Ixabepilone",
"    </a>",
"    is approved by the United States Food and Drug Administration (FDA) as monotherapy in patients whose tumors are resistant to anthracyclines, taxanes, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    and in combination with capecitabine. It was refused marketing authorization by the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) in 2008 due to its marginal benefit with significant peripheral neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29528/abstract/53\">",
"     53",
"    </a>",
"    ]. Alternate dosing schedules have also been investigated [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29528/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/27/11705?source=see_link&amp;anchor=H175493247#H175493247\">",
"     \"Systemic treatment for metastatic breast cancer: Combination chemotherapy\", section on 'Ixabepilone and capecitabine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H178125\">",
"    <span class=\"h2\">",
"     Eribulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/42/28325?source=see_link\">",
"     Eribulin",
"    </a>",
"    mesylate, a synthetic analogue of halichondrin B, a substance derived from a marine sponge, inhibits the polymerization of tubulin and microtubules. Phase II studies observed a significant level of activity in heavily pretreated patients with advanced breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29528/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the phase III EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) trial, 762 heavily pretreated patients were randomly assigned to either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/42/28325?source=see_link\">",
"     eribulin",
"    </a>",
"    (1.4",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    days 1 and 8 every 21 days) or other chemotherapy of the physician&rsquo;s and patient&rsquo;s choice [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29528/abstract/58\">",
"     58",
"    </a>",
"    ]. Treatment with eribulin compared to alternative therapy significantly improved median overall survival (the primary endpoint, 13.1 versus 10.6 months). The primary toxicity with eribulin was neutropenia, with grade 3 and 4 neutropenia in 45 percent of patients, and grade 3 and 4 febrile neutropenia in 5 percent. Peripheral neuropathy was the most common adverse event leading to discontinuation of eribulin, occurring in 5 percent of patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43530?source=see_link&amp;anchor=H30392699#H30392699\">",
"     \"Neurologic complications of non-platinum cancer chemotherapy\", section on 'Eribulin'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    In November 2010, the United States FDA approved",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/42/28325?source=see_link\">",
"     eribulin",
"    </a>",
"    for treatment of metastatic breast cancer patients who have previously received an anthracycline and taxane in the adjuvant or metastatic setting, and at least two prior metastatic chemotherapy regimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2386471\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy for metastatic breast cancer can be given as single agents or in combination.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Single agents dosed sequentially may have lower response rates but also have lower toxicity and no loss in survival when compared to combination chemotherapy. Specific chemotherapy recommendations in metastatic breast cancer are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/20/32072?source=see_link\">",
"       \"Systemic treatment for metastatic breast cancer: Selection of chemotherapy regimen\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Many conventional chemotherapy agents have single agent activity in metastatic breast cancer, with response rates ranging from 20 to 50 percent and response duration of two to six months.",
"     </li>",
"     <li>",
"      Among the most active agents are anthracyclines and taxanes, but their use is limited by prior exposure. (See",
"      <a class=\"local\" href=\"#H84534185\">",
"       'Anthracyclines'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H84529057\">",
"       'Taxanes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Common dosing schedules for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"       epirubicin",
"      </a>",
"      are doxorubicin (60 to 75",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      every three weeks or 20",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      weekly) and epirubicin (75 to 100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      every three weeks or 20 to 30",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      weekly).",
"     </li>",
"     <li>",
"      Both liposome-encapsulated and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"       pegylated liposomal doxorubicin",
"      </a>",
"      have demonstrated comparable efficacy to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , but with reduced cardiotoxicity.",
"     </li>",
"     <li>",
"      Weekly dosing of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      (80 to 100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      has an overall survival advantage over every three-week therapy. In contrast, every three week",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      is likely superior to weekly docetaxel.",
"     </li>",
"     <li>",
"      Nanoparticle albumin-bound",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      (nab-paclitaxel) has demonstrated better response rates and progression-free survival when compared to paclitaxel and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      (both three-weekly). &nbsp;It is also significantly more costly and has not been compared to weekly paclitaxel.",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       Capecitabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/59/953?source=see_link\">",
"       vinorelbine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10423?source=see_link\">",
"       ixabepilone",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/42/28325?source=see_link\">",
"       eribulin",
"      </a>",
"      are other active agents, particularly in anthracycline- and taxane-pretreated patients. (See",
"      <a class=\"local\" href=\"#H84534376\">",
"       'Capecitabine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H84534413\">",
"       'Gemcitabine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H84534819\">",
"       'Vinorelbine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H84535101\">",
"       'Etoposide'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H347515949\">",
"       'Ixabepilone'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H178125\">",
"       'Eribulin'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/1\">",
"      Chia SK, Speers CH, D'yachkova Y, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007; 110:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/2\">",
"      Gennari A, Conte P, Rosso R, et al. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 2005; 104:1742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/3\">",
"      Dafni U, Grimani I, Xyrafas A, et al. Fifteen-year trends in metastatic breast cancer survival in Greece. Breast Cancer Res Treat 2010; 119:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/4\">",
"      Greenberg PA, Hortobagyi GN, Smith TL, et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14:2197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/5\">",
"      Pagani O, Senkus E, Wood W, et al. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst 2010; 102:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/6\">",
"      Beslija S, Bonneterre J, Burstein HJ, et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 2009; 20:1771.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology are available online at file://www.nccn.org/professionals/physician_gls/f_guidelines.asp (Accessed on July 28, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/8\">",
"      O'Shaughnessy JA, Clark RS, Blum JL, et al. Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer. Clin Breast Cancer 2005; 6:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/9\">",
"      Robert NJ, Conkling PR, O'Rourke MA, et al. Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer. Breast Cancer Res Treat 2011; 126:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/10\">",
"      Mouridsen HT, Palshof T, Brahm M, Rahbek I. Evaluation of single-drug versus multiple-drug chemotherapy in the treatment of advanced breast cancer. Cancer Treat Rep 1977; 61:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/11\">",
"      Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 2010; 28:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/12\">",
"      Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003; 21:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/13\">",
"      Norris B, Pritchard KI, James K, et al. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. J Clin Oncol 2000; 18:2385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/14\">",
"      Paridaens R, Biganzoli L, Bruning P, et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol 2000; 18:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/15\">",
"      Henderson IC, Allegra JC, Woodcock T, et al. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989; 7:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/16\">",
"      Neidhart JA, Gochnour D, Roach R, et al. A comparison of mitoxantrone and doxorubicin in breast cancer. J Clin Oncol 1986; 4:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/17\">",
"      Bennett JM, Muss HB, Doroshow JH, et al. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma. J Clin Oncol 1988; 6:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/18\">",
"      Andreetta C, Minisini AM, Miscoria M, Puglisi F. First-line chemotherapy with or without biologic agents for metastatic breast cancer. Crit Rev Oncol Hematol 2010; 76:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/19\">",
"      Harris L, Batist G, Belt R, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002; 94:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/20\">",
"      O'Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004; 15:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/21\">",
"      Batist G, Ramakrishnan G, Rao CS, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001; 19:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/22\">",
"      Mauri D, Kamposioras K, Tsali L, et al. Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis. Cancer Treat Rev 2010; 36:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/23\">",
"      Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008; 26:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/24\">",
"      Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008; 358:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/25\">",
"      Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005; 23:5542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/26\">",
"      Perez EA, Vogel CL, Irwin DH, et al. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 2001; 19:4216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/27\">",
"      Sawaki M, Ito Y, Hashimoto D, et al. Paclitaxel administered weekly in patients with docetaxel-resistant metastatic breast cancer: a single-center study. Tumori 2004; 90:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/28\">",
"      Yonemori K, Katsumata N, Uno H, et al. Efficacy of weekly paclitaxel in patients with docetaxel-resistant metastatic breast cancer. Breast Cancer Res Treat 2005; 89:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/29\">",
"      Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006; 12:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/30\">",
"      Ibrahim NK, Samuels B, Page R, et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 2005; 23:6019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/31\">",
"      Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23:7794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/32\">",
"      Nyman DW, Campbell KJ, Hersh E, et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 2005; 23:7785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/33\">",
"      Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009; 27:3611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/34\">",
"      Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999; 17:2341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/35\">",
"      Piccart-Gebhart MJ, Burzykowski T, Buyse M, et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol 2008; 26:1980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/36\">",
"      Fumoleau P, Largillier R, Clippe C, et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 2004; 40:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/37\">",
"      Venturini M, Paridaens R, Rossner D, et al. An open-label, multicenter study of outpatient capecitabine monotherapy in 631 patients with pretreated advanced breast cancer. Oncology 2007; 72:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/38\">",
"      Oshaughnessy JA, Blum J, Moiseyenko V, et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001; 12:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/39\">",
"      Rossi D, Alessandroni P, Catalano V, et al. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer. Clin Breast Cancer 2007; 7:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/40\">",
"      Hennessy BT, Gauthier AM, Michaud LB, et al. Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature. Ann Oncol 2005; 16:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/41\">",
"      Zielinski C, Gralow J, Martin M. Optimising the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed? Ann Oncol 2010; 21:2145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/42\">",
"      Rha SY, Moon YH, Jeung HC, et al. Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Breast Cancer Res Treat 2005; 90:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/43\">",
"      Blackstein M, Vogel CL, Ambinder R, et al. Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology 2002; 62:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/44\">",
"      Feher O, Vodvarka P, Jassem J, et al. First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study. Ann Oncol 2005; 16:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/45\">",
"      Mart&iacute;n M, Ruiz A, Mu&ntilde;oz M, et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 2007; 8:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/46\">",
"      Fumoleau P, Delgado FM, Delozier T, et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993; 11:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/47\">",
"      Jones S, Winer E, Vogel C, et al. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 1995; 13:2567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/48\">",
"      Vogel C, O'Rourke M, Winer E, et al. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann Oncol 1999; 10:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/49\">",
"      Mart&iacute;n M, Lluch A, Casado A, et al. Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer. J Clin Oncol 1994; 12:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/50\">",
"      Pusztai L, Walters RS, Valero V, et al. Daily oral etoposide in patients with heavily pretreated metastatic breast cancer. Am J Clin Oncol 1998; 21:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/51\">",
"      Saphner T, Weller EA, Tormey DC, et al. 21-day oral etoposide for metastatic breast cancer: a phase II study and review of the literature. Am J Clin Oncol 2000; 23:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/52\">",
"      Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007; 25:3407.",
"     </a>",
"    </li>",
"    <li>",
"     European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use (CHMP) recommendation for refusal of marketing authorization for ixabepilone, available online at file://www.esmo.org/no_cache/view-news.html?tx_ttnews[tt_news]=480&amp;tx_ttnews[backPid]=585&amp;cHash=9385b0342b .",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/54\">",
"      Denduluri N, Low JA, Lee JJ, et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 2007; 25:3421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/55\">",
"      Low JA, Wedam SB, Lee JJ, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 2005; 23:2726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/56\">",
"      Vahdat LT, Pruitt B, Fabian CJ, et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2009; 27:2954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/57\">",
"      Cortes J, Vahdat L, Blum JL, et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 2010; 28:3922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29528/abstract/58\">",
"      Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011; 377:914.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 777 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-41.196.66.12-D2B050E0E1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_53_29528=[""].join("\n");
var outline_f28_53_29528=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2386471\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89090483\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H780566854\">",
"      ACTIVE CHEMOTHERAPY AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H84534185\">",
"      Anthracyclines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H84529057\">",
"      Taxanes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H89090299\">",
"      Taxanes versus anthracyclines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H84534376\">",
"      Capecitabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H84534413\">",
"      Gemcitabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H84534819\">",
"      Vinorelbine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H84535101\">",
"      Etoposide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H347515949\">",
"      Ixabepilone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H178125\">",
"      Eribulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2386471\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35831?source=related_link\">",
"      Metastatic breast cancer: Local treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43530?source=related_link\">",
"      Neurologic complications of non-platinum cancer chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/27/11705?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: Combination chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7354?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22202?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: Molecular targeted therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/20/32072?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: Selection of chemotherapy regimen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/55/21370?source=related_link\">",
"      Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40903?source=related_link\">",
"      Treatment of metastatic breast cancer in older women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_53_29529="Overview of the pathobiology of the non-Hodgkin lymphomas";
var content_f28_53_29529=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the pathobiology of the non-Hodgkin lymphomas",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/53/29529/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/53/29529/contributors\">",
"     Jennifer R Brown, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/53/29529/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/53/29529/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/53/29529/contributors\">",
"     Andrew Lister, MD, FRCP, FRCPath, FRCR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/53/29529/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/53/29529/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/53/29529/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-Hodgkin lymphoma (NHL) consists of a diverse group of malignant tumors of the lymphoid tissues variously derived from the clonal expansion of B-cells, T-cells, natural killer (NK)-cells or precursors of these cells. This topic will review the most common mechanisms underlying the pathobiology of the NHLs.",
"   </p>",
"   <p>",
"    Specifics regarding the pathobiology of the more common lymphoma subtypes are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diffuse large B cell lymphoma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/27/38329?source=see_link\">",
"       \"Pathobiology of diffuse large B cell lymphoma and primary mediastinal large B cell lymphoma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Mantle cell lymphoma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/1/44054?source=see_link\">",
"       \"Pathobiology of mantle cell lymphoma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Burkitt lymphoma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2791?source=see_link\">",
"       \"Pathobiology of Burkitt lymphoma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Small lymphocytic",
"      <span class=\"nowrap\">",
"       lymphoma/chronic",
"      </span>",
"      lymphocytic leukemia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42361?source=see_link\">",
"       \"Pathophysiology and genetic features of chronic lymphocytic leukemia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Follicular lymphoma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/41/24215?source=see_link\">",
"       \"Pathobiology of follicular lymphoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/41/24215?source=see_link&amp;anchor=H26243868#H26243868\">",
"       \"Pathobiology of follicular lymphoma\", section on 'Introduction'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lymphoplasmacytic lymphoma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38872?source=see_link&amp;anchor=H198194648#H198194648\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of lymphoplasmacytic lymphoma\", section on 'Pathogenesis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Extranodal marginal zone lymphoma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19610?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas\", section on 'Pathogenesis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Splenic marginal zone lymphoma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33416?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of splenic marginal zone lymphoma\", section on 'Pathogenesis'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4026474\">",
"    <span class=\"h1\">",
"     CELL OF ORIGIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphomas are derived from B and T lymphocytes or natural killer (NK) cells at varying stages of maturation, and many of the biologic features of these malignant cells reflect their normal counterparts. A cell of origin has been proposed for each type of NHL based upon morphologic, immunophenotypic, and genetic features of the malignant cells. However, in many cases this is not clear cut. Some NHLs classified as the same NHL subtype may be derived from cells at different stages of maturation (eg, germinal center B cell like diffuse large B cell lymphoma versus activated B cell like diffuse large B cell lymphoma). Other NHL subtypes do not have an easily identified cell of origin (eg, hairy cell leukemia, chronic lymphocytic leukemia). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/27/38329?source=see_link&amp;anchor=H19#H19\">",
"     \"Pathobiology of diffuse large B cell lymphoma and primary mediastinal large B cell lymphoma\", section on 'Gene expression heterogeneity of DLBCL'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20841?source=see_link&amp;anchor=H1445101937#H1445101937\">",
"     \"Clinical features and diagnosis of hairy cell leukemia\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    NK cells share immunophenotypic and functional features with",
"    <span class=\"nowrap\">",
"     gamma/delta",
"    </span>",
"    T lymphocytes making the distinction between tumors derived from NK and",
"    <span class=\"nowrap\">",
"     gamma/delta",
"    </span>",
"    T cells difficult. For cases in which this distinction is unclear, the term",
"    <span class=\"nowrap\">",
"     &ldquo;NK/T",
"    </span>",
"    cell&rdquo; NHL is used (eg, extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma, nasal type).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38692429\">",
"    <span class=\"h2\">",
"     B cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;B cell lymphomas can arise at any stage of normal B cell development, but most are derived from cells that have been exposed to the germinal center reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/1\">",
"     1",
"    </a>",
"    ]. Normal B cell development can be divided into three main stages (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link&amp;anchor=H1229513#H1229513\">",
"     \"Normal B and T lymphocyte development\", section on 'B cell development'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pre-germinal center &mdash; Normal early B cell development takes place in the bone marrow and results in the transformation of a B progenitor cell (pre-pro B cell) into a mature B cell. Mature B cells have undergone immunoglobulin VDJ gene rearrangement and express a complete IgM antibody molecule on the cell surface. After release from the bone marrow, antigen-na&iuml;ve mature B cells are exposed to antigen in the interfollicular area of the secondary lymphoid tissues (eg, lymph nodes, spleen). After this exposure, the majority migrate into the germinal center. A small population of antigen-na&iuml;ve mature B cells circulates in the peripheral blood or resides in primary lymphoid follicles and follicle mantle zones. These cells provide the initial IgM antibody response (",
"      <a class=\"graphic graphic_figure graphicRef51396 \" href=\"UTD.htm?40/19/41271\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Na&iuml;ve mature B cells in the mantle zone are thought to give rise to mantle cell lymphoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/1/44054?source=see_link&amp;anchor=H2#H2\">",
"       \"Pathobiology of mantle cell lymphoma\", section on 'Cell of origin'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Germinal center &mdash; Mature, antigen-exposed B cells proliferate in the center of a primary follicle among follicular dendritic cells to form a germinal center. These centroblasts mature into centrocytes as they transition into the light zone of the germinal center. In the germinal center, B cells undergo class-switch recombination (from IgM to IgG or IgA) and somatic hypermutation (to increase antibody affinity for antigen). In addition, the BCL6 gene and immunoglobulin heavy and light chain variable region genes undergo mutation in the germinal center and act as markers of germinal center transit.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Centroblasts are thought to give rise to Burkitt",
"      <span class=\"nowrap\">",
"       lymphoma/leukemia",
"      </span>",
"      and germinal center B cell (GCB) diffuse large B cell lymphoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/27/38329?source=see_link&amp;anchor=H2#H2\">",
"       \"Pathobiology of diffuse large B cell lymphoma and primary mediastinal large B cell lymphoma\", section on 'Cell of Origin'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2791?source=see_link&amp;anchor=H2#H2\">",
"       \"Pathobiology of Burkitt lymphoma\", section on 'Cell of origin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Centrocytes are thought to give rise to follicular lymphoma.",
"     </li>",
"     <li>",
"      Marginal zone B cells are thought to give rise to marginal zone lymphoma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Post-germinal center &mdash; After transit through the germinal center, B cells can become memory B cells or plasmablasts, which undergo further development to become plasma cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Plasmablasts are thought to give rise to activated B cell like (ABC) diffuse large B cell lymphoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/27/38329?source=see_link&amp;anchor=H2#H2\">",
"       \"Pathobiology of diffuse large B cell lymphoma and primary mediastinal large B cell lymphoma\", section on 'Cell of Origin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Plasma cells are thought to give rise to multiple myeloma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27977?source=see_link&amp;anchor=H2#H2\">",
"       \"Pathobiology of multiple myeloma\", section on 'Cell of origin'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38692684\">",
"    <span class=\"h2\">",
"     T cell or NK cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;T and natural killer (NK) cell lymphomas can arise at any stage of normal T or NK cell development. As described above, NK cells share phenotypic and functional features with",
"    <span class=\"nowrap\">",
"     gamma/delta",
"    </span>",
"    T lymphocytes making the distinction between tumors derived from these cells difficult. For cases in which this distinction is unclear, the term",
"    <span class=\"nowrap\">",
"     &ldquo;NK/T",
"    </span>",
"    cell&rdquo; NHL is used.",
"   </p>",
"   <p>",
"    Normally, prothymocytes reside in the bone marrow and produce lymphoid progenitors that travel to the thymus and undergo positive and negative selection resulting in mature, antigen-na&iuml;ve T cells. The T cell receptor (TCR) genes are rearranged during this process resulting in a heterodimeric receptor made of either alpha and beta (also called TCR2) or gamma and delta (also called TCR1) chains.",
"    <span class=\"nowrap\">",
"     Alpha/beta",
"    </span>",
"    T cells are released from the thymus as CD4 positive or CD8 positive na&iuml;ve T cells. Antigen exposure stimulates their transformation into T lymphoblasts which then become effector cells, memory cells, or follicular helper T cells of germinal centers. In contrast,",
"    <span class=\"nowrap\">",
"     gamma/delta",
"    </span>",
"    T cells undergo little cellular expansion within the thymus, but may expand considerably in the periphery. NK cells develop in the bone marrow and travel to the spleen, mucosa, and peripheral blood without maturing in the thymus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37733?source=see_link&amp;anchor=H4#H4\">",
"     \"T cell receptor genetics\", section on 'T cell receptor gene rearrangement'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Thymic T cells are thought to give rise to lymphoblastic T cell NHL.",
"     </li>",
"     <li>",
"      Post-thymic T cells and NK cells are thought to give rise to the other peripheral T cell NHLs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4026687\">",
"    <span class=\"h1\">",
"     GENERAL MECHANISMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with other malignancies, the pathogenesis of lymphomas represents a complex process involving the accumulation of multiple genetic lesions affecting proto-oncogenes and tumor suppressor genes. In some cases there is a genetic predisposition for the development of certain NHL subtypes (eg, familial",
"    <span class=\"nowrap\">",
"     CLL/SLL).",
"    </span>",
"    In addition, the lymph node microenvironment, which includes stromal cells, macrophages, regulatory T cells, and the lymph node vasculature, has been implicated in the promotion of lymphomagenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several important features distinguish the mechanism and type of genetic alterations associated with lymphoma from those associated with solid tumors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During most stages of NHL, the genome of the malignant cells is relatively stable. This is in contrast to the generalized random instability typical of many solid tumors, especially those of epithelial origin.",
"     </li>",
"     <li>",
"      Lymphoma cells generally lack microsatellite instability, the hallmark of molecular defects in DNA mismatch repair genes observed in some hereditary syndromes leading to a predisposition to developing cancer, as well as in most sporadic tumor types [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/3\">",
"       3",
"      </a>",
"      ]. Microsatellite instability has been described in a small percentage of lymphomas, specifically those arising in the context of immunodeficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      At current levels of characterization, the genome of most lymphoma types is characterized by few, sometimes single, non-random chromosomal abnormalities, commonly represented by balanced chromosomal translocations [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/5\">",
"       5",
"      </a>",
"      ]. In addition to these translocations, the advent of fluorescence in situ hybridization (FISH) and comparative genomic hybridization (CGH) has allowed the identification of a greater number of unbalanced chromosomal alterations in lymphomas than previously thought. Although often present at diagnosis, these unbalanced abnormalities increase with disease progression [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/6\">",
"       6",
"      </a>",
"      ]. One notable exception to the frequency of balanced translocations is",
"      <span class=\"nowrap\">",
"       CLL/SLL,",
"      </span>",
"      which typically has unbalanced genetic abnormalities. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Chromosomal translocations'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At the molecular level, the genetic lesions identified thus far in the lymphomas include the activation of oncogenes by chromosomal translocations, as well as the inactivation of tumor suppressor loci by chromosomal deletion or mutation. Of importance, the genome in certain lymphoma subtypes has been altered by the introduction of exogenous genes via a number of oncogenic viruses. Point mutations may also result in the changes in the epigenetic control of transcription (eg, TET mutations, DNMT3A mutations) or process of translation (eg, spliceosome mutations) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. The full spectrum of somatic mutations has yet to be defined. (See",
"    <a class=\"local\" href=\"#H38689727\">",
"     'Viral genome integration'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Deletions and mutations of the p53 tumor suppressor gene, which may represent the most common genetic alteration in human cancer, are relatively restricted to specific subsets of NHL, including late stages of follicular lymphoma, chronic lymphocytic",
"    <span class=\"nowrap\">",
"     leukemia/small",
"    </span>",
"    lymphocytic lymphoma",
"    <span class=\"nowrap\">",
"     (CLL/SLL),",
"    </span>",
"    mantle cell NHL, and Burkitt lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. The mechanisms of p53 inactivation in NHL are similar to those detected in human neoplasia in general, occurring through point mutation of one allele",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chromosomal deletion of the second allele [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The occurrence of NHL variants associated with specific chromosomal deletions also suggests the loss of currently unknown tumor suppressor genes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/6\">",
"     6",
"    </a>",
"    ]. The most frequent of these deletions involves the long arm of chromosome 6 (6q) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/14\">",
"     14",
"    </a>",
"    ]. The observations that 6q deletions may occur as the sole cytogenetic abnormality in some NHL cases, and are associated with poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/5\">",
"     5",
"    </a>",
"    ], strongly support a pathogenetic role for these alterations. Deletions of chromosome 13q14 represent the most frequent lesion in",
"    <span class=\"nowrap\">",
"     CLL/SLL,",
"    </span>",
"    occurring in more than 50 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/15\">",
"     15",
"    </a>",
"    ]. Mapping studies have determined that the minimal region of deletion does not include the retinoblastoma tumor suppressor gene, which is also located on chromosome 13q14, but rather is focused on MIR15-16 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/15\">",
"     15",
"    </a>",
"    ]. These micro-RNA genes, such as miR-15a or miR-16-1, may also act as tumor suppressors [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. MicroRNAs are small conserved noncoding RNAs that downregulate their target genes by specifically decreasing their mRNA levels [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/18\">",
"     18",
"    </a>",
"    ]. The B cell",
"    <span class=\"nowrap\">",
"     leukemia/lymphoma",
"    </span>",
"    2 (Bcl-2) gene is thought to be a target of",
"    <span class=\"nowrap\">",
"     miR-15a/miR16-1.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42361?source=see_link&amp;anchor=H10#H10\">",
"     \"Pathophysiology and genetic features of chronic lymphocytic leukemia\", section on 'del(13q14)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38691446\">",
"    <span class=\"h1\">",
"     MECHANISMS OF GENOME DAMAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precise mechanism(s) leading to chromosomal translocations in NHL are unknown, although specific translocations might be determined, in part, by the spatial organization of the respective chromosomes within the nucleus of lymphoid cells that are undergoing physiologic changes to their antigen receptor genes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/19\">",
"     19",
"    </a>",
"    ]. These aberrations might also represent mistakes within the mechanisms involved in antigen receptor gene rearrangements in lymphoid cells. This hypothesis is supported by the observation that most translocations in NHL involve chromosomal breakpoints within immunoglobulin (Ig) loci in B-cell NHL and within T-cell receptor (TCR) loci in T-cell NHL. In B-cell NHL, breakpoints within the Ig loci are often located precisely within joining (J) and switch (S) sequences, which normally mediate Ig gene rearrangements during B-cell development. Thus, translocations resulting from errors of the enzymatic machinery mediating Ig or TCR recombinations pathologically join sequences from different chromosomes instead of sequences within the same antigen receptor locus. These errors become apparent only when the consequences of the abnormal recombination provide a selective growth advantage to the cell. In addition, the genome in certain lymphoma subtypes has been altered by the introduction of exogenous genes via a number of oncogenic viruses.",
"   </p>",
"   <p>",
"    The following sections will review the mechanisms by which antigen receptor gene rearrangements and viral infections may increase the risk of lymphoma development.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38689713\">",
"    <span class=\"h2\">",
"     B cell germinal center reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of B cell lymphomas are derived from germinal center or post-germinal center B cells. During the normal germinal center reaction, there are two major genetic modifications, each of which are required for normal immune development, but also place the cell at risk of acquiring additional mutations that may be oncogenic:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Class-switch recombination changes the immunoglobulin heavy-chain from IgM to IgG, IgA, or IgE. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37702?source=see_link&amp;anchor=H13#H13\">",
"       \"Immunoglobulin genetics\", section on 'Immunoglobulin class-switching'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Somatic hypermutation is the introduction of point mutations and small deletions or insertions, usually affecting the variable regions of immunoglobulin heavy chain genes of germinal center B cells. Somatic hypermutation is a key component to the affinity maturation of the humoral immune response. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37702?source=see_link&amp;anchor=H9#H9\">",
"       \"Immunoglobulin genetics\", section on 'Somatic mutation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Under normal circumstances, the variable region of immunoglobulin heavy chain genes (IgV) of germinal center B-cells undergoes somatic hypermutation (SHM), introducing point mutations and small deletions or insertions that allow affinity maturation of the humoral immune response [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/20\">",
"     20",
"    </a>",
"    ]. This process requires activation-induced cytidine deaminase (AID), a mutation-generating enzyme [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/21\">",
"     21",
"    </a>",
"    ]. The genomic instability created by this somatic hypermutation process may also be responsible for the generation of chromosomal translocations between oncogenes and the immunoglobulin loci in human B-cell lymphomas (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Chromosomal translocations'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    BCL-6 is thought to be the critical mediator that allows germinal center B cells to tolerate the DNA strand breaks required for SHM and class switching without triggering apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/23\">",
"     23",
"    </a>",
"    ]. The normal SHM process in germinal center B-cells can also, to a lesser extent, involve BCL-6 itself, as well as other genes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Mutations in BCL-6 or chromosomal rearrangements involving BCL-6, perhaps triggered by SHM, appear to contribute to lymphomagenesis in general [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/26\">",
"     26",
"    </a>",
"    ], particularly to the aggressive and highly aggressive lymphomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/27/38329?source=see_link\">",
"     \"Pathobiology of diffuse large B cell lymphoma and primary mediastinal large B cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Aberrant SHM of BCL-6 and other proto-oncogenes, including PIM-1, c-MYC, PAX-5, and",
"    <span class=\"nowrap\">",
"     RhoH/TFF,",
"    </span>",
"    often involves the coding region of these genes, and has also been detected in a large number of lymphomas, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diffuse large B-cell lymphoma (DLBCL) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/27/38329?source=see_link&amp;anchor=H14#H14\">",
"       \"Pathobiology of diffuse large B cell lymphoma and primary mediastinal large B cell lymphoma\", section on 'Aberrant somatic hypermutation'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Primary central nervous system diffuse large B-cell lymphoma [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/27\">",
"       27",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      AIDS-associated lymphomas, including Burkitt lymphoma and DLBCL, but also seen in primary effusion lymphomas [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/28\">",
"       28",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20042?source=see_link&amp;anchor=H20#H20\">",
"       \"AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology\", section on 'BCL-6 expression'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Monoclonal post-transplant lymphoproliferative disorders, including DLBCL and BL [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/29\">",
"       29",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The cutaneous B-cell lymphomas, including primary cutaneous follicle center lymphoma and primary cutaneous large B-cell lymphoma, leg type [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/30\">",
"       30",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Transformation of follicular lymphoma (more commonly) and chronic lymphocytic leukemia (less commonly) to DLBCL [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/31\">",
"       31",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      MALT lymphoma and MALT lymphoma in transformation to DLBCL [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/32\">",
"       32",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hodgkin lymphoma, including nodular lymphocyte-predominant and classical variants [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/33\">",
"       33",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations confirm that the phenomenon of aberrant somatic hypermutation is more commonly associated with aggressive or transformed NHL variants, but that this mechanism is also seen in Hodgkin lymphoma and some lower grade lymphomas, suggesting a more general mechanism of lymphomagenesis. Some of the hypermutable genes are also susceptible to chromosomal translocations in the same regions, consistent with a role for hypermutation in generating translocations by DNA double-strand breaks. By mutating multiple genes, and possibly by favoring chromosomal translocations, aberrant hypermutation may be a major contributor to lymphomagenesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38689720\">",
"    <span class=\"h2\">",
"     T cell receptor gene rearrangement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of T cell lymphomas are derived from post-thymic T cells. During development, T cells undergo gene rearrangement of their T cell receptor (TCR). Gene rearrangement of these antigen-specific receptors is essential for the development of a highly diverse repertoire of TCRs required for an effective immune system, but also places the cell at risk for acquiring potentially oncogenic chromosomal translocations.",
"   </p>",
"   <p>",
"    Similar to Ig molecules, TCR proteins contain variable, diverse, joining, and constant regions. TCR genes rearrange via the same mechanisms and according to the same rules as immunoglobulin (Ig) genes in B cells. However, unlike B cell Ig genes, TCR genes do not undergo somatic hypermutation following initial rearrangement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37733?source=see_link\">",
"     \"T cell receptor genetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    T cell lymphomas demonstrate characteristic TCR gene recombination patterns and translocations between TCR loci and proto-oncogenes. This is perhaps best demonstrated in cases of precursor T-cell acute lymphoblastic",
"    <span class=\"nowrap\">",
"     leukemia/lymphoma",
"    </span>",
"    where about one-third of cases demonstrate chromosomal translocations involving the TCR alpha and delta loci at chromosome 14q11 and beta and gamma loci at 7q34 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30023?source=see_link&amp;anchor=H732731#H732731\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma\", section on 'Genetic analysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38689727\">",
"    <span class=\"h2\">",
"     Viral genome integration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oncogenic viruses introduce foreign genes into their target cells. Three distinct viruses are associated with the pathogenesis of specific NHL subtypes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/36\">",
"     36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Epstein-Barr virus (EBV)",
"     </li>",
"     <li>",
"      Human T-cell lymphotropic virus I (HTLV-I)",
"     </li>",
"     <li>",
"      Human Herpesvirus-8 (HHV-8)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, HIV infection increases the risk of lymphoma largely related to its immunosuppressive effects rather than through the introduction of oncogenic genes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20042?source=see_link&amp;anchor=H16#H16\">",
"     \"AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology\", section on 'HIV infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38690884\">",
"    <span class=\"h3\">",
"     Epstein-Barr virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Epstein-Barr virus (EBV) has been associated with the development of endemic, sporadic, and AIDS-associated Burkitt lymphoma and in the pathobiology of lymphoma in the setting of immunosuppressive therapy, including after organ transplantation or in the setting of chronic low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    therapy, usually used in the treatment of rheumatic diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/19,37-41\">",
"     19,37-41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2791?source=see_link&amp;anchor=H11#H11\">",
"     \"Pathobiology of Burkitt lymphoma\", section on 'Epstein Barr virus infection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20042?source=see_link&amp;anchor=H17#H17\">",
"     \"AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology\", section on 'EBV coinfection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31738?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Upon infection of a B lymphocyte, the EBV genome is transported into the nucleus, where it exists predominantly as an extrachromosomal circular molecule (episome). This process is mediated by the cohesive terminal repeats, which are represented by a variable number of tandem repeat (VNTR) sequences [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/42\">",
"     42",
"    </a>",
"    ]. Because of this heterogeneity, the number of VNTR sequences enclosed in newly formed episomes may differ considerably, representing a constant clonal marker of the episome and, consequently, of a single infected cell [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence for a pathogenetic role of the virus in NHL infected by EBV is circumstantial, but strong:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      EBV is able to significantly alter the growth of B-cells.",
"     </li>",
"     <li>",
"      EBV-infected lymphomas usually display a single form of fused EBV termini, suggesting that the entire population represents the clonally-expanded progeny of a single infected cell [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/42,43\">",
"       42,43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lymphomas that arise after organ transplantation or during chronic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      therapy will sometimes at least transiently regress following either withdrawal of the immunosuppression that presumably allowed EBV reactivation or use of a variety of anti-viral measures [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/44\">",
"       44",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link&amp;anchor=H16#H16\">",
"       \"Treatment and prevention of post-transplant lymphoproliferative disorders\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38690891\">",
"    <span class=\"h3\">",
"     HTLV-I virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection with human T-lymphotropic virus, type I (HTLV-I) has been implicated in adult T-cell leukemia-lymphoma (ATL) seen in the Caribbean and Japan. ATL is associated with HTLV-I infection of the tumor clone in 100 percent of the cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/45\">",
"     45",
"    </a>",
"    ]. HTLV-I induced T-cell transformation does not occur through transduction of a viral oncogene or activation of a human proto-oncogene adjacent to the HTLV-I integration site in the T-cell genome. Rather, the pathogenetic effect of HTLV-I in ATL seems to be due to the viral production of a transregulatory protein (HTLV-I Tax) that markedly increases expression of all viral genes and transcriptionally activates the expression of certain host genes.",
"   </p>",
"   <p>",
"    This is described in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/45/9945?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38690898\">",
"    <span class=\"h3\">",
"     HHV-8 virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human herpesvirus 8 (HHV-8) is a novel member of the gamma-herpesviridae family, closely related to Herpesvirus saimiri and was originally detected in biopsies of AIDS-related Kaposi's sarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/46\">",
"     46",
"    </a>",
"    ]. Among lymphomas, HHV-8 infection is selectively restricted to body-cavity-based lymphomas (eg, or primary effusion lymphoma), where the viral genome is found within the tumor cells in virtually 100 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism of viral carcinogenesis is not fully elucidated, but may involve viral proteins that are homologous to D-type cyclins",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    interleukin-6 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30969?source=see_link&amp;anchor=H3#H3\">",
"     \"AIDS-related lymphomas: Primary effusion lymphoma\", section on 'Pathogenesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19192?source=see_link\">",
"     \"Disease associations of human herpesvirus 8 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38691854\">",
"    <span class=\"h3\">",
"     HIV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although HIV infection is a risk factor for the development of NHL, HIV itself does not infect the neoplastic cells of AIDS-related lymphomas. The pathogenesis of NHL in the setting of HIV infection is poorly understood, but immune deregulation leading to loss of control of viruses, such as Epstein Barr virus is thought to play an important role. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20042?source=see_link&amp;anchor=H12#H12\">",
"     \"AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology\", section on 'Pathobiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38690905\">",
"    <span class=\"h3\">",
"     Simian virus 40",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although simian virus-40 (SV-40) is a polyoma virus with oncogenic potential in humans and animals, it likely does not play a role in the pathobiology of NHL. SV-40 nucleic acids have been identified in a large proportion of patients with mesothelioma and some brain cancers. Its actions are thought to result from inactivation of tumor suppressors including p53 and members of the retinoblastoma family by a peptide known as the SV-40 large T-antigen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7622?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology of malignant mesothelioma\", section on 'Viral oncogenes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/7/44151?source=see_link\">",
"     \"Clinical manifestations and diagnosis of JC, BK, and other polyomavirus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Concerns over the potential association between SV-40 and NHL were initially raised because of SV-40 contamination of poliovirus vaccines used in the United States from 1955 to 1963 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/51\">",
"     51",
"    </a>",
"    ]. However, two epidemiologic studies have cast doubt on the significance of potential exposure to SV-40:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, childhood exposure to SV-40 through receipt of contaminated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/58/35749?source=see_link\">",
"       poliovirus vaccine",
"      </a>",
"      was not associated with increased risk for AIDS-associated NHL [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a population-based case-control study, there was no evidence that SV-40 seropositive individuals were at increased risk for NHL [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CHROMOSOMAL TRANSLOCATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7114589\">",
"    <span class=\"h2\">",
"     Balanced translocations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chromosomal translocations represent the genetic hallmark of lymphoid malignancies. As in other malignancies, most NHL-associated translocations represent reciprocal and balanced recombinations between two specific chromosomes, which are recurrently associated with a given tumor type and are clonally represented in each affected patient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18167?source=see_link\">",
"     \"Chromosomal translocations, deletions, and inversions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most frequent cytogenetic abnormalities have been characterized at the molecular level, leading to the identification of genes that are altered in B-cells or T-cells, and can cause tumors in transgenic animal models. Most of these genetic lesions selectively associate with specific NHL subtypes, thus representing markers of potential diagnostic significance [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/19,54\">",
"     19,54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41049?source=see_link\">",
"     \"Genetic abnormalities in hematologic and lymphoid malignancies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/21/6489?source=see_link\">",
"     \"General aspects of cytogenetic analysis in hematologic malignancies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The common feature of all chromosomal translocations associated with NHL is the presence of proto-oncogenes in proximity to the chromosomal recombination sites. In most cases, the structure of the proto-oncogene, and in particular its coding domain, is not affected by the translocation. However, the pattern of expression of the gene is altered as a consequence of the juxtaposition of heterologous regulatory sequences derived from the partner chromosome (proto-oncogene deregulation). Two distinct types of proto-oncogene deregulation may occur:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Homotopic deregulation occurs when the chromosomal translocation alters the pattern of a proto-oncogene normally expressed in lymphocytes.",
"     </li>",
"     <li>",
"      Heterotopic deregulation occurs when a proto-oncogene normally not expressed in lymphoid cells is ectopically expressed in the lymphoma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In most types of NHL-associated translocations, the heterologous regulatory regions responsible for proto-oncogene deregulation are derived from antigen receptor loci, which are expressed at high levels in the target tissue.",
"   </p>",
"   <p>",
"    An alternative mechanism of oncogene activation by chromosomal translocation is the juxtaposition of two genes to form a chimeric gene coding for a novel chimeric protein. This mechanism, which is common in chromosomal translocations associated with acute myeloid leukemia and chronic myeloid leukemia, is not associated with NHL, with the exception of t(2;5)(p23;q35) as found in the NHL variant, anaplastic lymphoma, and t(11;18) as found in MALT lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/47/25337?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of anaplastic large cell lymphoma, ALK positive\", section on 'Pathogenesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19610?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas\", section on 'Extranodal (MALT) MZL'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Molecular cloning of the loci involved in the translocations most frequently associated with NHL has led to the identification of a number of proto-oncogenes involved in lymphomagenesis. The structural and functional consequences of each chromosomal translocation associated with NHL are described separately in the context of the molecular pathogenesis of the various NHL subtypes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Unbalanced chromosomal abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The current model of lymphoma pathogenesis suggests that balanced translocations are the initiating events, while unbalanced chromosomal gains and losses are likely to be associated with clonal evolution that occurs with disease progression. Studies in follicular lymphoma have found an average of four to eight additional chromosomal abnormalities in addition to the characteristic t(14;18) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/6,56\">",
"     6,56",
"    </a>",
"    ]. Many of these occur at specific reproducible chromosomal locations and, in the case of amplifications, have been associated with increased expression of genes in that region [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/57\">",
"     57",
"    </a>",
"    ]. Loss of 6q has been found in multivariate analysis to predict poor survival in follicular lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29529/abstract/58\">",
"     58",
"    </a>",
"    ], but as with most of the unbalanced chromosomal abnormalities, the gene involved is as yet unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/41/24215?source=see_link&amp;anchor=H26243882#H26243882\">",
"     \"Pathobiology of follicular lymphoma\", section on 'Other genetic lesions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38689705\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Non-Hodgkin lymphoma (NHL) consists of a diverse group of malignant tumors of the lymphoid tissues variously derived from the clonal expansion of B-cells, T-cells, natural killer (NK)-cells or precursors of these cells. As with other malignancies, the pathogenesis of lymphomas represents a complex process involving the accumulation of multiple genetic lesions affecting proto-oncogenes and tumor suppressor genes.",
"     </li>",
"     <li>",
"      A cell of origin has been proposed for each type of NHL based upon morphologic, immunophenotypic, and genetic features of the malignant cells. However, many cases are not clear cut. (See",
"      <a class=\"local\" href=\"#H4026474\">",
"       'Cell of origin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The vast majority of B cell lymphomas are derived from germinal center or post-germinal center B cells. Major genetic modifications occur during the normal germinal center reaction of B cells. These changes (class-switch recombination and somatic hypermutation) are required for normal immune development, but also place the cell at risk of acquiring additional mutations that may be oncogenic. (See",
"      <a class=\"local\" href=\"#H38689713\">",
"       'B cell germinal center reaction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of T cell lymphomas are derived from post-thymic T cells. Gene rearrangement of T cell receptors (TCRs) is essential for the development of a highly diverse repertoire of TCRs required for an effective immune system, but also places the cell at risk for acquiring potentially oncogenic chromosomal translocations. (See",
"      <a class=\"local\" href=\"#H38689720\">",
"       'T cell receptor gene rearrangement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oncogenic viruses introduce foreign genes into their target cells. Three distinct viruses are associated with the pathogenesis of specific NHL subtypes:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Epstein-Barr virus (EBV) &mdash; Associated with the development of Burkitt lymphoma and lymphoma in the setting of immunosuppressive therapy. (See",
"      <a class=\"local\" href=\"#H38690884\">",
"       'Epstein-Barr virus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Human T-cell lymphotropic virus I (HTLV-I) &mdash; Implicated in adult T-cell leukemia-lymphoma (ATL). (See",
"      <a class=\"local\" href=\"#H38690891\">",
"       'HTLV-I virus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Human Herpesvirus-8 (HHV-8) &mdash; Involved in the development of body-cavity-based lymphomas (eg, primary effusion lymphoma). (See",
"      <a class=\"local\" href=\"#H38690898\">",
"       'HHV-8 virus'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most NHL-associated chromosomal translocations represent reciprocal and balanced recombinations between two specific chromosomes, which are recurrently associated with a given tumor type and are clonally represented in each affected patient. This can result in:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The altered expression of a proto-oncogene normally expressed in lymphocytes (homotopic deregulation)",
"     </li>",
"     <li>",
"      The ectopic expression of a proto-oncogene normally not expressed in lymphoid cells (heterotopic deregulation)",
"     </li>",
"     <li>",
"      The juxtaposition of two genes to form a chimeric gene coding for a novel chimeric protein",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The current model of lymphoma pathogenesis suggests that balanced translocations are the initiating events, while unbalanced chromosomal gains and losses are likely to be associated with clonal evolution that occurs with disease progression. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Unbalanced chromosomal abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/1\">",
"      Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med 2010; 362:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/2\">",
"      Coupland SE. The challenge of the microenvironment in B-cell lymphomas. Histopathology 2011; 58:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/3\">",
"      Gamberi B, Gaidano G, Parsa N, et al. Microsatellite instability is rare in B-cell non-Hodgkin's lymphomas. Blood 1997; 89:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/4\">",
"      Duval A, Raphael M, Brennetot C, et al. The mutator pathway is a feature of immunodeficiency-related lymphomas. Proc Natl Acad Sci U S A 2004; 101:5002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/5\">",
"      Offit K, Wong G, Filippa DA, et al. Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma: clinical correlations. Blood 1991; 77:1508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/6\">",
"      Johansson B, Mertens F, Mitelman F. Cytogenetic evolution patterns in non-Hodgkin's lymphoma. Blood 1995; 86:3905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/7\">",
"      Couronn&eacute; L, Bastard C, Bernard OA. TET2 and DNMT3A mutations in human T-cell lymphoma. N Engl J Med 2012; 366:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/8\">",
"      Rossi D, Bruscaggin A, Spina V, et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood 2011; 118:6904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/9\">",
"      Quesada V, Conde L, Villamor N, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 2012; 44:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/10\">",
"      Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011; 365:2497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/11\">",
"      Gaidano G, Ballerini P, Gong JZ, et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 1991; 88:5413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/12\">",
"      Lo Coco F, Gaidano G, Louie DC, et al. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 1993; 82:2289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/13\">",
"      Sander CA, Yano T, Clark HM, et al. p53 mutation is associated with progression in follicular lymphomas. Blood 1993; 82:1994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/14\">",
"      Gaidano G, Hauptschein RS, Parsa NZ, et al. Deletions involving two distinct regions of 6q in B-cell non-Hodgkin lymphoma. Blood 1992; 80:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/15\">",
"      Kalachikov S, Migliazza A, Cayanis E, et al. Cloning and gene mapping of the chromosome 13q14 region deleted in chronic lymphocytic leukemia. Genomics 1997; 42:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/16\">",
"      Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002; 99:15524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/17\">",
"      Calin GA, Ferracin M, Cimmino A, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353:1793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/18\">",
"      Di Lisio L, Martinez N, Montes-Moreno S, et al. The role of miRNAs in the pathogenesis and diagnosis of B-cell lymphomas. Blood 2012; 120:1782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/19\">",
"      K&uuml;ppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 2005; 5:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/20\">",
"      Jacobs H, Bross L. Towards an understanding of somatic hypermutation. Curr Opin Immunol 2001; 13:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/21\">",
"      Ramiro AR, Jankovic M, Callen E, et al. Role of genomic instability and p53 in AID-induced c-myc-Igh translocations. Nature 2006; 440:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/22\">",
"      Klein U, Goossens T, Fischer M, et al. Somatic hypermutation in normal and transformed human B cells. Immunol Rev 1998; 162:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/23\">",
"      Phan RT, Dalla-Favera R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 2004; 432:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/24\">",
"      Shen HM, Peters A, Baron B, et al. Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes. Science 1998; 280:1750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/25\">",
"      Peng HZ, Du MQ, Koulis A, et al. Nonimmunoglobulin gene hypermutation in germinal center B cells. Blood 1999; 93:2167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/26\">",
"      Pasqualucci L, Bhagat G, Jankovic M, et al. AID is required for germinal center-derived lymphomagenesis. Nat Genet 2008; 40:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/27\">",
"      Montesinos-Rongen M, Van Roost D, Schaller C, et al. Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation. Blood 2004; 103:1869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/28\">",
"      Gaidano G, Pasqualucci L, Capello D, et al. Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma. Blood 2003; 102:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/29\">",
"      Cerri M, Capello D, Muti G, et al. Aberrant somatic hypermutation in post-transplant lymphoproliferative disorders. Br J Haematol 2004; 127:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/30\">",
"      Dijkman R, Tensen CP, Buettner M, et al. Primary cutaneous follicle center lymphoma and primary cutaneous large B-cell lymphoma, leg type, are both targeted by aberrant somatic hypermutation but demonstrate differential expression of AID. Blood 2006; 107:4926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/31\">",
"      Rossi D, Berra E, Cerri M, et al. Aberrant somatic hypermutation in transformation of follicular lymphoma and chronic lymphocytic leukemia to diffuse large B-cell lymphoma. Haematologica 2006; 91:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/32\">",
"      Deutsch AJ, Aigelsreiter A, Staber PB, et al. MALT lymphoma and extranodal diffuse large B-cell lymphoma are targeted by aberrant somatic hypermutation. Blood 2007; 109:3500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/33\">",
"      Liso A, Capello D, Marafioti T, et al. Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma. Blood 2006; 108:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/34\">",
"      Khalidi HS, Chang KL, Medeiros LJ, et al. Acute lymphoblastic leukemia. Survey of immunophenotype, French-American-British classification, frequency of myeloid antigen expression, and karyotypic abnormalities in 210 pediatric and adult cases. Am J Clin Pathol 1999; 111:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/35\">",
"      Uckun FM, Sensel MG, Sun L, et al. Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. Blood 1998; 91:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/36\">",
"      Lyons SF, Liebowitz DN. The roles of human viruses in the pathogenesis of lymphoma. Semin Oncol 1998; 25:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/37\">",
"      EPSTEIN MA, ACHONG BG, BARR YM. VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA. Lancet 1964; 1:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/38\">",
"      Tao Q, Robertson KD, Manns A, et al. Epstein-Barr virus (EBV) in endemic Burkitt's lymphoma: molecular analysis of primary tumor tissue. Blood 1998; 91:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/39\">",
"      Davi F, Delecluse HJ, Guiet P, et al. Burkitt-like lymphomas in AIDS patients: characterization within a series of 103 human immunodeficiency virus-associated non-Hodgkin's lymphomas. Burkitt's Lymphoma Study Group. J Clin Oncol 1998; 16:3788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/40\">",
"      Guti&eacute;rrez MI, Bhatia K, Barriga F, et al. Molecular epidemiology of Burkitt's lymphoma from South America: differences in breakpoint location and Epstein-Barr virus association from tumors in other world regions. Blood 1992; 79:3261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/41\">",
"      Subar M, Neri A, Inghirami G, et al. Frequent c-myc oncogene activation and infrequent presence of Epstein-Barr virus genome in AIDS-associated lymphoma. Blood 1988; 72:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/42\">",
"      Neri A, Barriga F, Inghirami G, et al. Epstein-Barr virus infection precedes clonal expansion in Burkitt's and acquired immunodeficiency syndrome-associated lymphoma. Blood 1991; 77:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/43\">",
"      Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 2004; 350:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/44\">",
"      Mariette X, Cazals-Hatem D, Warszawki J, et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 2002; 99:3909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/45\">",
"      Smith MR, Greene WC. Molecular biology of the type I human T-cell leukemia virus (HTLV-I) and adult T-cell leukemia. J Clin Invest 1991; 87:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/46\">",
"      Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/47\">",
"      Cesarman E, Chang Y, Moore PS, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995; 332:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/48\">",
"      Gaidano G, Capello D, Fassone L, et al. Molecular characterization of HHV-8 positive primary effusion lymphoma reveals pathogenetic and histogenetic features of the disease. J Clin Virol 2000; 16:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/49\">",
"      J&auml;rviluoma A, Koopal S, R&auml;s&auml;nen S, et al. KSHV viral cyclin binds to p27KIP1 in primary effusion lymphomas. Blood 2004; 104:3349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/50\">",
"      Asou H, Said JW, Yang R, et al. Mechanisms of growth control of Kaposi's sarcoma-associated herpes virus-associated primary effusion lymphoma cells. Blood 1998; 91:2475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/51\">",
"      Rizzo P, Di Resta I, Powers A, et al. Unique strains of SV40 in commercial poliovaccines from 1955 not readily identifiable with current testing for SV40 infection. Cancer Res 1999; 59:6103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/52\">",
"      Engels EA, Rodman LH, Frisch M, et al. Childhood exposure to simian virus 40-contaminated poliovirus vaccine and risk of AIDS-associated non-Hodgkin's lymphoma. Int J Cancer 2003; 106:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/53\">",
"      Engels EA, Viscidi RP, Galloway DA, et al. Case-control study of simian virus 40 and non-Hodgkin lymphoma in the United States. J Natl Cancer Inst 2004; 96:1368.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, Jaffe ES, Harris NL, Stein H, Vardiman JW (Eds), IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/55\">",
"      Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994; 263:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/56\">",
"      Horsman DE, Connors JM, Pantzar T, Gascoyne RD. Analysis of secondary chromosomal alterations in 165 cases of follicular lymphoma with t(14;18). Genes Chromosomes Cancer 2001; 30:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/57\">",
"      Lestou VS, Gascoyne RD, Sehn L, et al. Multicolour fluorescence in situ hybridization analysis of t(14;18)-positive follicular lymphoma and correlation with gene expression data and clinical outcome. Br J Haematol 2003; 122:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29529/abstract/58\">",
"      Viardot A, M&ouml;ller P, H&ouml;gel J, et al. Clinicopathologic correlations of genomic gains and losses in follicular lymphoma. J Clin Oncol 2002; 20:4523.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4711 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-3033BD7A4C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_53_29529=[""].join("\n");
var outline_f28_53_29529=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H38689705\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4026474\">",
"      CELL OF ORIGIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38692429\">",
"      B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38692684\">",
"      T cell or NK cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4026687\">",
"      GENERAL MECHANISMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38691446\">",
"      MECHANISMS OF GENOME DAMAGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38689713\">",
"      B cell germinal center reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38689720\">",
"      T cell receptor gene rearrangement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38689727\">",
"      Viral genome integration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38690884\">",
"      - Epstein-Barr virus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38690891\">",
"      - HTLV-I virus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38690898\">",
"      - HHV-8 virus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38691854\">",
"      - HIV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38690905\">",
"      - Simian virus 40",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CHROMOSOMAL TRANSLOCATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7114589\">",
"      Balanced translocations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Unbalanced chromosomal abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38689705\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4711\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4711|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/19/41271\" title=\"figure 1\">",
"      Mechanisms for development B cell NHL",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20042?source=related_link\">",
"      AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30969?source=related_link\">",
"      AIDS-related lymphomas: Primary effusion lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18167?source=related_link\">",
"      Chromosomal translocations, deletions, and inversions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20841?source=related_link\">",
"      Clinical features and diagnosis of hairy cell leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/7/44151?source=related_link\">",
"      Clinical manifestations and diagnosis of JC, BK, and other polyomavirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/45/9945?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/47/25337?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of anaplastic large cell lymphoma, ALK positive",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19610?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38872?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of lymphoplasmacytic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30023?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33416?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of splenic marginal zone lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19192?source=related_link\">",
"      Disease associations of human herpesvirus 8 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7622?source=related_link\">",
"      Epidemiology of malignant mesothelioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31738?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/21/6489?source=related_link\">",
"      General aspects of cytogenetic analysis in hematologic malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41049?source=related_link\">",
"      Genetic abnormalities in hematologic and lymphoid malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37702?source=related_link\">",
"      Immunoglobulin genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=related_link\">",
"      Normal B and T lymphocyte development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2791?source=related_link\">",
"      Pathobiology of Burkitt lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/27/38329?source=related_link\">",
"      Pathobiology of diffuse large B cell lymphoma and primary mediastinal large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/41/24215?source=related_link\">",
"      Pathobiology of follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/1/44054?source=related_link\">",
"      Pathobiology of mantle cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27977?source=related_link\">",
"      Pathobiology of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42361?source=related_link\">",
"      Pathophysiology and genetic features of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37733?source=related_link\">",
"      T cell receptor genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_53_29530="PTEN hamartoma tumor syndrome, including Cowden syndrome";
var content_f28_53_29530=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   PTEN hamartoma tumor syndrome, including Cowden syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/53/29530/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/53/29530/contributors\">",
"     Peter P Stanich, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/53/29530/contributors\">",
"     Noralane M Lindor, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/53/29530/contributors\">",
"     Mrinal M Patnaik, MBBS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/53/29530/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/53/29530/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/53/29530/contributors\">",
"     Benjamin A Raby, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/53/29530/contributors\">",
"     Carolyn Bridgemohan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/53/29530/contributors\">",
"     Susan J Bayliss, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/53/29530/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/53/29530/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/53/29530/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H5356445\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The phosphatase and tensin homolog (",
"    <em>",
"     PTEN",
"    </em>",
"    ) gene negatively regulates the phosphatidylinositol 3-kinase-AKT and mammalian target of rapamycin (mTOR) signaling pathways, which are critical for cell proliferation, cell cycle progression, and apoptosis. Loss of function of this gene contributes to oncogenesis, and as such,",
"    <em>",
"     PTEN",
"    </em>",
"    is considered to be a tumor suppressor gene.",
"   </p>",
"   <p>",
"    Germline mutations in PTEN have been described in a variety of rare syndromes that are collectively known as PTEN hamartoma tumor syndromes (PHTS). The defining clinical feature of PHTS is the presence of hamartomatous tumors, which are disorganized growths of native cells in native tissues.",
"   </p>",
"   <p>",
"    The phenotypic spectrum of PHTS includes the following entities:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cowden syndrome (also known as Cowden disease or multiple hamartoma syndrome) is the best-described PHTS. It is inherited in an autosomal dominant fashion. Besides multiple hamartomas in a variety of tissues, patients have characteristic dermatologic manifestations such as trichilemmomas, oral fibromas, and punctate palmoplantar keratoses, and an increased risk of breast, endometrial, thyroid, kidney and colorectal cancers.",
"     </li>",
"     <li>",
"      Bannayan-Riley-Ruvalcaba (also called Bannayan-Zonana) syndrome is another rare PHTS that is also inherited in an autosomal dominant fashion. In addition to hamartomas, these patients have multiple subcutaneous lipomas, macrocephaly, and penile lentigines (",
"      <a class=\"graphic graphic_picture graphicRef62253 \" href=\"UTD.htm?0/2/42\">",
"       picture 1",
"      </a>",
"      ); they lack the documented high penetrance of cancer seen in Cowden syndrome.",
"      <br/>",
"      <br/>",
"      Genotype analyses have concluded that a similar mutation spectrum in the",
"      <em>",
"       PTEN",
"      </em>",
"      gene is found in both Cowden and Bannayan-Riley-Ruvalcaba syndromes, leading to the conclusion that they are related allelic disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/1-3\">",
"       1-3",
"      </a>",
"      ]. Both conditions are now considered phenotypically distinct, age-related presentations of a similar genetic abnormality [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/4,5\">",
"       4,5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Adult Lhermitte-Duclos disease is characterized by hamartomatous outgrowths of the cerebellum (cerebellar dysplastic gangliocytoma) and has also been associated with",
"      <em>",
"       PTEN",
"      </em>",
"      mutations [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]. This syndrome may arise in conjunction with phenotypic Cowden syndrome or without other signs of PHTS. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35946?source=see_link&amp;anchor=H4#H4\">",
"       \"Uncommon brain tumors\", section on 'Dysplastic gangliocytoma of the cerebellum'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Two other conditions have been associated with",
"      <em>",
"       PTEN",
"      </em>",
"      mutations, and although they lack hamartomas, some argue that they should be incorporated into the definition of PHTS:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A Proteus-like syndrome, which is an exceedingly rare asymmetric overgrowth syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H462460056\">",
"       'Proteus and Proteus-like syndromes'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/10/2217?source=see_link&amp;anchor=H3700642#H3700642\">",
"       \"Capillary malformations (port wine stains): Clinical features, diagnosis, and associated syndromes\", section on 'Proteus syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Autism spectrum disorders with macrocephaly [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/54/3946?source=see_link&amp;anchor=H8#H8\">",
"       \"Etiology and evaluation of macrocephaly in infants and children\", section on 'Anatomic megalencephaly'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic review will review the major clinical syndromes that are associated with",
"    <em>",
"     PTEN",
"    </em>",
"    mutations, and therefore, they are considered part of the spectrum of PTEN hamartoma tumor syndromes (PHTS).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H462459902\">",
"    <span class=\"h1\">",
"     COWDEN SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cowden syndrome was first reported in 1963; an autosomal dominant pattern of inheritance was first suggested in 1972 and later confirmed [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although data are limited, the estimated prevalence of Cowden syndrome is 1 in 200,000 to 250,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/13\">",
"     13",
"    </a>",
"    ]. The true prevalence may be greater because many of the features, an enlarged head, benign neoplasms on the face, hands and feet, and breast, kidney and thyroid cancers, also occur in the general population, and not all such individuals are investigated for Cowden syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17510999\">",
"    <span class=\"h2\">",
"     Molecular genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The phosphatase and tensin homolog (",
"    <em>",
"     PTEN",
"    </em>",
"    ) gene is a negative regulator of the phosphoinositide-3-kinase (PI3K)-AKT and mTOR signaling pathways, which are critical for cell proliferation, cell cycle progression, and apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/14\">",
"     14",
"    </a>",
"    ]. Loss of function of this gene contributes to oncogenesis, and somatic mutations are frequently identified in various malignancies. As a result, the",
"    <em>",
"     PTEN",
"    </em>",
"    gene, which is located on chromosome 10q23 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/15\">",
"     15",
"    </a>",
"    ], is considered to be a tumor suppressor gene [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/16-18\">",
"     16-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Germline mutations in",
"    <em>",
"     PTEN",
"    </em>",
"    are found in many patients with Cowden syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/19\">",
"     19",
"    </a>",
"    ]. Although it was initially reported that up to 83 percent of individuals meeting clinical criteria for Cowden syndrome had a detectable",
"    <em>",
"     PTEN",
"    </em>",
"    mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/3\">",
"     3",
"    </a>",
"    ], this is likely an overestimate attributable to the highly selected nature of earlier Cowden&nbsp;syndrome cohorts. More recent estimates are that germline",
"    <em>",
"     PTEN",
"    </em>",
"    mutations are found in approximately 20 to 34 percent of individuals who meet clinical criteria for Cowden syndrome or who meet criteria for genetic testing [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Most mutations are unique to a given family. (See",
"    <a class=\"local\" href=\"#H462459982\">",
"     'Diagnostic and testing criteria'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Genetic testing for Cowden syndrome is discussed below. (See",
"    <a class=\"local\" href=\"#H462460007\">",
"     'Genetic testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Allelic heterogeneity has been observed in Cowden Syndrome, with subsets of patients with Cowden syndrome and Cowden-like syndrome (ie, with some features of the Cowden syndrome but who do not meet diagnostic criteria (see",
"    <a class=\"local\" href=\"#H462459982\">",
"     'Diagnostic and testing criteria'",
"    </a>",
"    below)) lacking detectable non-synonymous point mutations at the PTEN locus, but who harbor either large structural rearrangements in the",
"    <em>",
"     PTEN",
"    </em>",
"    gene, or mutations or deletions in the",
"    <em>",
"     PTEN",
"    </em>",
"    promoter region, resulting in markedly reduced PTEN expression. There is also evidence of locus heterogeneity, with alterations at one of two other loci:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In some patients who lack PTEN mutations, hypermethylation of the promoter of the",
"      <em>",
"       KLLN",
"      </em>",
"      (KILLIN) gene, leading to reduced expression of",
"      <em>",
"       KLLN",
"      </em>",
"      , has been described [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/22\">",
"       22",
"      </a>",
"      ]. The KLLN gene, which is located on chromosome 10q23, and functions as a p53-regulated inhibitor of DNA synthesis, shares the same transcription site as the PTEN gene [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Other patients have been reported with mutations in the succinate dehydrogenase (",
"      <em>",
"       SDH",
"      </em>",
"      ) gene, subunits B and D [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/22,24-26\">",
"       22,24-26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some genotype-phenotype correlations are reported in these patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with",
"      <em>",
"       SDH",
"      </em>",
"      mutation variants appear to have a higher prevalence of breast and thyroid cancers than those with",
"      <em>",
"       PTEN",
"      </em>",
"      mutation-positive disease [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/27\">",
"       27",
"      </a>",
"      ]. There is also evidence that SDH acts as a disease modifier in patients with PTEN mutations, as germline variations in",
"      <em>",
"       SDH",
"      </em>",
"      have also been reported in patients who have",
"      <em>",
"       PTEN",
"      </em>",
"      mutation-positive disease, and such patients appear to have more breast cancers compared to those with",
"      <em>",
"       PTEN",
"      </em>",
"      mutations alone.",
"     </li>",
"     <li>",
"      Patients with KLLN gene promoter hypermethylation may have a higher risk of breast and renal cancer than those with",
"      <em>",
"       PTEN",
"      </em>",
"      mutation-positive disease [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/22\">",
"       22",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H462459910\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Published data on clinical manifestations come mainly from small case series or compilations of published cases, most of which predated the development of consensus criteria for diagnosis and genetic testing for Cowden syndrome. As a result, the true frequencies of the clinical features of Cowden syndrome are not known [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H462459982\">",
"     'Diagnostic and testing criteria'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The range of clinical manifestations of Cowden syndrome includes hamartomatous tumors in multiple organ systems, both mucocutaneous and extracutaneous, and an increased risk for malignancy. Although nearly every internal malignancy has been reported in the setting of Cowden syndrome, the most common is breast cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H462459918\">",
"    <span class=\"h3\">",
"     Mucocutaneous",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin and oral findings are a distinctive and common manifestation of Cowden syndrome; they are often the initial finding that leads to the diagnosis. Although commonly noticed in the second decade of life, the age of onset may vary from 4 to 75 years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/11,29\">",
"     11,29",
"    </a>",
"    ]. The prevalence of mucocutaneous abnormalities in patients with Cowden syndrome was thought to be close to 100 percent based upon early case series, but this may be an overestimate based upon prevalence data driven by genetic testing [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/11,20,30,31\">",
"     11,20,30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The common lesions are trichilemmomas, acral keratoses, and facial",
"    <span class=\"nowrap\">",
"     papules/oral",
"    </span>",
"    papillomas:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Trichilemmomas (",
"      <a class=\"graphic graphic_picture graphicRef60952 \" href=\"UTD.htm?40/31/41459\">",
"       picture 2",
"      </a>",
"      ) are hamartomatous tumors of the outer root sheath of the hair follicle or other skin appendages that occur on the face and neck of patients with Cowden syndrome. They present as wart-like, skin-colored papules with slightly rough surfaces; histologically, the lesions contain large glycogen rich cells [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/32\">",
"       32",
"      </a>",
"      ]. A study found a complete loss of PTEN expression by immunohistochemistry in five of six (83 percent) trichilemmomas from patients with Cowden syndrome compared to only 1 of 33 (3 percent) sporadic trichilemmomas [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/33\">",
"       33",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21802?source=see_link&amp;anchor=H11694078#H11694078\">",
"       \"Cutaneous manifestations of internal malignancy\", section on 'Heritable conditions associated with malignancy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acral keratoses present as 1 to 4 mm keratotic verrucous papules that are located on the dorsal hands, wrists, or feet. Patients can also develop translucent punctate keratoses on the palms or soles [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/11,29,34\">",
"       11,29,34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Facial papules are the most frequent lesions and are found in up to 86 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/35\">",
"       35",
"      </a>",
"      ]. They have a predilection for periorificial regions, sometimes extending into the nostrils. Oral papules and papillomas (coalesced papules) on the lips, buccal mucous membranes or palate are pink or white smooth lesions of 1 to 4 mm in diameter. When they coalesce, they can form a distinctive cobblestone appearance (",
"      <a class=\"graphic graphic_picture graphicRef80290 \" href=\"UTD.htm?32/24/33155\">",
"       picture 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/32,34\">",
"       32,34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The differential diagnosis of the mucocutaneous findings includes tuberous sclerosis, Gardner syndrome, epidermodysplasia verruciformis, Brooke-Spiegler syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/36\">",
"     36",
"    </a>",
"    ], neurofibromatosis type I, and multiple fibrofolliculomas (Birt-Hogg-Dube syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/38/34410?source=see_link\">",
"     \"Tuberous sclerosis complex: Genetics, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35910?source=see_link\">",
"     \"Hereditary kidney cancer syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=see_link\">",
"     \"Neurofibromatosis type 1 (von Recklinghausen's disease)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=see_link&amp;anchor=H534324100#H534324100\">",
"     \"Clinical manifestations and diagnosis of familial adenomatous polyposis\", section on 'Gardner's syndrome'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    A recent study of PTEN-mutation carriers detailed an elevated risk for melanoma, with an 8.5-fold greater risk when compared to the average population and a 6 percent lifetime risk [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/37\">",
"     37",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H462459926\">",
"    <span class=\"h3\">",
"     Breast",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 50 percent of women with Cowden syndrome have benign breast conditions such as ductal hyperplasia, intraductal papillomatosis, adenosis, lobular atrophy, fibroadenomas, fibrocystic change, and densely fibrotic hyalinized nodules [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/11,35,38\">",
"     11,35,38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11081?source=see_link&amp;anchor=H19#H19\">",
"     \"Overview of benign breast disease\", section on 'Miscellaneous lesions of the breast'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Breast cancer is the most common malignancy in Cowden syndrome, although overall, germline mutations in",
"    <em>",
"     PTEN",
"    </em>",
"    are an uncommon cause of genetic predisposition to breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=see_link\">",
"     \"Characteristics of hereditary breast and ovarian cancer syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The lifetime risk of breast cancer for affected female patients is frequently reported at between 25 and 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/28,37,38,40\">",
"     28,37,38,40",
"    </a>",
"    ], although recent reports indicate a cumulative risk as high as 81 to 85 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/37\">",
"     37",
"    </a>",
"    ]. The onset is early, with a diagnosis at a mean of 38 to 46 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/28,38\">",
"     28,38",
"    </a>",
"    ]. Although most cases arise in women, there are rare reports of breast cancer in male patients with Cowden syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26186?source=see_link\">",
"     \"Breast cancer in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The malignant tumors are usually ductal in origin and are often surrounded by densely collagenized hamartomatous lesions, suggesting that the tumor arose from areas of hamartomatous change within the breast [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/38\">",
"     38",
"    </a>",
"    ]. There may be a tendency towards more aggressive disease in patients with Cowden syndrome:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An increased incidence of both multifocality and bilateral involvement has been observed for both benign and malignant breast disorders.",
"     </li>",
"     <li>",
"      In a report of 46 patients who presented to the Mayo Clinic over a 30-year period and who met diagnostic criteria for PHTS, five of the six breast cancers in this cohort were triple-negative (estrogen receptor, progesterone receptor, and HER2-negative) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/43\">",
"       43",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34441?source=see_link\">",
"       \"Epidemiology, risk factors and the clinical approach to ER/PR negative, HER2-negative (Triple-negative) breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of these associations, consensus recommendations for breast cancer surveillance in women with Cowden syndrome include semiannual clinical breast exam starting at age 20 to 25 years (or 5 to 10 years before the earliest known breast cancer in the family) and annual mammogram",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    breast MRI starting at age 30 to 35 (or 5 to 10 years before the earliest known breast cancer in the family) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H232666982\">",
"     'Cancer surveillance'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H462459934\">",
"    <span class=\"h3\">",
"     Thyroid",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequently reported extracutaneous manifestation of Cowden syndrome is thyroid disease, occurring in approximately two-thirds of patients.",
"    <strong>",
"    </strong>",
"    Benign thyroid abnormalities such as multinodular goiter, lymphocytic (Hashimoto) thyroiditis, and adenomas are very common in Cowden syndrome, and reported in up to 68 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/11,46,47\">",
"     11,46,47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28506?source=see_link&amp;anchor=H3#H3\">",
"     \"Diagnostic approach to and treatment of thyroid nodules\", section on 'History and physical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Individuals with Cowden syndrome and other detected mutations predisposing to a Cowden-like syndrome have an approximately 70-fold increased incidence of non-medullary thyroid cancer relative to the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/48\">",
"     48",
"    </a>",
"    ]. The reported risk of thyroid cancer in affected individuals ranges from 3 to 35 percent in large case series [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/28,31,37,40,43,46,48\">",
"     28,31,37,40,43,46,48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8440?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of papillary thyroid cancer\", section on 'Family history'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Notably, there are multiple reports of thyroid cancer diagnosed in children as young as age seven [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/48-51\">",
"     48-51",
"    </a>",
"    ]. Children presenting with thyroid cancer should be tested for",
"    <em>",
"     PTEN",
"    </em>",
"    mutations. (See",
"    <a class=\"local\" href=\"#H462460007\">",
"     'Genetic testing'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23191?source=see_link&amp;anchor=H5#H5\">",
"     \"Thyroid nodules and cancer in children\", section on 'Genetics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In most series, papillary neoplasms predominate. However, the histologic spectrum of thyroid cancers may depend on the genotype. As an example, in one report of 2723 patients with Cowden or Cowden-like syndrome, 664 had thyroid cancer (24 percent); follicular thyroid cancer was overrepresented in",
"    <em>",
"     PTEN",
"    </em>",
"    mutation-positive cases (25 percent of all cases) compared to those with",
"    <em>",
"     SDH",
"    </em>",
"    or",
"    <em>",
"     KLLN",
"    </em>",
"    mutations (7 and 13 percent of all cases, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/48\">",
"     48",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H462459942\">",
"    <span class=\"h3\">",
"     Genitourinary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several genitourinary lesions may arise in patients with Cowden syndrome:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Benign uterine abnormalities such as uterine fibroids and ovarian cysts are common findings in female patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/3/17465?source=see_link&amp;anchor=H23364224#H23364224\">",
"       \"Variants of uterine leiomyomas (fibroids)\", section on 'Cowden syndrome'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Men with Cowden syndrome may have multiple bilateral hyperechoic testicular lesions on ultrasound; they represent lipomatosis of the testes [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/52-54\">",
"       52-54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The risk of endometrial cancer is elevated in female patients, with a reported cumulative lifetime risk of 13 to 28 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/20,31,37,40\">",
"       20,31,37,40",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=see_link&amp;anchor=H8894433#H8894433\">",
"       \"Endometrial carcinoma: Epidemiology and risk factors\", section on 'Other genetic syndromes'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/6/37992?source=see_link&amp;anchor=H8895748#H8895748\">",
"       \"Endometrial carcinoma: Clinical features and diagnosis\", section on 'Other genetic syndromes'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Renal cell cancer is also increased, with a 13 to 34 percent cumulative life time risk [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/37,40,43\">",
"       37,40,43",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35910?source=see_link\">",
"       \"Hereditary kidney cancer syndromes\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5646167\">",
"    <span class=\"h3\">",
"     Gastrointestinal",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several gastrointestinal (GI) manifestations of Cowden syndrome.",
"    <strong>",
"    </strong>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H232666187\">",
"    <span class=\"h4\">",
"     Polyps",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of GI tract polyps among",
"    <em>",
"     PTEN",
"    </em>",
"    mutation carriers is as high as 66 to 93 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/31,55\">",
"     31,55",
"    </a>",
"    ]. Benign polyps can arise throughout the entire GI tract, and the histologic spectrum is diverse. Hamartomatous and inflammatory polyps are the most prevalent, but ganglioneuromatous, adenomatous, and hyperplastic polyps can also be found. Many patients have multiple histologic types of polyps [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/31,56,57\">",
"     31,56,57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32746?source=see_link&amp;anchor=H14623567#H14623567\">",
"     \"Approach to the patient with colonic polyps\", section on 'Neoplastic polyps'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/9/3224?source=see_link&amp;anchor=H21759704#H21759704\">",
"     \"Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families\", section on 'Juvenile polyposis syndrome and familial juvenile polyposis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H232666195\">",
"    <span class=\"h4\">",
"     Esophageal glycogen acanthosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glycogenic acanthosis of the esophagus typically appears as multiple, uniformly sized gray-white round elevations in an otherwise normal-appearing mucosa, usually in the midportion of the esophagus (",
"    <a class=\"graphic graphic_picture graphicRef56274 \" href=\"UTD.htm?33/57/34718\">",
"     picture 4",
"    </a>",
"    ). Although usually clinically irrelevant, when present in conjunction with hamartomatous GI tract polyps, further work-up for Cowden syndrome should occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/18/2346?source=see_link&amp;anchor=H15#H15\">",
"     \"Benign lesions of the esophagus\", section on 'Glycogen acanthosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H232666202\">",
"    <span class=\"h4\">",
"     Colorectal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only recently has an increased risk of early onset colorectal cancer been reported in patients with Cowden syndrome:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of",
"      <em>",
"       PTEN",
"      </em>",
"      mutation carriers, 13 percent of patients undergoing screening colonoscopy were found to have colorectal adenocarcinomas [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/31\">",
"       31",
"      </a>",
"      ]. The average age was 44.4 (range 35 to 49). In a report from the same research group of 368 PTEN-mutation positive patients, the risk of colorectal cancer was estimated at 10-fold higher that the general population, with an estimated lifetime risk of 9 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another series, the life-time risk of colorectal cancer in PTEN mutation carriers was 16 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of these associations, guidelines suggest that",
"    <em>",
"     PTEN",
"    </em>",
"    mutation carriers undergo routine endoscopic surveillance. (See",
"    <a class=\"local\" href=\"#H462460015\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H462459958\">",
"    <span class=\"h3\">",
"     Neurologic",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H232670781\">",
"    <span class=\"h4\">",
"     Tumors and vascular malformations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysplastic gangliocytoma of the cerebellum, or adult Lhermitte-Duclos disease, refers to a hamartomatous tumor of the cerebellar cortex that can occur in the setting of a",
"    <em>",
"     PTEN",
"    </em>",
"    mutation and Cowden syndrome in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. This benign entity is reported to develop in 6 to 32 percent of Cowden syndrome patients, with the lower estimate derived from a case series that did not include specific imaging of the head [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/31,40,58\">",
"     31,40,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms arise secondary to mass effect in the posterior fossa and commonly include headache, nausea and vomiting, ataxia, and papilledema [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35946?source=see_link&amp;anchor=H4#H4\">",
"     \"Uncommon brain tumors\", section on 'Dysplastic gangliocytoma of the cerebellum'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dysplastic gangliocytoma of the cerebellum can be familial or sporadic. It remains unclear whether all cases, even without features of Cowden syndrome, are caused by germline PTEN mutation, and whether somatic PTEN mutation occurs in sporadic cases; this should be further clarified as genetic testing becomes more readily available [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/60\">",
"     60",
"    </a>",
"    ]. However, many consider that dysplastic gangliocytoma of the cerebellum is a defining feature of Cowden syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/6,28,61\">",
"     6,28,61",
"    </a>",
"    ]. The International Cowden consortium includes dysplastic gangliocytoma of the cerebellum as a major criterion for Cowden syndrome (",
"    <a class=\"graphic graphic_table graphicRef64799 \" href=\"UTD.htm?38/46/39660\">",
"     table 1",
"    </a>",
"    ), and the consensus-based National Comprehensive Cancer Network [NCCN] guidelines consider this disease to represent a criterion for testing for Cowden syndrome (",
"    <a class=\"graphic graphic_table graphicRef72070 \" href=\"UTD.htm?28/34/29229\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. If diagnosed outside of a known PHTS, affected patients should be thoroughly investigated for other manifestations of Cowden syndrome and considered for",
"    <em>",
"     PTEN",
"    </em>",
"    mutation testing [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to dysplastic gangliocytoma of the cerebellum, intracranial vascular malformations such as venous and cavernous angiomas have been found in 30 percent of asymptomatic patients who underwent screening MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/58\">",
"     58",
"    </a>",
"    ]. In addition, meningiomas have also been associated with Cowden syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/28,58\">",
"     28,58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/54/20328?source=see_link&amp;anchor=H703809346#H703809346\">",
"     \"Meningioma: Epidemiology, risk factors, and pathology\", section on 'Other hereditary syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H462459966\">",
"    <span class=\"h4\">",
"     Macrocephaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Macrocephaly, defined as an occipital-frontal head circumference greater than the 97",
"    <sup>",
"     th",
"    </sup>",
"    percentile (greater than two standard deviations above the mean for a given age, sex, and gestation), has historically been reported in 21 to 38 percent of patients with Cowden syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/11,35\">",
"     11,35",
"    </a>",
"    ]. A more recent case series noted macrocephaly in 152 of 181 (94.4 percent) patients with confirmed",
"    <em>",
"     PTEN",
"    </em>",
"    mutation, with a mean occipital-frontal circumference 60 cm in females and 62.8 cm in males (3.5 standard deviations over the general population) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/66\">",
"     66",
"    </a>",
"    ]. Children with an increased brain size (anatomic megalencephaly) and clinical manifestations consistent with PTEN hamartoma tumor syndrome should be referred for PTEN testing. (See",
"    <a class=\"local\" href=\"#H462459990\">",
"     'Criteria for PTEN genetic testing'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/54/3946?source=see_link&amp;anchor=H8#H8\">",
"     \"Etiology and evaluation of macrocephaly in infants and children\", section on 'Anatomic megalencephaly'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/54/3946?source=see_link&amp;anchor=H32#H32\">",
"     \"Etiology and evaluation of macrocephaly in infants and children\", section on 'Other tests'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H462459974\">",
"    <span class=\"h4\">",
"     Mental retardation and developmental delay",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mental retardation or developmental delay has been reported in 11.5 percent of Cowden syndrome patients based upon a case series and review of published cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/35\">",
"     35",
"    </a>",
"    ]. Autism (typically with macrocephaly) has also been reported in conjunction with Cowden syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H462460064\">",
"     'Autism spectrum disorders and macrocephaly'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10806403\">",
"    <span class=\"h3\">",
"     Immune dysregulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune dysregulation (including defects in T and B cell homeostasis, autoimmunity, intestinal lymphoid hyperplasia, thymus hyperplasia, and thymoma as well as T-cell lymphoma) has been described in mice with heterozygous",
"    <em>",
"     PTEN",
"    </em>",
"    deletions, and murine models confirm a functional role for",
"    <span class=\"nowrap\">",
"     PTEN/PI3K",
"    </span>",
"    signaling pathways in a broad variety of cell types including B cell subsets [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. While at least some data suggest that PTEN deficiency in humans is associated with immune dysregulation that can be manifest as",
"    <span class=\"nowrap\">",
"     autoimmunity/tissue",
"    </span>",
"    inflammation and lymphoid hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/71\">",
"     71",
"    </a>",
"    ], immune dysfunction in humans carrying germline PTEN mutations has not been systematically analyzed, and at present, there is no immediate clinical implication of these very interesting findings in mice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H462459982\">",
"    <span class=\"h2\">",
"     Diagnostic and testing criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consensus-based diagnostic criteria for Cowden syndrome are available from the International Cowden Consortium (",
"    <a class=\"graphic graphic_table graphicRef64799 \" href=\"UTD.htm?38/46/39660\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. The diagnostic criteria are divided into pathognomonic criteria, major criteria, and minor criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pathognomonic criteria include mucocutaneous lesions such as facial trichilemmomas, acral keratoses, or papillomatous oral lesions.",
"     </li>",
"     <li>",
"      The major criteria are breast cancer, thyroid cancer, macrocephaly, endometrial cancer, and dysplastic gangliocytoma of the cerebellum. &nbsp;",
"     </li>",
"     <li>",
"      Minor criteria are benign structural thyroid disease, mental retardation, hamartomatous GI tract polyps, benign cystic breast disease, lipomas or fibromas, and genitourinary tumors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the absence of family history, an operational diagnosis can be made solely with pathognomic lesions if there are: six facial papules, of which at least three are trichilemmomas, six or more acral keratoses, facial papules and oral papillomatosis, or acral keratoses and oral papillomatosis. Two major criteria are diagnostic if one is macrocephaly or dysplastic gangliocytoma of the cerebellum. One major and three minor criteria or four minor criteria are also considered diagnostic.",
"   </p>",
"   <p>",
"    If there is a family history of Cowden syndrome, then one pathognomonic or major criterion or two minor criteria is required for a diagnosis.",
"   </p>",
"   <p>",
"    The specificity of the Consortium criteria is lower than previously estimated. Recent estimates are that only approximately 20 to 34 percent of individuals who meet these clinical criteria for Cowden syndrome or who meet criteria for genetic testing have germline",
"    <em>",
"     PTEN",
"    </em>",
"    mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/3,20,21\">",
"     3,20,21",
"    </a>",
"    ]. This has led to efforts to develop more robust criteria for PTEN testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H462459990\">",
"    <span class=\"h3\">",
"     Criteria for PTEN genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The NCCN has produced consensus testing criteria for Cowden syndrome that are periodically updated (",
"    <a class=\"graphic graphic_table graphicRef72070 \" href=\"UTD.htm?28/34/29229\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/64\">",
"     64",
"    </a>",
"    ]. The clinical testing criteria are slightly different than the criteria recommended for diagnosis by the International Cowden Consortium. Criteria to warrant testing include an individual from a family with a known",
"    <em>",
"     PTEN",
"    </em>",
"    mutation, a personal history of adult dysplastic gangliocytoma of the cerebellum, autism spectrum disorder with macrocephaly, biopsy-confirmed trichilemmomas, or a combination of major and minor clinical findings similar to the diagnostic criteria. If these conditions are met, it is recommended that the patient undergo pre-genetic testing counseling and then testing for",
"    <em>",
"     PTEN",
"    </em>",
"    mutation. If there is no known familial",
"    <em>",
"     PTEN",
"    </em>",
"    mutation, consideration should be given to initially testing the family member with the highest likelihood of having a",
"    <em>",
"     PTEN",
"    </em>",
"    mutation based upon the clinical presentation.",
"   </p>",
"   <p>",
"    The NCCN criteria are not refined for pediatric populations, and they do not provide quantitative estimates as to the probability of testing positive for a",
"    <em>",
"     PTEN",
"    </em>",
"    mutation. Two clinical scoring systems have been developed to help select adult and pediatric patients for",
"    <em>",
"     PTEN",
"    </em>",
"    mutation testing that may have improved sensitivity and specificity compared to the NCCN criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One scoring system was developed based upon data from a cohort of patients from one center and validated based upon data from patients at a second center [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/21\">",
"       21",
"      </a>",
"      ]. The adult prediction model involves demographic data such as sex and age, personal history of cancer as well as weighted scores for dermatologic, neurologic, breast, gynecologic, gastrointestinal, endocrine and genitourinary manifestations. The pediatric criteria are derived from the presence of macrocephaly and either autism or developmental delay, dermatologic findings, vascular abnormalities or gastrointestinal polyps. A clinical calculator is available online",
"      <a class=\"external\" href=\"file://lerner.ccf.org/gmi/ccscore/\">",
"       CCF score for PTEN test",
"      </a>",
"      . &nbsp;",
"     </li>",
"     <li>",
"      A second scoring system was created based upon data compiled from a single center and the primary laboratory offering",
"      <em>",
"       PTEN",
"      </em>",
"      mutation testing in the United States (which also served as the comparison center for the other clinical scoring system) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/20\">",
"       20",
"      </a>",
"      ]. Prediction models for adult females incorporate benign gastrointestinal and thyroid lesions, dermatologic findings, endometrial cancer, and macrocephaly. For adult males with macrocephaly, the model includes benign gastrointestinal and thyroid lesions. Prediction models were created for females under 18 incorporating benign skin lesions and macrocephaly and for males under 18 with macrocephaly involving lipomas, papillomatous papules, and penile freckling. A clinical calculator is available online",
"      <a class=\"external\" href=\"file://internalmedicine.osu.edu/genetics/research/tools-for-providers/\">",
"       OSU score for PTEN testing",
"      </a>",
"      . We prefer this calculator due to its simplicity and ease of use, even though it cannot be applied to males without macrocephaly.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H462460007\">",
"    <span class=\"h3\">",
"     Genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     PTEN",
"    </em>",
"    mutation testing, including sequence analysis of the entire coding region and",
"    <span class=\"nowrap\">",
"     deletion/duplication",
"    </span>",
"    analysis, is available from multiple clinical laboratories [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/61\">",
"     61",
"    </a>",
"    ]. The majority of",
"    <em>",
"     PTEN",
"    </em>",
"    mutations are detected by sequencing, but all types of mutations have been reported including missense, nonsense, splice site, insertions, and deletions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/3,24,25\">",
"     3,24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mutations have also been reported in the PTEN promoter and a test for mutations in this region of the gene has become clinically available. Clinical testing is also available for two other genes that have been associated with a Cowden-like presentation:",
"    <em>",
"     SDH",
"    </em>",
"    subunit B, and",
"    <em>",
"     SDH",
"    </em>",
"    subunit D.",
"    <em>",
"     KLLN",
"    </em>",
"    epimutation testing is not currently available on a clinical service basis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/22,26\">",
"     22,26",
"    </a>",
"    ]. However, clinical testing availability is expanding rapidly so the clinician may look up specific test availability in clinically approved molecular genetics diagnostic laboratories at",
"    <a class=\"external\" href=\"file://www.genetests.org/\">",
"     GeneTests",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H462460015\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cowden syndrome has effects on almost all organ systems and a multidisciplinary treatment team is needed, which includes dedicated genetic counseling. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/60/5064?source=see_link\">",
"     \"Genetic risk assessment for individuals at risk for hereditary breast and ovarian cancer syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=see_link\">",
"     \"Genetic counseling and testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following management recommendations apply to patients with documented",
"    <em>",
"     PTEN",
"    </em>",
"    ,",
"    <em>",
"     SDH,",
"    </em>",
"    or",
"    <em>",
"     KLLN",
"    </em>",
"    mutations as well as for those who fit the clinical diagnostic criteria for Cowden syndrome but lack a detected mutation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H232666982\">",
"    <span class=\"h3\">",
"     Cancer surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the high risk of malignancy, cancer surveillance is the major focus of medical management. The NCCN provides updated guidelines that outline a cancer surveillance program for both men and women with Cowden syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/72\">",
"     72",
"    </a>",
"    ]. In addition to genetic counseling and education regarding the syndrome and possible manifestations, recommendations for all patients include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Annual comprehensive physical exam, with particular attention to breast and thyroid, starting at 18 years of age or five years before the youngest age of diagnosis of a component cancer in the family",
"     </li>",
"     <li>",
"      Baseline thyroid ultrasound at 18 years and consideration of repeating annually thereafter",
"     </li>",
"     <li>",
"      Consideration of baseline colonoscopy at age 35 years then every 5 to 10 years or more frequently if symptoms or polyps are noted",
"     </li>",
"     <li>",
"      Consideration of annual dermatologic exam",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recommendations specifically for women include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Breast self-exam training and education starting at age 18 years",
"     </li>",
"     <li>",
"      Clinical breast exam every 6 to 12 months starting at age 25 years or 5 to 10 years before the earliest known breast cancer in the family",
"     </li>",
"     <li>",
"      Annual mammography and breast MRI screening starting at age 30 to 35 years or 5 to 10 years before the earliest known breast cancer in the family",
"     </li>",
"     <li>",
"      Education regarding endometrial cancer and prompt response to symptoms consistent with endometrial cancer",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The recommendation for early surveillance colonoscopy was added in 2011 in response to new data showing an increased risk of colorectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/31,40\">",
"     31,40",
"    </a>",
"    ]. Prior to undergoing colonoscopy, patients should be educated regarding possible outcomes if multiple polyps are found, including frequent surveillance colonoscopies and colectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given reports of thyroid cancer diagnosed younger than the recommended age to initiate imaging, some have recommended starting surveillance with thyroid ultrasound at the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/37,51\">",
"     37,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to these recommendations, several other screening tests not endorsed by the NCCN should be considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend annual urinalysis with cytology to screen for renal cell cancer starting at age 35 years or 5 to 10 years before the earliest known renal cancer in the family. Some have recommended an intensive renal imaging-based surveillance regimen, with twice yearly ultrasound or MRI starting five years before the earliest onset renal cancer in the family or age 40 [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Given reports of thyroid cancer diagnosed younger than the recommended age to initiate imaging, we agree with recommendations to start annual surveillance with thyroid ultrasound at the time of diagnosis.",
"     </li>",
"     <li>",
"      Screening for dysplastic gangliocytoma of the cerebellum has been recommended, but there is no evidence of improved outcomes with early detection [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/73\">",
"       73",
"      </a>",
"      ]. However, given the increased incidence of dysplastic gangliocytoma of the cerebellum and the non-specific and insidious symptoms, there should be a low index of suspicion in patients who meet criteria for Cowden&rsquo;s syndrome, and a low threshold to perform neuroimaging in any patient with Cowden syndrome who develops a persistent headache [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/74\">",
"       74",
"      </a>",
"      ]. MRI is the preferred imaging modality.",
"     </li>",
"     <li>",
"      Endometrial cancer surveillance with blind biopsies beginning at age 35 to 40 years or five years younger than the earliest familial endometrial cancer diagnosis for premenopausal women and annual transvaginal ultrasound examination can be considered for postmenopausal women, although these recommendations are no longer endorsed by the NCCN [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some experts have recommended a much more aggressive colorectal cancer surveillance with twice yearly colonoscopy, starting five years before the earliest onset colorectal cancer in the family or age 40 [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H232667011\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of the benign and malignant manifestations of Cowden syndrome is performed as per usual practice for sporadic occurrence.",
"   </p>",
"   <p>",
"    Although a benign entity, resection of a dysplastic gangliocytoma of the cerebellum is usually undertaken as hydrocephalus with potentially fatal herniation that can result from local growth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35946?source=see_link&amp;anchor=H4#H4\">",
"     \"Uncommon brain tumors\", section on 'Dysplastic gangliocytoma of the cerebellum'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We advise individualized colorectal cancer surveillance recommendations based on personal and familial history of the patient. Gastrointestinal polyps should be endoscopically resected given the varied histology, including frequent adenomatous polyps, and the risk for dysplastic change and colorectal cancer. Endoscopic techniques to improve visual differentiation of polyp histology, such as narrow band imaging, should be considered to allow for preferential removal of large polyps (&ge;1 cm) or those that appear to be adenomatous [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28968?source=see_link\">",
"     \"Endoscopic removal of large colonic polyps\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32746?source=see_link&amp;anchor=H15416963#H15416963\">",
"     \"Approach to the patient with colonic polyps\", section on 'Hamartomatous polyps'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Future treatment options may involve targeting the genetic pathways affected by loss of",
"    <em>",
"     PTEN",
"    </em>",
"    gene function.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    (also known as rapamycin), commonly used for immunosuppression following solid organ transplantation, suppresses cell proliferation by inhibiting the mammalian target of rapamycin (mTOR). In a mouse model of experimental Cowden syndrome, administration of sirolimus led to regression of mucocutaneous lesions and, if administered prior to their development, decreased the occurrence of mucocutaneous lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/75\">",
"     75",
"    </a>",
"    ]. There is a single case of sirolimus being used successfully to reduce tumor burden for over 17 months in a patient with",
"    <em>",
"     PTEN",
"    </em>",
"    mutation and multiple hamartomatous growths, with a phenotype of Proteus syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H462460056\">",
"     'Proteus and Proteus-like syndromes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    An ongoing phase II clinical trial sponsored by the National Cancer Institute (NCT00971789) is investigating the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    and its effect on disease progression for patients with Cowden syndrome and other PHTS with documented",
"    <em>",
"     PTEN",
"    </em>",
"    mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/77\">",
"     77",
"    </a>",
"    ]. Eligible patients should be encouraged to enroll.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H462460023\">",
"    <span class=\"h1\">",
"     BANNAYAN-RILEY-RUVALCABA SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bannayan-Riley-Ruvalcaba syndrome (BRRS, previously referred to as Ruvalcaba-Myrhe syndrome, Ruvalcaba-Myhre-Smith syndrome, Riley-Smith syndrome, Bannayan syndrome, or Bannayan-Zonana syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/78\">",
"     78",
"    </a>",
"    ]) is a rare autosomal dominant disorder that is also linked to germline",
"    <em>",
"     PTEN",
"    </em>",
"    mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/79\">",
"     79",
"    </a>",
"    ].",
"    <em>",
"     PTEN",
"    </em>",
"    mutations are present in 55 to 60 percent of patients with a clinical diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/1,20\">",
"     1,20",
"    </a>",
"    ]. Clinical manifestations arise early in childhood, one aspect that is markedly different from Cowden syndrome. Evaluation is often started in the first few years of life with a reported median age of diagnosis as young as five years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/80\">",
"     80",
"    </a>",
"    ]. Given that identical",
"    <em>",
"     PTEN",
"    </em>",
"    mutations have been described in families with BRRS or Cowden syndrome only [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/81\">",
"     81",
"    </a>",
"    ], and the partial clinical overlap, it is likely that Cowden syndrome and BRRS are different phenotypic presentations of the same syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H462460040\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical diagnostic criteria have not been established for BRRS. As with Cowden syndrome, published data on clinical manifestations come mainly from small case series or compilations of published cases. As a result, the true frequencies of the clinical features are not clearly known [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H462459982\">",
"     'Diagnostic and testing criteria'",
"    </a>",
"    above.) Widely-noted clinical findings include [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/50,82,83\">",
"     50,82,83",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Macrocephaly (at least two standard deviations above the mean)",
"     </li>",
"     <li>",
"      Penile lentigines (a very specific marker of the disease [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/84\">",
"       84",
"      </a>",
"      ]) (",
"      <a class=\"graphic graphic_picture graphicRef62253 \" href=\"UTD.htm?0/2/42\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      GI tract hamartomatous polyps",
"     </li>",
"     <li>",
"      Lipomas",
"     </li>",
"     <li>",
"      Vascular anomalies including arteriovenous shunts, and fistulae [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/85\">",
"       85",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Intramuscular lesions with mixture of adipose tissue, fibrous tissue and abnormal vessels (labeled a PTEN hamartoma of soft tissue [",
"      <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/86\">",
"       86",
"      </a>",
"      ])",
"     </li>",
"     <li>",
"      Hashimoto thyroiditis and other thyroid disorders including thyroid cancer",
"     </li>",
"     <li>",
"      Mild-to-severe developmental delay or deficiency",
"     </li>",
"     <li>",
"      Proximal muscle myopathy",
"     </li>",
"     <li>",
"      High palate",
"     </li>",
"     <li>",
"      Joint hypermobility",
"     </li>",
"     <li>",
"      Eye abnormalities such as downslant, strabismus, and amblyopia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An increased risk of internal malignancy has not been consistently documented with BRRS, although several childhood onset non-medullary thyroid cancers have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/4,47,50,51\">",
"     4,47,50,51",
"    </a>",
"    ]. Multiple other clinical findings, such as facial dysmorphology and ophthalmologic abnormalities, have been reported but are less consistently described [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differential diagnosis includes CLOVE syndrome (congenital lipomatous overgrowth, vascular malformations, and epidermal nevi) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/88,89\">",
"     88,89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H462460048\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no published guidelines from expert groups that list criteria for mutation testing.",
"    <strong>",
"     &nbsp;",
"    </strong>",
"    The clinical scoring systems noted above for Cowden syndrome can also be used to select patients with suspected BRRS for",
"    <em>",
"     PTEN",
"    </em>",
"    mutation testing [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H462459990\">",
"     'Criteria for PTEN genetic testing'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    BRRS has effects in multiple organ systems and a multidisciplinary treatment team is needed, including dedicated genetic counseling. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=see_link\">",
"     \"Genetic counseling and testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatments for symptomatic manifestations should follow standard practices.",
"   </p>",
"   <p>",
"    There are no consensus guidelines for cancer surveillance in patients with BRRS. We recommend following the complete Cowden syndrome cancer surveillance recommendations if a",
"    <em>",
"     PTEN",
"    </em>",
"    mutation is present, given the significant link between this genetic abnormality and cancer risk, and suggest also following these guidelines if clinical manifestations are consistent with the syndrome but a",
"    <em>",
"     PTEN",
"    </em>",
"    mutation is not documented. (See",
"    <a class=\"local\" href=\"#H232666982\">",
"     'Cancer surveillance'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H462460056\">",
"    <span class=\"h1\">",
"     PROTEUS AND PROTEUS-LIKE SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proteus syndrome is an exceedingly rare complex disorder comprising malformations and overgrowth of multiple tissues that has gained some notoriety as the probable diagnosis of Joseph Merrick, better known as the Elephant Man [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/90\">",
"     90",
"    </a>",
"    ]. The disorder was originally designated Proteus syndrome because of its variability of clinical expression [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H634863\">",
"    <span class=\"h2\">",
"     Molecular genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;All cases are sporadic. Somatic activating mutations in the",
"    <em>",
"     AKT1",
"    </em>",
"    oncogene have been delineated as the genetic cause of Proteus syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/92\">",
"     92",
"    </a>",
"    ]. There have been reports of",
"    <em>",
"     PTEN",
"    </em>",
"    mutations in some patients with phenotypic similarities to the Proteus syndrome (termed by some, Proteus-like syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/93-95\">",
"     93-95",
"    </a>",
"    ]), but whether these were appropriately diagnosed is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/8,96\">",
"     8,96",
"    </a>",
"    ]. This has led to the recommendation that patients with phenotypic features suggestive of Proteus syndrome but with",
"    <em>",
"     PTEN",
"    </em>",
"    mutations be labeled as having Segmental Overgrowth, Lipomatosis, Arteriovenous Malformation, and Epidermal Nevus (SOLAMEN) syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/97\">",
"     97",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H634870\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Proteus syndrome is characterized by rapidly progressive, asymmetric postnatal overgrowth of tissues, with hyperostoses, vascular malformations, dysregulation of fatty tissues (both atrophy and overgrowth), and skin manifestations such as verrucous epidermal nevi or cerebriform connective tissue nevi (",
"    <a class=\"graphic graphic_picture graphicRef73826 \" href=\"UTD.htm?33/53/34642\">",
"     picture 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/98\">",
"     98",
"    </a>",
"    ]. While tissue overgrowth is progressive in nature, it typically appears to plateau after adolescence [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/99,100\">",
"     99,100",
"    </a>",
"    ]. When present, a cerebriform connective tissue nevus (plantar collagenoma) is almost pathognomonic for Proteus syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/101\">",
"     101",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/10/2217?source=see_link&amp;anchor=H3700642#H3700642\">",
"     \"Capillary malformations (port wine stains): Clinical features, diagnosis, and associated syndromes\", section on 'Proteus syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cystic lung abnormalities are found in 12 to 13 percent of affected individuals, which may progress to cystic emphysematous pulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/102\">",
"     102",
"    </a>",
"    ]. Several unusual types of tumors (eg, monomorphic adenoma of the parotid gland and bilateral ovarian cystadenomas at an early age) are specifically associated with Proteus syndrome, although varied other tumors have been described including breast, endometrial and testicular cancer, but no reported cases of thyroid cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/98,103,104\">",
"     98,103,104",
"    </a>",
"    ]. While most superficial lipomas are benign, intraabdominal and intrathoracic lipomas have an increased potential for invasive behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H634877\">",
"    <span class=\"h2\">",
"     Diagnosis, differential diagnosis, and management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis is made clinically. Based upon the reported features, diagnostic criteria for the Proteus syndrome (",
"    <a class=\"graphic graphic_table graphicRef52150 \" href=\"UTD.htm?43/45/44763\">",
"     table 3",
"    </a>",
"    ) were developed by an expert consensus panel [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/101\">",
"     101",
"    </a>",
"    ]. Genetic testing for somatic AKT mutations is not commercially available. However, clinical testing availability is expanding rapidly so the clinician may look up specific test availability in clinically approved molecular genetics diagnostic laboratories at",
"    <a class=\"external\" href=\"file://www.genetests.org/\">",
"     GeneTests",
"    </a>",
"    . The differential diagnosis includes Klippel-Trenaunay syndrome, Parkes-Weber syndrome, neurofibromatosis type 1, epidermal nevus syndrome, Bannayan-Riley-Ruvalcaba syndrome,",
"    <span class=\"nowrap\">",
"     hemihyperplasia/lipomatosis",
"    </span>",
"    syndrome, familial lipomatosis, encephalocraniocutaneous lipomatosis, and syndrome (congenital lipomatous overgrowth, vascular malformations, and epidermal nevi) caused by the PIK3CA gene mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/88,89,101\">",
"     88,89,101",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H462460023\">",
"     'Bannayan-Riley-Ruvalcaba syndrome'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30038?source=see_link\">",
"     \"Vascular lesions in the newborn\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=see_link\">",
"     \"Neurofibromatosis type 1 (von Recklinghausen's disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Morbidity in these patients includes various orthopedic complications and an elevated risk for venous thromboses and pulmonary thromboembolism [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/105,106\">",
"     105,106",
"    </a>",
"    ]. Given the rarity of this disorder and the severity of its manifestations, early referral to an experienced treatment center is recommended if this diagnosis is considered.",
"   </p>",
"   <p>",
"    The optimal surveillance strategy is not established. Given the lack of typical malignancies associated with PHTS, the suggestion by some experts to follow the cancer surveillance guidelines developed for Cowden syndrome in all cases of Proteus syndrome is premature. It is reasonable, however, to follow these guidelines in patients who have the",
"    <em>",
"     PTEN",
"    </em>",
"    -associated SOLAMEN syndrome given the connection between the genetic abnormality and neoplastic change. (See",
"    <a class=\"local\" href=\"#H232666982\">",
"     'Cancer surveillance'",
"    </a>",
"    above.) Guidelines for patient evaluation are available from an expert panel, and include [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/101\">",
"     101",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serial clinical photography",
"     </li>",
"     <li>",
"      Initial skeletal survey with targeted follow-up radiographs",
"     </li>",
"     <li>",
"      MRI of all clinically affected areas and MRI of the chest and abdomen ini the absence of symptoms",
"     </li>",
"     <li>",
"      Dermatologic and orthopedic consultation",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H462460064\">",
"    <span class=\"h1\">",
"     AUTISM SPECTRUM DISORDERS AND MACROCEPHALY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autism spectrum disorders or developmental delay with macrocephaly and without other signs of a PTEN hamartoma tumor syndrome (PHTS) are associated with germline",
"    <em>",
"     PTEN",
"    </em>",
"    mutations in 1 to 8 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/107-109\">",
"     107-109",
"    </a>",
"    ]. One prospective series that specifically excluded patients with PHTS found mutations in 3 of 18 (17 percent) patients with autism spectrum disorders and extreme macrocephaly [",
"    <a class=\"abstract\" href=\"UTD.htm?28/53/29530/abstract/9\">",
"     9",
"    </a>",
"    ]. Although these reports describe patients that do not meet criteria for a PHTS diagnosis, they do not describe the clinical outcomes of these patients nor comment on the development of PHTS when these subjects reach adulthood. Autism and macrocephaly arise early in life and may be childhood manifestations of PHTS rather than a discrete phenotype. Long-term follow-up of these patients will be needed to determine their risk for development of other manifestations of PHTS and especially malignancies. Until this is clarified, if a",
"    <em>",
"     PTEN",
"    </em>",
"    mutation is detected, it is reasonable to follow the NCCN screening recommendations for Cowden syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/54/3946?source=see_link&amp;anchor=H8#H8\">",
"     \"Etiology and evaluation of macrocephaly in infants and children\", section on 'Anatomic megalencephaly'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H462460072\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The PTEN hamartoma tumor syndrome (PHTS) is primarily comprised of the Cowden and Bannayan-Riley-Ruvalcaba syndromes, autosomal dominant disorders that are associated with mutations in the",
"      <em>",
"       PTEN",
"      </em>",
"      tumor suppressor gene, and an increased risk of both benign and malignant tumors. (See",
"      <a class=\"local\" href=\"#H5356445\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with Cowden syndrome have characteristic mucocutaneous lesions and an elevated risk of breast, thyroid, endometrial, colorectal, and renal cancers as well as various benign manifestations such as macrocephaly and dysplastic gangliocytoma of the cerebellum. (See",
"      <a class=\"local\" href=\"#H462459910\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Clinical diagnostic criteria have been established for Cowden syndrome as well as proposed criteria for genetic testing for PTEN mutations. (See",
"      <a class=\"local\" href=\"#H462459982\">",
"       'Diagnostic and testing criteria'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Treatment of the benign and malignant manifestations of Cowden syndrome are performed as per usual practice for sporadic occurrence. (See",
"      <a class=\"local\" href=\"#H232667011\">",
"       'Treatment'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      A major focus of management of individuals with Cowden syndrome focuses on cancer surveillance (see",
"      <a class=\"local\" href=\"#H232666982\">",
"       'Cancer surveillance'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We recommend annual comprehensive physical exam, annual thyroid ultrasound, colonoscopy at age 35 and annual urinalysis with cytology. In women, we recommend biannual or annual clinical breast exam and annual mammography and breast MRI.",
"     </li>",
"     <li>",
"      In addition, endometrial cancer surveillance with blind biopsies beginning at age 35 to 40, or five years younger than the earliest familial endometrial cancer diagnosis, for premenopausal women and annual transvaginal ultrasound examination for postmenopausal women can be considered, although this recommendation is no longer endorsed by the NCCN.",
"     </li>",
"     <li>",
"      We do not recommend screening for brain tumors. However, given the increased incidence of dysplastic gangliocytoma of the cerebellum and the non-specific and insidious symptoms, there should be a low index of suspicion in patients who meet criteria for Cowden syndrome, and a low threshold to perform neuroimaging in any patient with Cowden syndrome who develops a persistent headache. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bannayan-Riley-Ruvalcaba syndrome is characterized by macrocephaly, penile lentigines, lipomas, vascular abnormalities, hamartomatous gastrointestinal polyps, and developmental delay. They lack the documented high penetrance of cancer seen in Cowden syndrome, although several cases of thyroid cancer have been reported. (See",
"      <a class=\"local\" href=\"#H462460023\">",
"       'Bannayan-Riley-Ruvalcaba syndrome'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Given the effects in multiple organ systems, a multidisciplinary treatment team is needed, including dedicated genetic counseling. There are no consensus diagnostic criteria or management recommendations for Bannayan-Riley-Ruvalcaba syndrome. We recommend following the cancer surveillance protocol for Cowden syndrome in patients who have a documented",
"      <em>",
"       PTEN",
"      </em>",
"      mutation or a clinical diagnosis. (See",
"      <a class=\"local\" href=\"#H462460048\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several other syndromes have been linked with",
"      <em>",
"       PTEN",
"      </em>",
"      mutations including Proteus-like (SOLAMEN) syndrome and autism with macrocephaly. It is unclear if these conditions have a similarly elevated risk of malignancy, but if a",
"      <em>",
"       PTEN",
"      </em>",
"      mutation is found it is reasonable to use the recommended cancer surveillance for Cowden syndrome. (See",
"      <a class=\"local\" href=\"#H462460056\">",
"       'Proteus and Proteus-like syndromes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H462460064\">",
"       'Autism spectrum disorders and macrocephaly'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/1\">",
"      Marsh DJ, Kum JB, Lunetta KL, et al. PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet 1999; 8:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/2\">",
"      Lachlan KL, Lucassen AM, Bunyan D, Temple IK. Cowden syndrome and Bannayan Riley Ruvalcaba syndrome represent one condition with variable expression and age-related penetrance: results of a clinical study of PTEN mutation carriers. J Med Genet 2007; 44:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/3\">",
"      Marsh DJ, Coulon V, Lunetta KL, et al. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet 1998; 7:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/4\">",
"      Zori RT, Marsh DJ, Graham GE, et al. Germline PTEN mutation in a family with Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome. Am J Med Genet 1998; 80:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/5\">",
"      Wanner M, Celebi JT, Peacocke M. Identification of a PTEN mutation in a family with Cowden syndrome and Bannayan-Zonana syndrome. J Am Acad Dermatol 2001; 44:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/6\">",
"      Zhou XP, Marsh DJ, Morrison CD, et al. Germline inactivation of PTEN and dysregulation of the phosphoinositol-3-kinase/Akt pathway cause human Lhermitte-Duclos disease in adults. Am J Hum Genet 2003; 73:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/7\">",
"      Abel TW, Baker SJ, Fraser MM, et al. Lhermitte-Duclos disease: a report of 31 cases with immunohistochemical analysis of the PTEN/AKT/mTOR pathway. J Neuropathol Exp Neurol 2005; 64:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/8\">",
"      Zhou X, Hampel H, Thiele H, et al. Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes. Lancet 2001; 358:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/9\">",
"      Butler MG, Dasouki MJ, Zhou XP, et al. Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J Med Genet 2005; 42:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/10\">",
"      LLOYD KM 2nd, DENNIS M. Cowden's disease. A possible new symptom complex with multiple system involvement. Ann Intern Med 1963; 58:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/11\">",
"      Starink TM, van der Veen JP, Arwert F, et al. The Cowden syndrome: a clinical and genetic study in 21 patients. Clin Genet 1986; 29:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/12\">",
"      Weary PE, Gorlin RJ, Gentry WC Jr, et al. Multiple hamartoma syndrome (Cowden's disease). Arch Dermatol 1972; 106:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/13\">",
"      Nelen MR, Kremer H, Konings IB, et al. Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations. Eur J Hum Genet 1999; 7:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/14\">",
"      Stambolic V, Suzuki A, de la Pompa JL, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998; 95:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/15\">",
"      Nelen MR, Padberg GW, Peeters EA, et al. Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet 1996; 13:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/16\">",
"      Keniry M, Parsons R. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 2008; 27:5477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/17\">",
"      Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004; 22:2954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/18\">",
"      Krymskaya VP, Goncharova EA. PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects. Cell Cycle 2009; 8:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/19\">",
"      Liaw D, Marsh DJ, Li J, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997; 16:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/20\">",
"      Pilarski R, Stephens JA, Noss R, et al. Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome clinical features. J Med Genet 2011; 48:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/21\">",
"      Tan MH, Mester J, Peterson C, et al. A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands. Am J Hum Genet 2011; 88:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/22\">",
"      Bennett KL, Mester J, Eng C. Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome. JAMA 2010; 304:2724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/23\">",
"      Cho YJ, Liang P. Killin is a p53-regulated nuclear inhibitor of DNA synthesis. Proc Natl Acad Sci U S A 2008; 105:5396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/24\">",
"      Chibon F, Primois C, Bressieux JM, et al. Contribution of PTEN large rearrangements in Cowden disease: a multiplex amplifiable probe hybridisation (MAPH) screening approach. J Med Genet 2008; 45:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/25\">",
"      Zhou XP, Waite KA, Pilarski R, et al. Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway. Am J Hum Genet 2003; 73:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/26\">",
"      Ni Y, Zbuk KM, Sadler T, et al. Germline mutations and variants in the succinate dehydrogenase genes in Cowden and Cowden-like syndromes. Am J Hum Genet 2008; 83:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/27\">",
"      Ni Y, He X, Chen J, et al. Germline SDHx variants modify breast and thyroid cancer risks in Cowden and Cowden-like syndrome via FAD/NAD-dependant destabilization of p53. Hum Mol Genet 2012; 21:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/28\">",
"      Pilarski R. Cowden syndrome: a critical review of the clinical literature. J Genet Couns 2009; 18:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/29\">",
"      Hildenbrand C, Burgdorf WH, Lautenschlager S. Cowden syndrome-diagnostic skin signs. Dermatology 2001; 202:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/30\">",
"      Salem OS, Steck WD. Cowden's disease (multiple hamartoma and neoplasia syndrome). A case report and review of the English literature. J Am Acad Dermatol 1983; 8:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/31\">",
"      Heald B, Mester J, Rybicki L, et al. Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. Gastroenterology 2010; 139:1927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/32\">",
"      Brownstein MH, Mehregan AH, Bikowski JB, et al. The dermatopathology of Cowden's syndrome. Br J Dermatol 1979; 100:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/33\">",
"      Al-Zaid T, Ditelberg JS, Prieto VG, et al. Trichilemmomas show loss of PTEN in Cowden syndrome but only rarely in sporadic tumors. J Cutan Pathol 2012; 39:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/34\">",
"      Masmoudi A, Chermi ZM, Marrekchi S, et al. Cowden syndrome. J Dermatol Case Rep 2011; 5:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/35\">",
"      Hanssen AM, Werquin H, Suys E, Fryns JP. Cowden syndrome: report of a large family with macrocephaly and increased severity of signs in subsequent generations. Clin Genet 1993; 44:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/36\">",
"      Ponti G, Nasti S, Losi L, et al. Brooke-Spiegler syndrome: report of two cases not associated with a mutation in the CYLD and PTCH tumor-suppressor genes. J Cutan Pathol 2012; 39:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/37\">",
"      Tan MH, Mester JL, Ngeow J, et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 2012; 18:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/38\">",
"      Schrager CA, Schneider D, Gruener AC, et al. Clinical and pathological features of breast disease in Cowden's syndrome: an underrecognized syndrome with an increased risk of breast cancer. Hum Pathol 1998; 29:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/39\">",
"      FitzGerald MG, Marsh DJ, Wahrer D, et al. Germline mutations in PTEN are an infrequent cause of genetic predisposition to breast cancer. Oncogene 1998; 17:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/40\">",
"      Riegert-Johnson DL, Gleeson FC, Roberts M, et al. Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients. Hered Cancer Clin Pract 2010; 8:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/41\">",
"      Fackenthal JD, Marsh DJ, Richardson AL, et al. Male breast cancer in Cowden syndrome patients with germline PTEN mutations. J Med Genet 2001; 38:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/42\">",
"      Gustafson S, Zbuk KM, Scacheri C, Eng C. Cowden syndrome. Semin Oncol 2007; 34:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/43\">",
"      Patnaik MM, Raza SS, Khambatta S, et al. Oncophenotypic review and clinical correlates of phosphatase and tensin homolog on chromosome 10 hamartoma tumor syndrome. J Clin Oncol 2010; 28:e767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/44\">",
"      Daly MB, Axilbund JE, Buys S, et al. Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw 2010; 8:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/45\">",
"      Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007; 57:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/46\">",
"      Harach HR, Soubeyran I, Brown A, et al. Thyroid pathologic findings in patients with Cowden disease. Ann Diagn Pathol 1999; 3:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/47\">",
"      Laury AR, Bongiovanni M, Tille JC, et al. Thyroid pathology in PTEN-hamartoma tumor syndrome: characteristic findings of a distinct entity. Thyroid 2011; 21:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/48\">",
"      Ngeow J, Mester J, Rybicki LA, et al. Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterations. J Clin Endocrinol Metab 2011; 96:E2063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/49\">",
"      Longy M, Lacombe D. Cowden disease. Report of a family and review. Ann Genet 1996; 39:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/50\">",
"      Tan WH, Baris HN, Burrows PE, et al. The spectrum of vascular anomalies in patients with PTEN mutations: implications for diagnosis and management. J Med Genet 2007; 44:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/51\">",
"      Smith JR, Marqusee E, Webb S, et al. Thyroid nodules and cancer in children with PTEN hamartoma tumor syndrome. J Clin Endocrinol Metab 2011; 96:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/52\">",
"      Woodhouse J, Ferguson MM. Multiple hyperechoic testicular lesions are a common finding on ultrasound in Cowden disease and represent lipomatosis of the testis. Br J Radiol 2006; 79:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/53\">",
"      Woodhouse JB, Delahunt B, English SF, et al. Testicular lipomatosis in Cowden's syndrome. Mod Pathol 2005; 18:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/54\">",
"      Alnajjar HM, Sahai A, Keane A, Gordon S. Testicular pain as a presentation of Cowden syndrome. Ann R Coll Surg Engl 2011; 93:e51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/55\">",
"      Kato M, Mizuki A, Hayashi T, et al. Cowden's disease diagnosed through mucocutaneous lesions and gastrointestinal polyposis with recurrent hematochezia, unrevealed by initial diagnosis. Intern Med 2000; 39:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/56\">",
"      Stanich PP, Owens VL, Sweetser S, et al. Colonic polyposis and neoplasia in Cowden syndrome. Mayo Clin Proc 2011; 86:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/57\">",
"      Levi Z, Baris HN, Kedar I, et al. Upper and Lower Gastrointestinal Findings in PTEN Mutation&ndash;Positive Cowden Syndrome Patients Participating in an Active Surveillance Program. Clinical and Translational Gastroenterology 2011; 2:e5. Available online at file://www.nature.com/ctg/journal/v2/n11/full/ctg20114a.html.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/58\">",
"      Lok C, Viseux V, Avril MF, et al. Brain magnetic resonance imaging in patients with Cowden syndrome. Medicine (Baltimore) 2005; 84:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/59\">",
"      Nowak DA, Trost HA. Lhermitte-Duclos disease (dysplastic cerebellar gangliocytoma): a malformation, hamartoma or neoplasm? Acta Neurol Scand 2002; 105:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/60\">",
"      Vinchon M, Blond S, Lejeune JP, et al. Association of Lhermitte-Duclos and Cowden disease: report of a new case and review of the literature. J Neurol Neurosurg Psychiatry 1994; 57:699.",
"     </a>",
"    </li>",
"    <li>",
"     Eng C. PTEN hamartoma tumor syndrome (PHTS). In: GeneReviews, Pagon RA, Bird TD, Dolan CR, et al (Eds), University of Washington, Seattle (last updated July 21, 2011) 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/62\">",
"      Eng C. Will the real Cowden syndrome please stand up: revised diagnostic criteria. J Med Genet 2000; 37:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/63\">",
"      Pilarski R, Eng C. Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome. J Med Genet 2004; 41:323.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast and ovarian. In: NCCN Clinical Practice Guidelines in Oncology, V.1.2011 ed, 2011. Vol Volume 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/65\">",
"      Robinson S, Cohen AR. Cowden disease and Lhermitte-Duclos disease: characterization of a new phakomatosis. Neurosurgery 2000; 46:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/66\">",
"      Mester JL, Tilot AK, Rybicki LA, et al. Analysis of prevalence and degree of macrocephaly in patients with germline PTEN mutations and of brain weight in Pten knock-in murine model. Eur J Hum Genet 2011; 19:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/67\">",
"      Goffin A, Hoefsloot LH, Bosgoed E, et al. PTEN mutation in a family with Cowden syndrome and autism. Am J Med Genet 2001; 105:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/68\">",
"      Conti S, Cond&ograve; M, Posar A, et al. Phosphatase and tensin homolog (PTEN) gene mutations and autism: literature review and a case report of a patient with Cowden syndrome, autistic disorder, and epilepsy. J Child Neurol 2012; 27:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/69\">",
"      Di Cristofano A, Kotsi P, Peng YF, et al. Impaired Fas response and autoimmunity in Pten+/- mice. Science 1999; 285:2122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/70\">",
"      Baracho GV, Miletic AV, Omori SA, et al. Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation. Curr Opin Immunol 2011; 23:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/71\">",
"      Heindl M, H&auml;ndel N, Ngeow J, et al. Autoimmunity, intestinal lymphoid hyperplasia, and defects in mucosal B-cell homeostasis in patients with PTEN hamartoma tumor syndrome. Gastroenterology 2012; 142:1093.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) Guidelines for Genetic/Familial High Risk Assessment available online at www.nccn.org (Accessed on January 09, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/73\">",
"      Robinson S, Cohen AR. Cowden disease and Lhermitte-Duclos disease: an update. Case report and review of the literature. Neurosurg Focus 2006; 20:E6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/74\">",
"      Fistarol SK, Anliker MD, Itin PH. Cowden disease or multiple hamartoma syndrome--cutaneous clue to internal malignancy. Eur J Dermatol 2002; 12:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/75\">",
"      Squarize CH, Castilho RM, Gutkind JS. Chemoprevention and treatment of experimental Cowden's disease by mTOR inhibition with rapamycin. Cancer Res 2008; 68:7066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/76\">",
"      Marsh DJ, Trahair TN, Martin JL, et al. Rapamycin treatment for a child with germline PTEN mutation. Nat Clin Pract Oncol 2008; 5:357.",
"     </a>",
"    </li>",
"    <li>",
"     Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes. www.clinicaltrials.gov (Accessed on November 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/78\">",
"      Cohen MM Jr. Bannayan-Riley-Ruvalcaba syndrome: renaming three formerly recognized syndromes as one etiologic entity. Am J Med Genet 1990; 35:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/79\">",
"      Marsh DJ, Dahia PL, Zheng Z, et al. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet 1997; 16:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/80\">",
"      Lynch NE, Lynch SA, McMenamin J, Webb D. Bannayan-Riley-Ruvalcaba syndrome: a cause of extreme macrocephaly and neurodevelopmental delay. Arch Dis Child 2009; 94:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/81\">",
"      Bonneau D, Longy M. Mutations of the human PTEN gene. Hum Mutat 2000; 16:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/82\">",
"      Gorlin RJ, Cohen MM Jr, Condon LM, Burke BA. Bannayan-Riley-Ruvalcaba syndrome. Am J Med Genet 1992; 44:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/83\">",
"      Parisi MA, Dinulos MB, Leppig KA, et al. The spectrum and evolution of phenotypic findings in PTEN mutation positive cases of Bannayan-Riley-Ruvalcaba syndrome. J Med Genet 2001; 38:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/84\">",
"      Hendriks YM, Verhallen JT, van der Smagt JJ, et al. Bannayan-Riley-Ruvalcaba syndrome: further delineation of the phenotype and management of PTEN mutation-positive cases. Fam Cancer 2003; 2:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/85\">",
"      Litzendorf M, Hoang K, Vaccaro P. Recurrent and extensive vascular malformations in a patient with Bannayan--Riley--Ruvalcaba syndrome. Ann Vasc Surg 2011; 25:1138.e15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/86\">",
"      Kurek KC, Howard E, Tennant LB, et al. PTEN hamartoma of soft tissue: a distinctive lesion in PTEN syndromes. Am J Surg Pathol 2012; 36:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/87\">",
"      Erkek E, Hizel S, Sanl&yacute; C, et al. Clinical and histopathological findings in Bannayan-Riley-Ruvalcaba syndrome. J Am Acad Dermatol 2005; 53:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/88\">",
"      Alomari AI. Characterization of a distinct syndrome that associates complex truncal overgrowth, vascular, and acral anomalies: a descriptive study of 18 cases of CLOVES syndrome. Clin Dysmorphol 2009; 18:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/89\">",
"      Sapp JC, Turner JT, van de Kamp JM, et al. Newly delineated syndrome of congenital lipomatous overgrowth, vascular malformations, and epidermal nevi (CLOVE syndrome) in seven patients. Am J Med Genet A 2007; 143A:2944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/90\">",
"      Tibbles JA, Cohen MM Jr. The Proteus syndrome: the Elephant Man diagnosed. Br Med J (Clin Res Ed) 1986; 293:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/91\">",
"      Wiedemann HR, Burgio GR, Aldenhoff P, et al. The proteus syndrome. Partial gigantism of the hands and/or feet, nevi, hemihypertrophy, subcutaneous tumors, macrocephaly or other skull anomalies and possible accelerated growth and visceral affections. Eur J Pediatr 1983; 140:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/92\">",
"      Lindhurst MJ, Sapp JC, Teer JK, et al. A mosaic activating mutation in AKT1 associated with the Proteus syndrome. N Engl J Med 2011; 365:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/93\">",
"      Zhou XP, Marsh DJ, Hampel H, et al. Germline and germline mosaic PTEN mutations associated with a Proteus-like syndrome of hemihypertrophy, lower limb asymmetry, arteriovenous malformations and lipomatosis. Hum Mol Genet 2000; 9:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/94\">",
"      Smith JM, Kirk EP, Theodosopoulos G, et al. Germline mutation of the tumour suppressor PTEN in Proteus syndrome. J Med Genet 2002; 39:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/95\">",
"      Loffeld A, McLellan NJ, Cole T, et al. Epidermal naevus in Proteus syndrome showing loss of heterozygosity for an inherited PTEN mutation. Br J Dermatol 2006; 154:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/96\">",
"      Cohen MM Jr, Turner JT, Biesecker LG. Proteus syndrome: misdiagnosis with PTEN mutations. Am J Med Genet A 2003; 122A:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/97\">",
"      Caux F, Plauchu H, Chibon F, et al. Segmental overgrowth, lipomatosis, arteriovenous malformation and epidermal nevus (SOLAMEN) syndrome is related to mosaic PTEN nullizygosity. Eur J Hum Genet 2007; 15:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/98\">",
"      Biesecker L. The challenges of Proteus syndrome: diagnosis and management. Eur J Hum Genet 2006; 14:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/99\">",
"      Gordon PL, Wilroy RS, Lasater OE, Cohen MM Jr. Neoplasms in Proteus syndrome. Am J Med Genet 1995; 57:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/100\">",
"      Cohen MM Jr. Proteus syndrome: clinical evidence for somatic mosaicism and selective review. Am J Med Genet 1993; 47:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/101\">",
"      Biesecker LG, Happle R, Mulliken JB, et al. Proteus syndrome: diagnostic criteria, differential diagnosis, and patient evaluation. Am J Med Genet 1999; 84:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/102\">",
"      Newman B, Urbach AH, Orenstein D, Dickman PS. Proteus syndrome: emphasis on the pulmonary manifestations. Pediatr Radiol 1994; 24:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/103\">",
"      Iqbal J, He G, Biesecker LG, et al. Morphological characterization of the breast in Proteus syndrome complicated by ductal carcinoma in situ. Ann Clin Lab Sci 2006; 36:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/104\">",
"      Cohen MM Jr. Overgrowth syndromes: an update. Adv Pediatr 1999; 46:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/105\">",
"      Biesecker LG. The multifaceted challenges of Proteus syndrome. JAMA 2001; 285:2240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/106\">",
"      Slavotinek AM, Vacha SJ, Peters KF, Biesecker LG. Sudden death caused by pulmonary thromboembolism in Proteus syndrome. Clin Genet 2000; 58:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/107\">",
"      McBride KL, Varga EA, Pastore MT, et al. Confirmation study of PTEN mutations among individuals with autism or developmental delays/mental retardation and macrocephaly. Autism Res 2010; 3:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/108\">",
"      Orrico A, Galli L, Buoni S, et al. Novel PTEN mutations in neurodevelopmental disorders and macrocephaly. Clin Genet 2009; 75:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/53/29530/abstract/109\">",
"      Buxbaum JD, Cai G, Chaste P, et al. Mutation screening of the PTEN gene in patients with autism spectrum disorders and macrocephaly. Am J Med Genet B Neuropsychiatr Genet 2007; 144B:484.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16543 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D34A3220F9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_53_29530=[""].join("\n");
var outline_f28_53_29530=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H462460072\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5356445\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H462459902\">",
"      COWDEN SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17510999\">",
"      Molecular genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H462459910\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H462459918\">",
"      - Mucocutaneous",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H462459926\">",
"      - Breast",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H462459934\">",
"      - Thyroid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H462459942\">",
"      - Genitourinary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5646167\">",
"      - Gastrointestinal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H232666187\">",
"      Polyps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H232666195\">",
"      Esophageal glycogen acanthosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H232666202\">",
"      Colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H462459958\">",
"      - Neurologic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H232670781\">",
"      Tumors and vascular malformations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H462459966\">",
"      Macrocephaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H462459974\">",
"      Mental retardation and developmental delay",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10806403\">",
"      - Immune dysregulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H462459982\">",
"      Diagnostic and testing criteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H462459990\">",
"      - Criteria for PTEN genetic testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H462460007\">",
"      - Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H462460015\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H232666982\">",
"      - Cancer surveillance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H232667011\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H462460023\">",
"      BANNAYAN-RILEY-RUVALCABA SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H462460040\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H462460048\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H462460056\">",
"      PROTEUS AND PROTEUS-LIKE SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H634863\">",
"      Molecular genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H634870\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H634877\">",
"      Diagnosis, differential diagnosis, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H462460064\">",
"      AUTISM SPECTRUM DISORDERS AND MACROCEPHALY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H462460072\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/16543\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/16543|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/2/42\" title=\"picture 1\">",
"      Penile lentigines pigmented macules of the penis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/31/41459\" title=\"picture 2\">",
"      Papules in Cowden syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/24/33155\" title=\"picture 3\">",
"      Oral papillomas in Cowden syndrome patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/57/34718\" title=\"picture 4\">",
"      Glycogen acanthosis Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/53/34642\" title=\"picture 5\">",
"      Cerebriform connective tissue nevus plantar foot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/16543|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/46/39660\" title=\"table 1\">",
"      Consensus criteria for Cowden syndrome diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/34/29229\" title=\"table 2\">",
"      Cowden syndrome testing and clinical criteria of the NCCN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/45/44763\" title=\"table 3\">",
"      Recommendations for diagnostic criteria for Proteus syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32746?source=related_link\">",
"      Approach to the patient with colonic polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/18/2346?source=related_link\">",
"      Benign lesions of the esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26186?source=related_link\">",
"      Breast cancer in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/10/2217?source=related_link\">",
"      Capillary malformations (port wine stains): Clinical features, diagnosis, and associated syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=related_link\">",
"      Characteristics of hereditary breast and ovarian cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=related_link\">",
"      Clinical manifestations and diagnosis of familial adenomatous polyposis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21802?source=related_link\">",
"      Cutaneous manifestations of internal malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28506?source=related_link\">",
"      Diagnostic approach to and treatment of thyroid nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/6/37992?source=related_link\">",
"      Endometrial carcinoma: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=related_link\">",
"      Endometrial carcinoma: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28968?source=related_link\">",
"      Endoscopic removal of large colonic polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34441?source=related_link\">",
"      Epidemiology, risk factors and the clinical approach to ER/PR negative, HER2-negative (Triple-negative) breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/54/3946?source=related_link\">",
"      Etiology and evaluation of macrocephaly in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=related_link\">",
"      Genetic counseling and testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/60/5064?source=related_link\">",
"      Genetic risk assessment for individuals at risk for hereditary breast and ovarian cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35910?source=related_link\">",
"      Hereditary kidney cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/54/20328?source=related_link\">",
"      Meningioma: Epidemiology, risk factors, and pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=related_link\">",
"      Neurofibromatosis type 1 (von Recklinghausen's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11081?source=related_link\">",
"      Overview of benign breast disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8440?source=related_link\">",
"      Overview of papillary thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/9/3224?source=related_link\">",
"      Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23191?source=related_link\">",
"      Thyroid nodules and cancer in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/38/34410?source=related_link\">",
"      Tuberous sclerosis complex: Genetics, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35946?source=related_link\">",
"      Uncommon brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/3/17465?source=related_link\">",
"      Variants of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30038?source=related_link\">",
"      Vascular lesions in the newborn",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_53_29531="Abbrev screen depres cancer";
var content_f28_53_29531=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F61549&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F61549&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Abbreviated screening methods for the assessment of depression in cancer patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Single-item interview assessing depressed mood (adapted from SADS)",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Two-item interview assessing depressed mood and loss of interest in activities (adapted from SADS)",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Visual analog scale for depressed mood (adapted from Memorial Pain Assessment Card)",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        13-item Beck Depression Inventory (adapted from 21-item Beck Depression Inventory)",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brief Case-Find for Depression (BCD)",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Four-question algorithm for screening depression (energy level, anhedonia, depressive feelings, psychomotor agitation/retardation)",
"        <sup>",
"         [5]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Single-item interview assessing psychological distress in the MOS SF36 (36-item short-form) health survey",
"        <sup>",
"         [6]",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SADS: Schedule for Affective Disorders and Schizophrenia.",
"    </div>",
"    <div class=\"reference\">",
"     1. Chochinov, HM, et al. Am J Psych 1997; 154:674.",
"     <br>",
"      2. Fishman, B, et al. Cancer 1987; 60:1151.",
"      <br>",
"       3. Beck, AT, et al. Postgrad Med 1972; 52:81.",
"       <br>",
"        4. Jefford, M, et al. Br J Cancer 2004; 91:900.",
"        <br>",
"         5. Robinson, J. Palliat Med 2005; 19:278.",
"         <br>",
"          6. Ware, JE. Med Care 1992; 30:473.",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_53_29531=[""].join("\n");
var outline_f28_53_29531=null;
var title_f28_53_29532="Molecular classification of colorectal carcinoma";
var content_f28_53_29532=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F72239&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F72239&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Molecular classification of colorectal carcinoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Heredity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chromosomal instability pathway",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mismatch repair pathway",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Serrated/CIMP pathway",
"       </td>",
"       <td class=\"subtitle1\">",
"        Hybrid pathway",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Hereditary and sporadic",
"       </td>",
"       <td class=\"subtitle2\">",
"        Hereditary",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Hereditary and sporadic",
"       </td>",
"       <td class=\"subtitle2\">",
"        Sporadic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CIMP status",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MSI status",
"       </td>",
"       <td>",
"        MSS",
"       </td>",
"       <td>",
"        MSI-H",
"       </td>",
"       <td>",
"        MSI-H",
"       </td>",
"       <td>",
"        MSI-L",
"       </td>",
"       <td>",
"        MSI-L or MSS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chromosomal instability",
"       </td>",
"       <td>",
"        Present",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        Present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         KRAS",
"        </em>",
"        mutation",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        ---",
"       </td>",
"       <td>",
"        ---",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         BRAF",
"        </em>",
"        mutation",
"       </td>",
"       <td>",
"        ---",
"       </td>",
"       <td>",
"        ---",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        ---",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MLH1 status",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Mutation",
"       </td>",
"       <td>",
"        Methylated",
"       </td>",
"       <td>",
"        Partial methylation",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MGMT methylation",
"       </td>",
"       <td>",
"        ---",
"       </td>",
"       <td>",
"        ---",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CIMP: CpG island methylator phenotype; MSS: microsatellite stability; MSI: microsatellite instability; MSI-H: high-level microsatellite instability; MSI-L: low-level microsatellite instability; MGMT: O-6-methlyguanine DNA methyltransferase; +++: present; +/-: might or might not be present; ---: absent.",
"    </div>",
"    <div class=\"reference\">",
"     Noffsinger AE. Serrated polyps and colorectal cancer: New pathway to malignancy. Annu Rev Pathol 2009; 4:343. Reprinted, with permission, from the Annual Review of Pathology. Copyright &copy; 2009 Volume 4, 2009 by Annual Reviews. www.annualreviews.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_53_29532=[""].join("\n");
var outline_f28_53_29532=null;
var title_f28_53_29533="Treatment of MCTD";
var content_f28_53_29533=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F63295&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F63295&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of mixed connective tissue disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Problems",
"       </td>",
"       <td class=\"subtitle1\">",
"        Treatments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fatigue, arthralgias, myalgias",
"       </td>",
"       <td>",
"        NSAIDs, antimalarials, low-dose prednisone (&lt;10 mg/day). Trial use of modafanil.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arthritis",
"       </td>",
"       <td>",
"        NSAIDs, antimalarials, methotrexate, consider TNF inhibition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Raynaud phenomenon",
"       </td>",
"       <td>",
"        Keep warm, avoid finger trauma, avoid beta-blockers, stop smoking, dihydropyridine Ca channel blocker (eg, nifedipine), alpha sympatholytics (eg, prazosin), consider endothelin receptor antagonist (eg, bosentan) in recalcitrant cases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute-onset digital gangrene",
"       </td>",
"       <td>",
"        Local chemical sympathectomy (infiltration of lidocaine at base of involved digit), anticoagulation, topical nitrates, consider hospitlalization for intra-arterial prostacyclin, start endothelin receptor antagonist therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myositis",
"       </td>",
"       <td>",
"        <p>",
"         Acute onset/severe - prednisone (60 to 100 mg/day)",
"        </p>",
"        <p>",
"         Chronic/low grade - prednisone (10 to 30 mg/day, remain alert for steroid myopathy, aseptic necrosis of bone, and accelerated osteoporosis)",
"        </p>",
"        <p>",
"         Consider methotrexate and/or IVIG in recalcitrant cases",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Membranous glomerulonephropathy",
"       </td>",
"       <td>",
"        <p>",
"         Mild - no treatment required",
"        </p>",
"        <p>",
"         Progressive proteinuria - trial of ACE inhibitor, trial of low-dose aspirin combined with dipyridamole",
"        </p>",
"        <p>",
"         Severe - trial of prednisone (15 to 60 mg/day) plus monthly pulse cyclophosphamide or daily chlorambucil",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nephrotic syndrome",
"       </td>",
"       <td>",
"        <p>",
"         Steroids alone seldom effective. Low dose aspirin combined with dipyridamole to prevent thrombotic complications. ACE inhibitor to reduce protein loss. Trial of prednisone, 15 to 60 mg/day plus monthly pulse cyclophosphamide or daily chlorambucil.",
"        </p>",
"        <p>",
"         May require dialysis/transplantation",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pleurisy",
"       </td>",
"       <td>",
"        NSAID or short course of prednisone (about 20 mg/day)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aseptic meningitis",
"       </td>",
"       <td>",
"        Discontinue NSAIDs, short course of high-dose prednisone (about 60 mg/day)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myocarditis",
"       </td>",
"       <td>",
"        Trial of steroids and cyclophosphamide; avoid digoxin since it predisposes to ventricular arrhythmias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Incomplete heart block",
"       </td>",
"       <td>",
"        Avoid chloroquine as it prediposes to complete heart block",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asymptomatic pulmonary hypertension",
"       </td>",
"       <td>",
"        Trial of steroids and cyclophosphamide, low dose aspirin and angiotensin-converting enzyme inhibitors. Consider endothelin receptor antagonist (oral bosentan).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptomatic pulmonary hypertension",
"       </td>",
"       <td>",
"        Trial of intravenous prostacylin, angiotensin-converting enzyme inhibitors, anticoagulation. Endothelin receptor antagonist (oral bosentan). Sildenafil trial. Heart-lung transplantation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vascular headache",
"       </td>",
"       <td>",
"        Trial of propranolol or alternative-day aspirin (350 mg). Symptomatic use of sumatriptin.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dysphagia",
"       </td>",
"       <td>",
"        <p>",
"         Mild - No treatment",
"        </p>",
"        <p>",
"         With reflux - proton pump inhibitor. Consider Nissen fundoplication.",
"        </p>",
"        <p>",
"         Severe - Calcium channel antagonist, alone or in combination with an anti-cholinergic agent",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intestinal dysmotility",
"       </td>",
"       <td>",
"        Prokinetic agents such as metoclopramide and erythromycin. For small bowel bacterial overgrowth, tetracycline or erythromycin.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heartburn/dyspepsia",
"       </td>",
"       <td>",
"        Raise head of bed, discontinue smoking, lose weight and avoid caffeine. H2 antagonists, H+ proton pump blockers, metoclopramide trial. Consider H. pylori infection in recalcitrant cases.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trigeminal neuropathy",
"       </td>",
"       <td>",
"        No effective therapy for numbness. Trial of an anti-epileptic (eg, gabapentin) or TCA (eg, nortryptiline) for pain.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pericarditis",
"       </td>",
"       <td>",
"        NSAID or short course of prednisone (about 20 mg/day). Tamponade will require percutaneous or surgical drainage.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scleroderma-like renal crisis",
"       </td>",
"       <td>",
"        ACE inhibitor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autoimmune anemia/thrombocytopenia",
"       </td>",
"       <td>",
"        High-dose steroids (prednisone about 80 mg/day) with taper dependent on clinical course. Consider danazol, IVIG and immunosuppression in recalcitrant cases.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thrombotic thrombocytopenic purpura",
"       </td>",
"       <td>",
"        Immediate infusion of fresh frozen plasma. May require plasma exchange and transfusion of platelet depleted RBCs. Consider splenectomy in recalcitrant cases.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Osteoporosis",
"       </td>",
"       <td>",
"        Calcium/vitamin D supplements, estrogen replaced or raloxifene, bisphosphonates, nasal calcitonin, carboxyl truncated PTH analogs such as hPTH-(1-34)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_53_29533=[""].join("\n");
var outline_f28_53_29533=null;
var title_f28_53_29534="Timeline course HUS in children";
var content_f28_53_29534=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75352&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75352&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 519px\">",
"   <div class=\"ttl\">",
"    Progression of E coli O157:H7 infections in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 499px; height: 309px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    About 3 days after ingestion of the organism, the patient develops diarrhea, abdominal pain, fever, and vomiting. The diarrhea becomes bloody 1 to 3 days later, rarely on the first day. In 80 to 90 percent of infected children with positive cultures, visible blood is present in the stools. When bloody diarrhea first develops, the patient has a normal platelet count, creatinine concentration, and packed-cell volume, with no red-cell fragmentation. However, if studies of the coagulation and fibrinolytic systems are done early in the illness, there is evidence that thrombin generation is increased, fibrin deposition is occurring, and plasminogen activation is suppressed.",
"    <div class=\"footnotes\">",
"     HUS: hemolytic uremic syndrome.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Tarr, PI, Gordon, CA, Chandler, WL. Shiga-toxin-producing Escherichia coliand haemolytic uraemic syndrome. Lancet 2005; 365:1073. Copyright &copy;2005 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_53_29534=[""].join("\n");
var outline_f28_53_29534=null;
var title_f28_53_29535="Crohns string sign SBFT";
var content_f28_53_29535=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    String sign in Crohn's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 198px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Small bowel follow through study shows marked narrowing, irregularity and ulceration in the distal ileum (arrows) in a patient with Crohn's disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_53_29535=[""].join("\n");
var outline_f28_53_29535=null;
